

REVIEW ON USE OF CANNABIS FOR MEDICAL PURPOSES

Prepared for: Workplace Safety Insurance Board

20 January 2021



Table of Contents

List of Tables	3
List of Figures	3
Abbreviations	4
Executive Summary	. 5
Methods	. 7
Research question Inclusion/exclusion criteria Cannabis formulations Search strategy Assessing quality of evidence and risk of bias	7 7 8 9
Results	. 9
WSIB-approved indications	25
Neuropathic pain Spasticity due to spinal cord injury Chemotherapy-induced nausea and vomiting HIV/AIDS-associated anorexia Palliative care	25 26 27
Other indications	
Non-cancer pain Anxiety Post-traumatic stress disorder Epilepsy Schizophrenia	28 29 30
Other Psychotic disorders	
Tourette Syndrome Multiple Sclerosis Parkinson's disease Alzheimer's disease	31 31 32
Current Canadian guidelines.	
Summary of evidence for effectiveness of medical cannabis	



Movement disorders 41
Other diseases 41
Safety 42
Discussion
Appendices
Appendix 1. Search methodology, terms and output 47
Appendix 2. Excluded studies (with reasons for exclusion)
Appendix 3. Assessing quality of evidence and risk of bias
AMSTAR2
Assessment of risk of bias for systematic reviews of original studies using AMSTAR2 167
Health Evidence (McMaster University) 170
Assessment of risk of bias of systematic reviews of systematic reviews using the Health Evidence Tool
Appendix 4: Reviews sorted by indication and cannabis formulation ^{*, **}
Appendix 5: Major evidence for prescribing cannabis and non-pharmaceutical cannabinoids using
evidence from major grey literature
Appendix 6: Reported adverse events with cannabis and non-pharmaceutical cannabinoids 184
References



List of Tables

	Table 1: Studies excluded at levels 1 and 2 by exclusion reason/group	.10
	Table 2: Characteristics of included reviews	.14
	Table 3: Canadian guidelines for prescribing medical cannabis and non-pharmaceutic	al
canna	abinoids	.34
	Table 4: Summary of evidence for use of cannabis-based medicines	.39

List of Figures

Figure 1: PRISMA flow diagram for eligible studies on medical cannabis	12
Figure 2: Frequency of indications examined in the included reviews	13
Figure 3: Frequency of adverse events examined in the included reviews	43



Abbreviations

ADHD	Attention deficit hyperactivity disorder
ALS	Amyotrophic lateral sclerosis
ASD	Autism spectrum disorder
CBD	Cannabidiol
CE	Cannabis extract
CINV	Chemotherapy induced nausea and vomiting
Core SR	Systematic reviews of original studies included in this current review
CNCP	Chronic non-cancer pain
DIN	Drug identification number
MC	Medical cannabis
MS	Multiple sclerosis
NPC	Non-pharmaceutical cannabinoids
NPN	Natural product number
NRSI	Non-randomized study of intervention
OCE	Oral cannabis extract
PCB	Pharmaceutical cannabinoids
PTSD	Post-traumatic stress disorder
ROB	Risk of bias
RCT	Randomized controlled trial
RSR	Reviews of systematic reviews included in this current review
SAD	Social anxiety disorders
SCET	Standardized cannabis extract with THC
SCT	Standardized cannabis with THC
SR	Systematic review
THC	Delta 9-tetrahydrocannabinol



Executive Summary

Cannabis has long been used internationally as a recreational compound and as a therapeutic option for the symptomatic management of many conditions (<u>1</u>). Also known as marijuana, hashish, bhang, cannador, charas or ganja, cannabis comprises two main species (Cannabis sativa and Cannabis indica), which gave rise to hundreds of strains, with numerous chemical compositions and pharmacologic profiles (<u>2</u>, <u>3</u>).

Cannabis-based medicines are chemical compounds that are either extracted directly from different parts of the cannabis plant or are synthetically prepared (<u>2-4</u>). These compounds exhibit a stimulatory effect on the internal endocannabinoid system, which regulates many neurocognitive functions such as pain, memory, reward processing, mood, and appetite (<u>2</u>, <u>4</u>).

The two most heavily used medical cannabinoids are cannabidiol (CBD) and delta-9tetrahydrocannabinol (THC) ($\underline{1}$, $\underline{4}$). A medical cannabis medication may contain any one of them separately, combined in variable concentrations, or combined with other types of cannabinoids or medications ($\underline{1}$, $\underline{4}$). Should they exist together, a delicate balance must be maintained between the non-psychoactive CBD and psychoactive THC to avoid the adverse effects caused by the latter ($\underline{1}$).

With the dawn of legalization of cannabis use, many research studies were launched internationally, fueled in part by the motivations of medical cannabis manufacturers, and also due in part to an increasing public demand for new modalities to treat symptoms that are refractory to standard and traditional treatments, with the goal of subsequently improving quality of life.

Original research projects have been predominantly observational in nature with very few clinical trials and randomized controlled trials (RCTs). RCTs would provide high quality evidence on the benefits of cannabis-based medicines for treatment of different conditions, particularly with palliation and with pain and movement disorders.

While pharmaceutical cannabinoids have a reasonable history of evidence for treatment of certain conditions, the current level of evidence for medical cannabis and non-pharmaceutical cannabinoids is largely limited, inconsistent, and predominantly of low quality.



Nevertheless, the current review highlights evidence regarding the benefits of some nonpharmaceutical cannabis-based medicines for treatment of symptoms in particular conditions, such as neuropathic pain; chronic pain conditions (cancer, non-cancer, arthritis-related, MSrelated); in palliative care (cancer and HIV/AIDS) for pain, anorexia, nausea, and vomiting; and for spasticity (MS and spinal cord injuries).

The current review includes some limitations, particularly due to the synthesis of information collected via the different systematic reviews rather than collecting the required information directly from original studies. This led to issues stemming from the wide range of study designs included in most of the reviews. The included reviews often lacked valuable information such as details of chemical composition of the cannabis preparations, doses, routes of administration, and treatment duration, which collectively have many pharmacokinetic and pharmacodynamic implications.



Methods

Research question

This review aims at determining whether there is any updated evidence since the last WSIB review regarding the indications for use of medical cannabis for treatment of patients with neuropathic pain, spasticity resulting from a spinal cord injury, chemotherapy-associated nausea and vomiting, HIV/AIDS-associated anorexia, and palliative care, as well as evidence for other indications.

Inclusion/exclusion criteria

The current approach entailed a systematic review of reviews. Two types of reviews were included in the current evidence synthesis: a) Systematic reviews of original studies (Core SR) and, b) Reviews of systematic reviews (RSR). Eligible studies examined the human use of any type of medical cannabis formulation (with the exception of pharmaceutical formulations, which are used for treatment of different conditions). Exclusion criteria were non-systematic reviews; reviews conducted on non-humans; reviews that only examined pharmaceutical cannabis formulations; reviews that focused on cannabis addiction, withdrawal or adverse reactions; reviews that discussed non-health indications of medical cannabis, such as political, legal or economic; and reviews published prior to 2016.

Inclusion in the current review was based on evidence reported on the use of any cannabis formulation that can be accessed legally in Canada except for currently registered cannabis medications commonly referred to as pharmaceutical cannabinoids. Only published evidence was examined for reporting on non-pharmaceutical cannabinoids, which includes any cannabis-based medications as long as they do not currently possess a drug identification number (DIN) or a natural product number (NPN)

Cannabis formulations

The review refers to cannabis/cannabinoid formulations using the same terminology reported in the original WSIB review, except for pharmaceutical preparations. These



preparations include cannabinoids with a DIN or NPN such as Sativex[®], Nabiximol[®], Dronabinol[®], Epidiolex, Marinol and Ajulemic acid, as per regulations of Health Canada and WSIB. In such a case, there was a deliberate categorization of the formulation as pharmaceutical even though it is reported in the original review as, for instance, a medical cannabis/cannabinoid or plant-based cannabinoid.

Search strategy

In this review, publications published from 2016 to the present date were examined. In doing so, a comprehensive, multi-step search strategy to identify published, peer-reviewed, systematic reviews was implemented. No filters were applied to limit the search output. The search was conducted in accordance with the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) ($\underline{5}$) and following the specific guidance provided by the Cochrane Collaboration ($\underline{6}$).

The search strategy for human studies was designed and implemented between March 23-25, 2020. Three major bibliographic databases were searched (Medline Ovid, EMBASE and PubMed) using specific keywords. See Appendix 1 for details on the searched sources, used terms, and search output. Additionally, bibliographies were inspected of examined reviews for additional relevant studies not already identified via the original search.

Identified references from all sources were collated using the EndNote (7) reference management application. EndNote was used to identify potential duplicates, with manual resolution employed to remove additional actual duplicates. Screening of titles and abstracts (level 1) and full-text examination (level 2) were performed independently by two reviewers to identify systematic reviews eligible for inclusion in the review. The review was completed through a multi-level assessment process, using the <u>Distiller SR</u> application (8). Conflicts identified in each step were resolved via consensus prior to moving to the next level.

Data abstraction spreadsheets were developed using Microsoft Office Excel and used to abstract the following information: study design, study population characteristics, exposure assessment, and authors' reported conclusion. Reviewers' comments, if any, were also included. Key characteristics of the included studies are summarized in Table 2 in this report



and provided in full detail in the Supplementary Materials.

Assessing quality of evidence and risk of bias

For assessing the quality of evidence from included systematic reviews of original studies, the AMSTAR2 tool was used (9). This tool, designed only for reviews of clinical trials and non-randomized studies of interventions, includes 16 questions, 7 critical and 9 non-critical. Based on the assessment results, a review would be granted one of four levels of confidence: high, moderate, low, or critically low.

For assessing the quality of evidence in RSR, we used a Health Evidence tool developed by McMaster University (<u>10-12</u>). Whereas this tool is also designed for assessing systematic reviews of original studies, similar to AMSTAR2, it was still applicable to RSR while providing clear guidance on question interpretation without any manipulation to the questions or the scoring system. Based on responses to its ten questions, each review would be assigned an overall rating of "strong", "moderate", or "weak".

Questions used by the two tools as well as results of the assessment of all included reviews are detailed in Appendix 3.

Results

The search strategy resulted in retrieval of 13,229 records from three bibliographic databases. Restricting these records to reviews reduced the available records to 5,101. Electronic and manual de-duplication resulted in removal of 1,677 records, and identification of 3,424 eligible reviews. The cohort of eligible reviews was restricted to those published between 2016 and 2020 (n=468). Title and abstract screening of these reviews led to the exclusion of 336 records, leaving 132 studies for full-text examination.

Upon exclusion of 81 additional studies, 51 systematic reviews were retained for qualitative analysis. However, the current review examines only 49 systematic reviews, including 42 'core' systematic reviews of original studies (<u>13-54</u>) and 7 reviews of systematic reviews (RSR) (<u>55-61</u>). Secondary reviews refer to reviews included in the RSRs.



Two reviews (<u>62</u>, <u>63</u>) were excluded: Elliot et al. (2019) was excluded as it was superseded by Elliot et al. 2020 (<u>62</u>), and Aviram et al. (2017) was excluded due to repeating information in Table 1 that was suspected to be reported in error. As descriptive tables are the most crucial parts of systematic reviews, Aviram et al. could not be included in confidence (<u>63</u>).

A detailed PRISMA flow diagram (5) summarizing the flow of studies during the selection process is shown in Figure 1. A summary of studies excluded at levels 1 and 2, grouped by reason of exclusion is shown in Table 1, and listed in detail in Appendix 2.

Level	Exclusion group	Reason for exclusion	# of References
Title &	Duplicate reference	Duplicate reference	37
abstract screening	Irrelevant population	Irrelevant population	3
0		Irrelevant exposure	6
	Irrelevant exposure	Only pharmaceutical cannabinoids	3
		Addiction/Withdrawal	199
	Irrelevant indication	No therapeutic indication	44
		Irrelevant study focus	23
	Irrelevant publication	Irrelevant study design	17
	type	Non-English reference	4
Full-text		Irrelevant exposure	1
examinatior	ו Irrelevant exposure	Mixed cannabinoids	1
		Only pharmaceutical cannabinoids	4
	Irrelevant outcome	No outcome data	1
		Addiction/Withdrawal	6
	Irrelevant population	Irrelevant population	1
	Unavailable full-text	Unavailable full-text	23
	Irrelevant publication type	Irrelevant study design	44

Table 1: Studies excluded at levels 1 and 2 by exclusion reason/group



Forty-nine eligible systematic reviews were retained for qualitative assessment, including 7 reviews of systematic reviews. These reviews reported on a wide range of experimental (clinical trials) and observational studies (cohort, case-control, cross-sectional, case reports, case series, chart reviews). A summary of the major characteristics of these systematic reviews is provided in Table 2.

These reviews reported on original studies or reviews that examined the association of many cannabis-based formulations and cannabinoids (plant-based, synthetic, unspecified), for treating patients with a wide range of indications. These indications included pain conditions, palliative care (cancer, HIV/AIDS), movement disorders, psychiatric and neurocognitive diseases/disorders, and other conditions. A detailed listing of the different cannabis formulations with the corresponding indications is provided in Appendix 4

Multiple sclerosis represented the indication most frequently examined with different cannabis formulations, followed by pain conditions (neuropathic and non-neuropathic), post-traumatic stress disorder (PTSD) and epilepsy (including for children). Figure 2 illustrates all the cannabis-indication associations examined by the included reviews.

Individual non-pharmaceutical cannabinoids (mainly CBD, THC, CBD:THC) were reported more frequently compared to medical cannabis preparations (whole plant, extract, resin, cigarettes).

Regarding the risk of bias assessment, 9 systematic reviews reflected a high level of confidence (low risk of bias) in their reporting of evidence compared to 1, 3, and 36 for moderate, low and critically low levels of confidence (low confidence implies high risk of bias), respectively.

Authors concluded there was a positive level of evidence for use of medical cannabis and/or cannabinoids for different indications in 16 reviews, whereas the conclusion in 12 reviews was that the level of evidence was 'possible' and in 4 reviews the level of evidence was 'negative'. Conclusions could not be identified in the authors' discussions or summaries in 17 of the included reviews.




Figure 1: PRISMA flow diagram for eligible studies on medical cannabis






Figure 2: Frequency of indications examined in the included reviews



Table 2: Characteristics of included reviews

Systematic	Number	Types of	Examined	Indications	Authors'	Level of
Review	Relevant Original studies (Number secondary SRs)	studies	formulations		conclusion	confidence
Boland 2020 (<u>13</u>)	1	СТ	THC, THC:CBD	Cancer (pain), dementia	U	Η
Charernboon 2020 (<u>14</u>)	2	СТ	THC	Dementia	U	CL
de Carvalho 2020 (<u>15</u>)	16	СТ	Cannabis, CBD	Epilepsy	Ρ	CL
Elliott 2020 (<u>16</u>)	13	CT, cohort, CRS, case series	CBD, CBD:THC	Epilepsy (pediatric)	Ρ	CL
Hindocha 2020 (<u>17</u>)	7	CT, CRV, case reports, case series	Herbal cannabis, cannabis resin, THC, CBD, CBD oil	PTSD	Ps	CL
Johal 2020 (<u>18</u>)	5	СТ	Cannabis (inhaled), THC	HIV (sensory neuropathy), MS (spasticity), chronic	Ρ	CL



Systematic Review	Number Relevant Original studies (Number secondary SRs)	Types of studies	Examined formulations	Indications non-cancer pain,	Authors' conclusion	Level of confidence
Khan 2020 (<u>19</u>)	15	CT, CRV, case reports, case series	CBD	neuropathic pain ADHD, SAD, cancer (pain), dementia, epilepsy (pediatric), HIV (sensory neuropathy), MS (spasticity), chronic non-cancer pain	Ρ	CL
Mun 2020 (<u>20</u>)	21	СТ	Cannabis, cannabinoids	Chronic non-cancer pain, neuropathic pain	Ps	CL
Rabgay 2020 (<u>21</u>)	10	СТ	Cannabis (standardized dried)	Neuropathic pain, PTSD, ADHD	Ρ	CL



Systematic	Number	Types of	Examined	Indications	Authors'	Level of
Review	Relevant Original studies (Number secondary SRs)	studies	formulations		conclusion	confidence
Sarris 2020 (<u>22</u>)	7	CT, CRV, case series	Cannabis, CBD	SAD, cancer (pain), dementia, epilepsy (pediatric)	Ps	CL
Amaniti 2019 (<u>23</u>)	2	СТ	Cannabis cigarettes	HIV (sensory neuropathy)	Ρ	CL
Black 2019 (<u>24</u>)	31	CT, cohort, CC, CRS, Quasi experimental	Cannabis sativa, cannabis resin, CBD extract, Marijuana	ADHD, ALS, Alzheimer's disease (agitation), anorexia nervosa, SAD, cancer (cachexia), CINV, cognition	Ps	L
Bonaccorso 2019 (<u>25</u>)	13	СТ	CBD, THC	Huntington's disease, MS (bladder dysfunction, gait disorders, spasticity) pain	Ps	CL



Systematic	Number	Types of	Examined	Indications	Authors'	Level of
Review	Relevant Original studies (Number secondary SRs)	studies	formulations		conclusion	confidence
Calapai 2019 (<u>26</u>)	4	СТ	CBD	SAD	Ρ	CL
Hoch 2019 (<u>55</u>)		СТ	CBD, THC	Alzheimer's disease (dementia), SAD, schizophrenia, Tourette syndrome	Ρ	Н
Khoury 2019 (<u>27</u>)	7	CT, case reports	CBD	SAD, cancer (cachexia)	Ps	CL
Millar 2019 (<u>28</u>)	35	CT, case reports, case series	CBD	SAD, cancer (cachexia, pain), CINV, cognition, Crohn's disease (pain), depression, epilepsy	Ρ	CL
Orsolini 2019 (<u>29</u>)	4	СТ	THC, CBD	PTSD, Tourette syndrome/tics	Ps	CL



Systematic	Number	Types of	Examined	Indications	Authors'	Level of
Review	Relevant Original studies (Number secondary SRs)	studies formulations		conclusion	confidence	
Wang 2019 (<u>30</u>)	3	СТ	CE, THC, THC:CBD	Cancer (cachexia, pain), CINV	Ρ	CL
Yanes 2019 (<u>31</u>)	16	СТ	MC/CE	Pain	Ps	CL
Advani 2018 (<u>32</u>)	1	СТ	CE, THC	Cancer (cachexia)	U	CL
Allan 2018 (<u>61</u>)	0 (28)	СТ	Cannabinoids	Neuropathic pain, CINV, spasticity (mainly MS)	Ρ	н
Behm 2018 (<u>33</u>)	2	СТ	CE, THC cannabis cigarettes	MS (gait disorders)	U	CL
De Vita 2018 (<u>34</u>)	12	СТ	Plant-based cannabis cigarettes with THC- specific dosages, THS standardized CE, THC	Experimental pain, neuropathic pain (adults), neuropathic pain (HIV/AIDS)	Ρ	CL
Ishak 2018 (<u>35</u>)	1	CRS	Cannabis	Depression, epilepsy, health-related quality of life, HIV/AIDS	Ρ	CL



Systematic Review		Types of	Examined	Indications	Authors'	Level of
	Relevant Original studies (Number secondary SRs)	studies formulatio	formulations		conclusion	confidence
				(sensory neuropathy), Huntington's disease		
Kafil 2018 (<u>36</u>)	2	СТ	Cannabis, CBD	Ulcerative colitis	U	L
Mucke 2018 (<u>37</u>)	2	СТ	Herbal Cannabis Marijuana cigarettes	Palliative care (cancer), PTSD	Ν	CL
Mucke 2018a (<u>38</u>)	2	СТ	Herbal cannabis	Neuropathic pain (adults)	U	Н
Nielsen 2018 (<u>56</u>)	0 (11)	CT, CC, CRS	MC, cannabinoids, whole plant extract	MS (spasticity and pain)	Ρ	Н
Stockings 2018 (<u>39</u>)	31	CT, cohort, CC, CRS, case report	MC, CE, CBD, THC:CBD, THCA	Epilepsy, health- related quality of life, HIV/AIDS (sensory neuropathy), Huntington's disease, MS (bladder	Ρ	Η



Systematic Review	Number Relevant Original studies (Number secondary SRs)	Types of studies	Examined formulations	Indications	Authors' conclusion	Level of confidence
				dysfunction, gait disorders, spasticity)		
Stockings 2018a (<u>40</u>)	39	CT cohort, CC, CRS	Cannabis sativa, THC, CBD, THC-HS, CT-3	Chronic non-cancer pain, experimental pain, neuropathic pain (adults)	Ν	L
Torres-Moreno 2018 (<u>41</u>)	5	СТ	Cannabis sativa plant extract	MS (bladder dysfunction, gait disorders, spasticity)	Ps	CL
Zhang 2018 (<u>42</u>)	1	СТ	THC	Tourette syndrome/tics	Ν	CL
da Rovare 2017 (<u>43</u>)	6	СТ	Cannabis cigarettes, whole-plant CE (THC:CBD)	MS (spasticity), acute pain, chronic pain, chronic non-cancer pain	Ps	CL



Systematic Review Goldenberg 2017	Number Relevant Original studies (Number secondary SRs)	Types of studies CT, cohort,	Examined formulations MC	Indications Health-related quality	Authors' conclusion	Level of confidence
(<u>44</u>)	0	CRS		of life	0	02
Hauser 2017 (<u>57</u>)	0 (11)	CT, cohort	Medical marijuana, FAAH inhibitor, THC	Cancer (pain), neuropathic pain, CINV, cognition, Crohn's disease (pain), depression, epilepsy	U	Н
Houze 2017 (<u>58</u>)	0 (2)	СТ	Cannabis	Chronic pain	Р	Н
Lim 2017 (<u>45</u>)	11	СТ	THC, CBD, THC-CBD cannador	Anorexia nervosa, SAD, cancer (cachexia, pain), CINV	U	CL
Norton 2017 (<u>46</u>)	3	CRS, pilot studies	Cannabis	Crohn's disease (pain), depression, epilepsy	U	CL



Systematic Review	Number Relevant Original studies (Number secondary SRs)	Types of studies	Examined formulations	Indications	Authors' conclusion	
Nugent 2017 (<u>47</u>)	11	CT, cohort	THC	Chronic pain, experimental pain	Ν	CL
O'Neil 2017 (<u>59</u>)	3 (2)	CT, cohort, CC	Plant-based cannabis, synthetic cannabis	PTSD, Tourette syndrome/tics, traumatic brain injury	U	Μ
Osborne 2017 (<u>48</u>)	8	C, cohort	CE, THC, CBD, THC- CBD	Cognition, Crohn's disease (pain), depression	Ps	CL
Stevens 2017 (<u>49</u>)	1	СТ	THC	Acute pain	U	CL
Wong 2017 (<u>50</u>)	13	CT, CRS, CRV, case series, case report	OCE, OCE (CBD enriched), THC, CBD	CINV, cognition, Crohn's disease (pain), depression, epilepsy	Ρ	CL
Fitzcharles 2016 (<u>51</u>)	1	СТ	PF-04457845		U	CL



Systematic	Number	Types of	Examined	Indications	Authors'	Level of
Review	Relevant	studies	formulations		conclusion	confidence
	Original studies					
	(Number					
	secondary SRs)					
Gruenbaum 2016 (<u>52</u>)	1	CR	Marijuana	Traumatic brain injury	Ρ	CL
Merlin 2016 (<u>53</u>)	1	СТ	Cannabis cigarettes	Neuropathic pain (HIV/AIDS)	U	CL
Tafelski 2016 (<u>60</u>)	1	СТ	THC	CINV	U	Н
Wilkinson 2016 (<u>54</u>)	9	CT, cohort, CRV, case reports	Cannabis (smoked), THC	Alzheimer's disease (agitation), anorexia nervosa, GAD	U	CL

Type of studies: CC: case-control; CRS: cross-sectional; CRV: chart review; CT: clinical trial

<u>Examined formulations:</u> Cannabinoids: unspecified cannabinoids; CBD: cannabidiol; CE: cannabis extract, FAAH: fatty acid amide hydrolase; MC: medical cannabis; OCE: oral cannabis extract; SCET: standardized cannabis extract with THC; SCT: standardized cannabis with THC, THC: Delta-9-tetrahydrocannabinol (THC)

<u>Indications:</u> ADHD: attention deficit hyperactivity disorder; ALS: amyotrophic lateral sclerosis; ASD: autism spectrum disorder; CINV: chemotherapy induced nausea and vomiting; IBD: inflammatory bowel disease; MS: multiple sclerosis; PTSD: posttraumatic stress disorder; SAD: social anxiety disorder;



Systematic	Number	Types of	Examined	Indications	Authors'	Level of
Review	Relevant	studies	formulations		conclusion	confidence
	Original studie	S				
	(Number					
	secondary SRs	5)				



WSIB-approved indications

Neuropathic pain

Neuropathic pain is a clinical state that results from an identifiable lesion or a disease of the somatosensory nervous system (<u>64</u>), which may be caused by certain abnormalities, trauma, or other underlying causes such as stroke or diabetes mellitus.

As per WSIB policy, cannabis can be prescribed for cases of neuropathic pain that are refractory to standard pharmaceutical and non-pharmacological treatments. An acceptable pharmaceutical treatment must involve a minimum of three first-line and/or second-line medications and a pharmaceutical cannabinoid (65).

Since 2016, ten systematic reviews reported on the effectiveness of medical cannabis preparations (cannabis sativa, medical marijuana, herbal cannabis, SCT and THC) for treatment of neuropathic pain in general (<u>18</u>, <u>21</u>, <u>31</u>, <u>37</u>, <u>40</u>, <u>47</u>, <u>57</u>, <u>61</u>), and in HIV/AIDS patients in particular (<u>53</u>). Additionally, one of these reviews reported on effective use of THC and FAAH hydrolase inhibitor for neuropathic pain and in cancer chemotherapy, respectively (<u>57</u>).

One review (53) reported that median pain was reduced twice as much (34% vs. 17%) in the cannabis group compared to the placebo group. A recent major RSR (61) reported a reduction in neuropathic pain (Odds ratio of 1.37, p-value <0.05) with cannabinoids (pharmaceutical and non-pharmaceutical formulations combined) that corresponded to attaining at least a 30% reduction in symptoms. Three other reviews reported no high-quality evidence to support use of any medical cannabis preparation for treatment of neuropathic pain.

Three recent clinical guidelines reported strong ($\underline{66}$), reasonable ($\underline{67}$), and consistent ($\underline{68}$) evidence for use of medical cannabis and cannabinoids for treating patients with neuropathic pain.

Spasticity due to spinal cord injury

Spinal cord injury is a serious condition with many disabling consequences, such



as neuropathic pain and spasticity, negatively impacting a person's entire lifestyle, activity, and employment. Spasticity involves an increase in muscle tone or stiffness of different body muscles due to factors including injury to the spinal cord. The spread and depth of spinal cord-associated spasticity depends on factors such as the degree, duration, and position of cord injury.

One systematic review reported moderate quality of evidence regarding the effectiveness of using cannabinoids in spasticity following spinal cord injuries (43). Current guidelines set by the College of Physicians and Surgeons of Alberta reported the evidence as reasonable for this indication should standard therapies fail (67); strength of evidence was reported as limited by Health Canada guidelines (68).

Chemotherapy-induced nausea and vomiting

Nausea and vomiting are common, serious, and onerous adverse reactions occurring in patients undergoing cancer therapy. Chemotherapy-induced nausea and vomiting (CINV) is categorized into acute, delayed, anticipatory, and breakthrough types (<u>69</u>). Despite the efficiency of the current modalities for treating most CINV cases, cannabinoids were investigated for treating refractory and breakthrough cases based on the potential for stimulating brain cannabinoid receptors with the resulting inhibition of emesis (<u>60</u>).

Three systematic reviews reported on the use of cannabinoids as THC for management of CINV. Whereas one (60) reported no effect of non-pharmaceutical cannabinoids, two other reviews (50, 61) reported success in preventing vomiting (open label trial) as well as reducing the episodes of nausea and vomiting (two double-blinded RCTs).

Whereas the published evidence, including Canadian (<u>68</u>) and German guidelines (<u>60</u>), does not sufficiently support using cannabis for treatment for CINV, the evidence was reported as being reasonable (<u>67</u>) by the College of Physicians and Surgeons of Alberta.



HIV/AIDS-associated anorexia

HIV/AIDS-associated anorexia is a state of loss of appetite leading to reduced energy intake that is exacerbated with increased resting energy loss. This state may be caused by many factors including HIV infection, a superimposed infection, or treatment of either one of them. Two systematic reviews examined the use of medical cannabis for treating this condition (<u>37</u>, <u>57</u>). Both reviews reported lack of sufficient evidence to support the use of cannabis. Similarly, guidelines by Health Canada (<u>68</u>) reported limited evidence for use of medical cannabis to treat HIV/AIDS-associated anorexia.

Palliative care

Palliative care refers to the collective strategy aiming at improving the quality of life for patients with life-threatening illnesses, including terminal cases of cancer and HIV/AIDS. Quality of life measures include reducing pain, improving appetite, and improving physical and emotional functioning.

Three systematic reviews reported the lack of adequate evidence for a benefit of using of medical cannabis/marijuana or cannabinoids in palliative care, particularly with cancer pain, anorexia, nausea, and vomiting (<u>13</u>, <u>31</u>, <u>37</u>, <u>57</u>). A 2019 review (<u>30</u>) reported that cannabinoids were effective in improving appetite in cancer patients while reducing their quality of life, which may reflect an adverse reaction to the prescribed cannabinoids. Alternatively, one review reported no significant differences in body weight, appetite, or physical, social, cognitive, and functioning with medical cannabis extract or cannabinoids (THC) (<u>32</u>).

Two clinical guidelines characterized the evidence as reasonable ($\underline{70}$) and with potential ($\underline{1}$), respectively, for prescribing medical cannabis or cannabinoids for palliative treatment of cancer-related symptoms.



Other indications

Non-cancer pain

This section identifies reviews and guidelines that discussed non-cancer types of pain; however, the non-cancer pain types included in these reviews may reflect various groupings, including chronic (nociceptive), neuropathic, acute, and post-operative pain. This group of pain conditions includes non-cancer types of pain such as chronic (nociceptive), neuropathic, acute, and post-operative pain. Eight reviews reported consistent (21, 31, 34, 35, 58), moderate (18, 43), or insufficient (47) quality of evidence for using medical cannabis and cannabinoids in treating chronic non-cancer pain (CNCP) when in comparison to placebo.

Three additional reviews (20, 40, 57) reported a limited level of evidence for effectiveness of cannabinoids in treating some types of CNCP such as musculoskeletal pain (fibromyalgia) and rheumatoid arthritis (57), with low quality evidence of improved sleep and patient global impression of change. Two reviews reported no effectiveness of cannabinoids: cannabidiol (CBD) for treating CNCP (28), or THC or AZD1940 for acute pain (49).

Recent clinical guidelines characterized the evidence as consistent/reasonable (<u>68</u>, <u>71</u>) for treating chronic pain of various etiologies, especially in cases where conventional treatments have failed. Evidence was reported as limited to moderate (<u>66</u>, <u>68</u>) though for using cannabis with headache, migraine and muscloskeletal pain types

Anxiety

Anxiety is an emotional state that is characterized by fear and tension, which may be caused by a number of factors and situations, and may be accompanied with physical symptoms such as sweating, hypertension, palpitations, and dizziness. Prolonged or disproportionate anxiety may be disabling and can lead to a range of disorders including social anxiety disorder (SAD) (72, 73). In SAD, anxiety in certain social situations may be significant enough to disturb a person's daily interactions with others (74). Enduring,



extreme, and uncontrollable stresses may lead to a more generalized form of anxiety (GAD), which would seriously interfere with a person's daily life and may be mistakenly confused with other types of anxiety, panic disorders, and obsessive-compulsive disorders (<u>75</u>)

Seven reviews reported on the use of medical cannabis/cannabinoids for treatment of patients with anxiety. Six reviews (<u>19</u>, <u>22</u>, <u>26-28</u>, <u>45</u>) reported positive results with CBD for treating patients with SAD, based on increasing positive responses and reduced anxiety, cognitive impairment, and discomfort. However, the results of these studies were inconclusive. Only one review reported no effect of medical cannabis (Cannabis sativa, CBD, THC and THC-CBD) for treatment of patients with anxiety disorders (<u>24</u>). Whereas the College of Physicians and Surgeons of Alberta (<u>70</u>) reported reasonable evidence for using medical cannabis/cannabinoids for treating anxiety, an earlier report by Health Canada (<u>68</u>) referred to this evidence as limited.

Post-traumatic stress disorder

Post-traumatic stress disorder (PTSD) is an anxiety disorder that impacts individuals upon being involved or having witnessed an extremely traumatic event, such as war, crime, or a natural disaster (72).

Eight systematic reviews reported on use of different formulations of medical cannabis (herbal cannabis, plant-based cannabis and cannabis resin), and cannabinoids (CBD, THC, CBD:THC). Despite the presence of positive results in some sporadic small-sized studies and case reports, the evidence was consistently reported by all of these reviews as being insufficient and of poor-quality for treating PTSD patients (<u>17</u>, <u>19</u>, <u>22</u>, <u>24</u>, <u>29</u>, <u>50</u>, <u>54</u>, <u>59</u>). Similarly, the latest guidelines by Health Canada and the Alberta Medical Association report the evidence for using medical cannabis and cannabinoids with PTSD patients as being limited (<u>68</u>) to mixed (<u>76</u>), respectively.



Epilepsy

Epilepsy is a neurological disease that results from disproportionate discharge of electrical impulses from the brain. This state is characterized by recurrent brief attacks of involuntary movement (seizures), which may be localized (partial) or involve the entire body (generalized). With wide variations in their frequency of occurrence, these seizures range from brief lapse of attention to prolonged and violent generalized convulsions, with the potential for associated loss of consciousness and control of bowel or bladder functions (<u>77</u>).

Five recent reviews reported positive and increasing evidence for effectiveness of CBD in reducing seizure frequency or severity in epileptic patients (<u>15</u>, <u>28</u>, <u>39</u>, <u>50</u>), and in treatment-resistant children and adolescents in particular (<u>16</u>, <u>39</u>). Health Canada's guidelines reported weak, yet emerging, evidence for anti-epileptiform and anti-convulsive properties with CBD, while having mixed pro- and anti-epileptiform and pro- and anti-convulsive effects with THC (<u>68</u>)

Schizophrenia

Schizophrenia is a serious mental illness starting in early adulthood and is characterized by incoherent or illogical thoughts, bizarre behavior and speech, and delusions or hallucinations (72).

Five reviews (<u>19</u>, <u>22</u>, <u>26</u>, <u>27</u>, <u>55</u>) reported promising evidence, though insufficient, with the use of CBD for patients with schizophrenia, except in treatment-resistant cases. Alternatively, one review reported no improvements in cognition or selective attention in schizophrenia patients (<u>28</u>). No Canadian guidelines were found in relation to use of cannabis-based formulations for treating patients with schizophrenia.

Other Psychotic disorders

This group comprised many disorders, such as bipolar disorder, schizoaffective disorders, postpartum psychosis that is characterized by false beliefs (delusions) and



false perceptions (hallucinations) that reflected loss of grasp on reality. These disorders may be caused by diseases such as HIV, tumors, epilepsy, stroke, Parkinson's disease, dementia, alcohol abuse, and as adverse medication reactions (<u>78</u>).

Six reviews reported a growing, though still limited, evidence of use of cannabisbased medicines for treatment of psychoses (25, 27, 28, 45, 55), or psychotic symptoms in other diseases such as Parkinson's disease (19). However, one review reported no evidence for effectiveness of any cannabinoid type for treatment of any psychotic symptoms (24). Guidelines by Health Canada (68) rated the evidence of using CBD for treating THC-induced psychosis as emerging.

Tourette Syndrome

Tourette syndrome (TS) is a neurological disorder characterized by uncontrollable, involuntary, and repetitive movements and sounds called tics. Tics often start in childhood, reaching their worst level in early teenage years and often improving in late teenage years and early adulthood (<u>79</u>).

Seven recent reviews reported positive, yet insufficient, evidence of low quality for using medical cannabis (54), THC (24, 45, 50, 54, 55), and CBD (19) for treating patients with TS, whereas one review (42) reported no evidence for use of THC with TS. Guidelines by Health Canada (68) rated the evidence of using THC for treating TS as limited.

Multiple Sclerosis

Multiple Sclerosis (MS) is an autoimmune disease of the nervous system involving a degradation of the myelin covering of the nerves. Such degradation leads to a wide range of symptoms resulting from impaired or failed transmission of the nerve impulses: for instance, impairment of cognitive and visual functions, bladder problems, lost skin sensation, muscle weakness, and emotional instability (<u>80</u>)

Six systematic reviews reported on the use of medical cannabis/cannabinoids in



treating different symptoms of MS. Four reviews reported sufficient, high-quality evidence for using medical cannabis (<u>18</u>) and cannabinoids (<u>31</u>, <u>41</u>, <u>56</u>, <u>61</u>) for treating MS pain and spasticity. However, a fifth review (<u>43</u>) reported the evidence as moderate with cannabinoids. Two reviews reported limited and inconsistent evidence for the effectiveness of using cannabinoids for treating gait symptoms (<u>33</u>) and bladder dysfunction (<u>41</u>) in MS patients.

Reasonable evidence was reported by the College of Physicians and Surgeons of Alberta, for using cannabinoids in relieving spasticity due to MS or spinal cord injury, particularly for cases that were refractory to standard therapies (67). However, this evidence was reported as limited by Health Canada for prescribing medical cannabis and cannabinoids with MS-related spasticity, pain, bladder dysfunction, depression, anxiety, and sleep disturbance (68).

Parkinson's disease

Parkinson's disease (PD) is a movement disorder characterized by inadvertent and uncontrollable movements resulting from the progressive loss of certain neurons in charge of producing dopamine; a chemical substance needed for formulating smooth, purposeful movements (<u>81</u>).

Three reviews reported mixed evidence for using CBD (<u>25</u>, <u>28</u>, <u>45</u>) and THC (<u>45</u>) to treat patients with Parkinson's disease. Health Canada guidelines (<u>68</u>) reported the evidence as mixed for using medical cannabis, cannabis extract (THC/CBD), and cannabinoids for treating PD patients.

Alzheimer's disease

Alzheimer's disease is an irreversible type of dementia disorder involving gradual memory loss and confusion, which may commonly be mistaken for a normal aging process. These initial symptoms later develop into many behavioral and personality changes, followed by progressive deterioration in other cognitive abilities due to a



progressive atrophy of brain tissue $(\underline{82})$.

Three reviews reported mixed evidence for the use of cannabinoids (THC) for treating symptoms of Alzheimer's disease, including agitation, mood, and sleeplessness (<u>45</u>, <u>54</u>, <u>55</u>). Health Canada guidelines (<u>68</u>) reported limited evidence for using medical cannabinoids (oral, THC) for treating Alzheimer's disease patients.



Current Canadian guidelines

Many Canadian regulatory and professional entities reported on the level of evidence for using medical cannabis or nonpharmaceutical cannabinoids for treatment of a variety of conditions. Evidence was 'strong' or 'reasonable' with neuropathic pain, and 'possible' or 'potential' with non-neuropathic pain and palliative care (cancer, HIV/AIDS). Evidence of use with other indications ranged between 'mixed', 'limited', 'inadequate', and 'none'. Table 3 provides a summary of the Canadian regulatory and professional guidelines, whereas additional scientific reviews with guideline suggestions are provided in Appendix 5.

Source	Agent	Indications	Level of
			evidence ¹
College of physicians	Medicinal cannabinoids	Pain (neuropathic, palliative conditions), CINV,	Reasonable
and surgeons of	(unspecified)	spasticity (MS, spinal cord injury)	
Alberta 2019 (<u>67</u>)		Prerequisite: cases unresponsive to standard therapy	
College of physicians	Cannabis	Cancer symptoms (pain, anorexia, insomnia, anxiety,	Reasonable
and surgeons of	Medicinal cannabinoids	nausea and vomiting)	
Alberta 2019a (<u>70</u>)	(unspecified)		
Canadian Pain Task	Cannabis	Pain (neuropathic)	Strong
Force 2019 (<u>66</u>)	Cannabis	Pain (musculoskeletal, fibromyalgia, headaches,	Moderate

Table 3: Canadian guidelines for prescribing medical cannabis and non-pharmaceutical cannabinoids

¹ As reported by the Canadian guidelines

20 January 2021



Source	Agent	Indications	Level of evidence ¹
		cancer, MS, arthritis)	
Health Canada 2018 (<u>68</u>)	cannabis and prescription cannabinoids	Quality of life for a variety of different disorders.	Mixed
	Cannabis and certain cannabinoids	CINV	Limited
	Cannabis	HIV/AIDS (wasting syndrome, anorexia), cancer, anorexia nervosa	Limited
	Cannabis	MS and spinal cord injury and disease (including spasticity, spasms, pain, sleep and symptoms of bladder dysfunction)	Limited
	Cannabinoids (THC/CBD)	MS and spinal cord injury and disease (including spasticity, spasms, pain, sleep and symptoms of bladder dysfunction)	Unreported
	Certain cannabinoids	ALS	Mixed
	Cannabis (THC- and CBD- predominant strains)	Epilepsy	Weak
	CBD (in herbal and oil	Epilepsy (seizure frequency, quality of life) among	Unreported



Source	Agent	Indications	Level of evidence ¹
	preparations)	adolescents with rare and serious forms of drug-	
		resistant epilepsy	
	Cannabis (smoked)	Pain (acute, experimentally-induced)	Limited/
	Cannabis (extract),		mixed
	Cannabinoids (oral THC)		
	Cannabis and	Pain (neuropathic, chronic non-cancer), especially in	Consistent
	Cannabinoids (smoked,	cases unresponsive to standard treatments	
	vaporized)		
	Cannabinoids (THC)	"Opioid-sparing" effects and cannabinoid-opioid	Mixed
		synergy	
	Cannabis/ cannabinoids	Pain (headache, migraine)	Limited/
	(unspecified)		mixed
	Cannabis (inhaled)	Dystonia	Positive
	CBD (oral)		
	THC (oral)	Dystonia	Mixed
	Cannabis (smoked)	Huntington's disease	Limited
	Cannabis (smoked)	Parkinson's disease	Mixed



Source	Agent	Indications	Level of evidence ¹
	Cannabis extract		
	(THC/CBD)		
	Cannabinoids (unspecified)	Parkinson's disease	Mixed
	THC (oral)	Tourette's syndrome (tics).	Limited
	Cannabis (THC,	Asthma	Mixed
	aerosolized)	Warning: inhaling cannabis smoke/vape may irritate	
		the lung and worsen asthmatic symptoms	
	Cannabis (THC, CBD/THC)	Anxiety and depression (e.g. patients with HIV/AIDS,	Limited
	Cannabinoids (unspecified)	MS, and chronic neuropathic pain).	
	Cannabis	Sleep disorders (low doses)	Limited
	THC		
	Cannabinoids (THC, oral)	PTSD	Limited
	CBD	THC-induced psychosis	Emerging
	Cannabinoids (THC, oral)	Alzheimer's disease and dementia	Limited
	Cannabinoids (THC, CBD,	Inflammatory skin diseases (dermatitis, psoriasis,	Mixed

Review on Use of Cannabis for Medical Purposes



Source	Agent	Indications	Level of evidence ¹
	HU210)	pruritus)	
	Cannabis (smoked)	Inflammatory bowel diseases (Crohn's disease, ulcerative colitis)	Limited
	THC	Metabolic syndrome, obesity, diabetes	Limited
	Cannabis	Cancer-associated (chemosensory alterations, weight loss, depression, pain)	Limited
Alberta Medical Association 2018 (<u>76</u>)	Medical marijuana	PTSD	Mixed
BC Cancer, British Columbia 2018 (<u>1</u>)	Cannabis	Cancer-related symptoms (including nausea, anorexia, pain and peripheral neuropathy)	Potential
Canadian Rheumatology Association 2018 (<u>83</u>)	Medical cannabis	Rheumatic diseases (pain relief, sleep promotion) <u>Prerequisite:</u> cases unresponsive to standard treatment strategies	Limited
Arthritis Society 2018 (<u>71</u>)	Cannabis	Pain (chronic), other arthritis symptoms	Potential alternative



Summary of evidence for effectiveness of medical cannabis

A summary of the published evidence on the effectiveness of different cannabis-based formulations for treatment of different indications, is provided in Table 4, including additional indications with scarce published evidence that were not detailed in this current review.

Indication	Formulation	Evidence	Study(s)
Neuropathic pain	Cannabis sativa, medical	Consistent	(<u>18, 21, 37, 40, 47</u> ,
	marijuana, herbal cannabis,		<u>53, 57, 61, 65-68</u>)
	standardized dried cannabis,		
	SCT, THC		
Spasticity (Spinal	Cannabinoids	Insufficient	(<u>43, 67</u>)
cord injury)			
CINV	Cannabinoids	Inconsistent	(<u>50, 60, 61, 67, 68</u>)
Anorexia	Medical cannabis	Limited	(<u>37, 57, 68</u>)
(HIV/AIDS)			
Palliative care	Medical cannabis,	Reasonable	(<u>1</u> , <u>70</u>)
	cannabinoids		
Chronic non-	Medical cannabis,	Consistent	(<u>18, 21, 31, 34, 35,</u>
cancer pain	cannabinoids		<u>43, 58, 68, 71</u>)
(CNCP) ²			
Anxiety	Medical cannabis,	Inconclusive	(<u>19, 22, 26-28, 45,</u>
	cannabinoids		<u>68</u>)
PTSD	Medical cannabis (herbal	Insufficient	(<u>17, 19, 22, 24, 29,</u>
	cannabis, plant-based		<u>50, 54, 59, 68, 76</u>)

Table 4: Summary of evidence for use of cannabis-based medicines

² CNCP: may also include neuropathic pain



Indication	Formulation	Evidence	Study(s)	
	cannabis and cannabis			
	resin), and cannabinoids			
	(CBD, THC, CBD:THC).			
Epilepsy	CBD	Insufficient	(<u>15, 16, 28, 39, 50</u> ,	
		(emerging)	<u>68</u>)	
Schizophrenia	CBD	Insufficient	(<u>19, 22, 26-28, 55</u>)	
		(promising)		
Other psychotic	Cannabis-based medicines	Insufficient	(<u>19, 24, 25, 27, 28,</u>	
disorders		(emerging)	<u>45, 55, 68</u>)	
Tourette syndrome	THC	Insufficient	(<u>19, 24, 42, 45, 50,</u>	
			<u>54, 55, 68</u>)	
MS	Medical cannabis,	Inconsistent	(<u>18</u> , <u>33</u> , <u>41</u> , <u>43</u> , <u>56</u> ,	
	cannabinoids		<u>61, 67, 68</u>)	
Parkinson's	Medical cannabis, cannabis	Inconsistent	(<u>25, 28, 45, 68</u>)	
disease	extract (THC/CBD),			
	cannabinoids (CBD, THC)			
Alzheimer's	Medical cannabinoids (oral,	Inconsistent	(<u>45</u> , <u>54</u> , <u>55</u> , <u>68</u>)	
disease	THC)			
Other indications ³				
Neurocognitive diseases/disorders				
ALS	cannabinoids	No evidence	(<u>45</u>)	
ASD	CBD	Emerging	(<u>19</u> , <u>25</u> , <u>26</u>)	

³ Indications with scarce evidence that are not discussed in detailes in this report



Indication	Formulation	Evidence	Study(s)
ADHD	CBD	Potential	(<u>22</u>)
	Cannabinoids	Scarce	(<u>24</u>)
Depression	CBD	Promising	(<u>26</u>)
	Cannabinoids	Scarce	(<u>24</u>)
Dementia	Cannabinoids	No benefit	(<u>57</u>)
	ТНС	Insufficient (agitation)	(<u>45</u>)
Insomnia	CBD	Reduce insomnia	(<u>19</u> , <u>22</u>)
Movement disord	lers		
Dystonia	cannabinoids	No evidence	(<u>45</u>)
Huntington's	CBD	Positive	(<u>28</u>)
disease	THC	Inadequate	(<u>45</u>)
Other diseases			
Diabetes Mellitus	CBD	No significant change	(<u>28</u>)
Crohn's disease	CBD	Inadequate	(<u>28</u> , <u>57</u>)
Ulcerative colitis	Medical marijuana	No evidence	(<u>57</u>)
Fatty liver disease	CBD	No significant change	(<u>28</u>)
Anorexia	Cannabinoids	No benefit	(<u>57</u>)



Indication	Formulation	Evidence	Study(s)
Graft vs host	CBD	Effective	(<u>28</u>)
disease			

Safety

Reporting on adverse events associated with the different cannabis formulations was not consistently performed by the included reviews. Approximately half (47%) of reviews did not report clearly on adverse events associated with medical cannabis or non-pharmaceutical cannabinoids, whereas some reported on such information for the entire range of formulations without specifics.

Of the adverse events reported by the included reviews (see Figure 3), dizziness, cognitive disturbances, euphoria/dysphoria, fatigue, and somnolence were the most commonly reported. All individual cases of adverse events were grouped under the miscellaneous category. More details on these adverse events are provided in Appendix 6.

There is not enough evidence to conclude any difference in safety between the different cannabis or cannabinoid formulations, either in general or in relation to specific diseases and/or specific populations.




Figure 3: Frequency of adverse events examined in the included reviews





Discussion

Cannabis has been a well-known illicit drug popularly used on a global scale for many years due to its psychoactive properties. In the past few decades, a sharp rise in public and professional interest has placed a focus on new uses of cannabis and its different components and formulations for treatment of medical diseases and conditions, particularly those that are refractory to standard or traditional therapies. These interests were further heightened by the legalization of cannabis use in many countries, including Canada, which passed the Cannabis Act in the fall of 2018.

A few cannabis-based medications, collectively referred to as pharmaceutical cannabinoids, have already been prescribed by doctors in many countries, including Canada, for years. The success of these medications and increase in public pressure on physicians fueled more interest in investigating the effectiveness and safety of other cannabis-based medications, currently referred to as non-pharmaceutical cannabinoids, for treatment of other diseases and conditions.

This systematic review summarizes the published, peer-reviewed evidence, as well as regulatory and professional positions, on the use of non-pharmaceutical cannabis-based medicines to inform decision-making on their use for treatment of conditions.

As the current review focused on synthesizing the evidence generated by recently published systematic reviews, the evidence synthesis was subsequently limited by the type, breadth, and depth of information provided in these systematic reviews. Reporting in these reviews was inconsistent regarding the types, composition, doses, routes of administration, and frequency and duration of treatment with cannabis-based formulations, as well as on the methods of assessment of effectiveness in treating the different indications.

Systematic reviews included in this current review reflected a wide range of objectives that did not necessarily match those of the current review, leading to omission of valuable information. For example, the objective of the 'core' review by Ishak et al 2018 (35) was to report on the impact of current treatments, including medical cannabis, on HIV-associated pain and depression (HIV-associated). The authors reported on effectiveness of cannabis only in relation to these two comorbidities, whereas the individual studies included in the



Ishak et al. review (such as Woolridge et al. 2005 (<u>84</u>)) reported on additional HIV-associated indications such as anorexia, nausea, anxiety, neuropathy, tingling, numbness, weight loss, headache, tremor, diarrhea, constipation, tiredness, memory loss, slurred speech, and visual defects.

One of the major limitations of this review involved lack of consensus among included systematic reviews on the definition and composition of the examined cannabis-based formulations. Whereas original studies may have been more explicit in profiling the examined formulations, the systematic reviews used different definitions or categorizations for describing the examined formulations. One possible explanation in any given review is that lack of detail resulted from an attempt to pool results and generate meaningful conclusions. Moreover, one formulation examined in one study might be reported differently across two or more systematic reviews that report on this original study. A few reviews generated additional confusion through using the term pharmaceutical grade cannabinoids to describe non-pharmaceutical cannabinoids, with no details on their chemical composition.

Many of the systematic reviews reported on cannabis and cannabinoid formulations without any specification, resulting in limited extrapolation of those results to formulations. The majority of the studies described used pure presentations of CBD or formulations with known concentrations of CBD and THC and, hence, their results cannot be extended to non-purified forms, extracts, or smoked cannabis.

Most of the systematic reviews reflected a high level of heterogeneity in the designs of included studies, patient populations, interventions, comparisons, and outcome assessment, which made the pooling and usability of their information difficult. This also manifested itself in the absence of valuable information on the examined cannabis formulations such as, for instance, the chemical composition, doses, frequency and routes of administration, and treatment duration, all of which collectively have many pharmacokinetic and pharmacodynamic implications on the assessment of suitability of a specific formulation and for a specific indication. For example, pooling different cannabis formulations (such as plant-based with synthetic or with pharmaceutical or with non-pharmaceutical cannabinoids) may undermine, mask, or amplify the effects of one of them in favour of the other. For a proper assessment of safety of a specific formulation, evidence must be synthesized based on



specific chemical composition (e.g., CBD-THC: 1-1 is different from 1-9), route of administration (inhaled route may not be suitable for those with respiratory conditions like asthma), and dosing protocol (frequency of administration, duration of treatment) which may require some adjustments for people with certain comorbidities.

Another commonly encountered issue involved the inconsistent use of and reporting on outcome measures such as change in symptom severity, frequency, remission, hospitalization, and patient or care person's subjective versus objective perception of improvement – consistently defined outcome measures would be informative in any assessment of the efficacy of uses of medical cannabis.

Reporting on the risk of bias by many of the included 'core' reviews was insufficient, inconsistent, inappropriate, or not reported, with the resulting reduction in the level of confidence in their reported evidence (80% of 'core' reviews ranked as low or critically low). Whereas the current review used the most robust tool for assessing the risk of bias and overall quality of evidence with 'core' reviews (AMSTAR2 (9)), this tool was not flexible for use with RSR. A decision was made to apply a different review tool that could be applied for use with RSRs. (Health Evidence (10-12)). These two tools have similar domains but are not calibrated to each, as they involve different scoring and different items for scoring. Using two tools within one review may have introduced inconsistencies on the quality assessment in any synthesis of evidence across studies, especially when judging a pool of reviews (Core and RSR together) for the overall strength of evidence.

This review helped to identify formulations with promising evidence, as well as disease indications in high demand for new treatment modalities, such as multiple sclerosis and different chronic pain conditions.



Appendices

Appendix 1. Search methodology, terms and output

Strategy

Search Question	Efficacy and safety of use of medical cannabis and non- pharmaceutical cannabinoids?		
Major	1. Medical cannabis		
Concepts	2. Indications		
Search	Concept 1	Concept 2	
Terms	Cannabis, medical marijuana, cannabinoids	Pain, neuropsychiatric disorders, movement disorders, chemotherapy-associated side effects, palliative care	

Output

Searched databases	Results	Level of selection
Medline	2,324	
EMBASE	8,020	-
PubMed	2,883	Cannabis + all outcomes
Total - all reference types	13,229	-
Total - all reference types - no duplicates	9,444	-
Total - reviews only - no duplicates	3,424	All years
Final - reviews only (2016-2020)	468	2016 – 2020



Concept	#	Medline query	Results
	1	exp Cannabis/	8,936
	2	cannabis.tw.	16,256
	3	(medic* adj3 cannabis).tw.	1,328
	4	exp Medical Marijuana/	1,118
	5	(med* adj3 marijuana).tw.	1,219
	6	or/1-5	22,111
	7	exp Pain/	389,613
	8	(neuropath* adj3 pain*).tw.	22,592
	9	exp Pain Management/	32,928
	10	(pain* adj3 manag*).tw.	35,125
	11	exp Chronic Pain/	13,735
	12	(chronic* adj3 pain*).tw.	63,051
	13	exp Cancer Pain/	1,160
	14	(cancer* adj3 pain*).tw.	11,321
	15	exp Pain, Intractable/	6,166
	16	(intractable adj3 pain*).tw.	3,955
	17	exp Pain, Postoperative/	40,244
	18	(postoperative adj3 pain*).tw.	28,712
	19	exp Pain, Referred/	340
	20	(referr* adj3 pain*).tw.	3,612

Medline Ovid ⁴

⁴ MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present



Concept	#	Medline query	Results
	21	exp Breakthrough Pain/	302
	22	breakthrough pain*.tw.	941
	23	exp Neuralgia/	20,045
	24	neuralgi*.tw.	13,290
	25	exp Causalgia/	675
	26	causalgi*.tw.	588
	27	exp neuralgia, postherpetic/	1,052
	28	(postherpetic adj3 neuralgi*).tw.	1,990
	29	exp Piriformis Muscle Syndrome/	129
	30	piriformis muscle syndrome.tw.	49
	31	bilateral neuralgia*.tw.	7
	32	exp Nociceptive Pain/	1,316
	33	(nocicep adj3 pain*).tw.	1
	34	exp Headache Disorders/	33,890
	35	headache disorder*.tw.	2,652
	36	exp Headache/	27,417
	37	exp Tension-Type Headache/	1,965
	38	tension-type headache*.tw.	2,946
	39	exp Cluster Headache/	2,590
	40	cluster headache*.tw.	3,045
	41	Paroxysmal Hemicrania/	108
	42	(paroxysmal adj3 hemicrania*).tw.	420



Concept	#	Medline query	Results
	43	SUNCT Syndrome/	148
	44	SUNCT syndrome.tw.	175
	45	Trigeminal Autonomic Cephalalgias/	195
	46	cephalalgia*.tw.	681
	47	cephalodynia*.tw.	1
	48	hemicrania.tw.	868
	49	headache*.tw.	81,962
	50	Migraine Disorders/	24,888
	51	Ophthalmoplegic Migraine/	54
	52	migraine*.tw.	33,961
	53	exp Earache/	764
	54	earache*.tw.	440
	55	(ear* adj3 pain*).tw.	5,309
	56	exp Eye Pain/	641
	57	(eye adj3 pain*).tw.	1,890
	58	exp Facial Neuralgia/	10,005
	59	(fac* adj3 neuralgi*).tw.	652
	60	exp Facial Pain/	8,974
	61	(fac* adj3 pain*).tw.	14,418
	62	exp Trigeminal Neuralgia/	6,705
	63	(trigeminal adj3 neuralgi*).tw.	6,092
	64	exp Trigeminal Nerve Injuries/	1,692



Concept #	<i>‡</i>	Medline query	Results
6	65	(trigeminal adj3 injur*).tw.	296
6	66	(trigeminal adj3 pain*).tw.	1,348
6	67	exp Glossalgia/	286
6	68	exp Neck Pain/	6,864
6	69	(neck adj3 pain*).tw.	12,150
7	70	exp Shoulder Pain/	4,724
7	71	(shoulder* adj3 pain*).tw.	9,393
7	72	exp Back Pain/	38,363
7	73	(back adj3 pain*).tw.	48,487
7	74	exp Low Back Pain/	21,419
7	75	low back pain*.tw.	26,324
7	76	exp Failed Back Surgery Syndrome/	314
7	77	failed back surgery syndrome.tw.	730
7	78	exp Flank Pain/	613
7	79	(flank* adj3 pain).tw.	3,634
8	30	exp Mastodynia/	165
8	31	mastodynia*.tw.	203
8	32	(breast* adj3 pain*).tw.	2,148
8	33	exp Pelvic Girdle Pain/	133
8	34	exp Pudendal Neuralgia/	91
8	35	(pudendal adj3 neuralgi*).tw.	128
8	36	exp Sciatica/	4,968



Concept	#	Medline query	Results
	87	(sciatic* adj3 neuralgia*).tw.	86
	88	(sciatic* adj3 pain*).tw.	1,908
	89	exp Morton Neuroma/	50
	90	morton neuroma*.tw.	70
	91	exp Metatarsalgia/	312
	92	metatarsalgia*.tw.	711
	93	exp Musculoskeletal Pain/	4,843
	94	(musculoskeletal adj3 pain*).tw.	6,951
	95	exp Myalgia/	1,627
	96	myalgi*.tw.	9,417
	97	exp Myofascial Pain Syndromes/	6,454
	98	(myofascial adj3 pain*).tw.	2,248
	99	exp Arthralgia/	12,849
	100	arthralgi*.tw.	8,192
	101	exp Mastodynia/	165
	102	mastodynia*.tw.	203
	103	Palliative Medicine/	335
	104	Palliative Care/	53,082
	105	"Hospice and Palliative Care Nursing"/	800
	106	Terminal Care/	27,663
	107	(terminal* adj3 car*).tw.	31,426
	108	palliative.tw.	60,617



Concept #	-	Medline query	Results
10	09	hospice.tw.	11,385
1	10	exp Dystonia/	9,574
1	11	Dystonic Disorders/	2,599
1	12	(general* adj3 dystonia*).tw.	1,012
1	13	(focal adj3 dystonia*).tw.	1,646
1	14	(multi* adj3 dystonia*).tw.	136
1	15	(adult* adj3 dystonia*).tw.	319
1	16	(segment* adj3 dystonia*).tw.	336
1	17	hemidystonia*.tw.	195
1	18	(secondary adj3 dystonia*).tw.	454
1	19	writer* cramp*.tw.	569
12	20	exp Meige Syndrome/	293
1:	21	meige syndrome.tw.	144
12	22	Torticollis/	3,539
1:	23	torticollis.tw.	3,187
1:	24	cervical dystonia*.tw.	1,516
1:	25	intermittent torticollis.tw.	5
1:	26	spasmodic torticollis.tw.	799
1:	27	wryneck.tw.	27
1:	28	exp Spasm/	9,695
1:	29	exp Hemifacial Spasm/	1,134
1:	30	spasm*.tw.	26,963



Concept	#	Medline query	Results
	131	(Fac* adj3 spasm*).tw.	636
	132	hemifacial spasm*.tw.	2,004
	133	hemifacial myokymia*.tw.	3
	134	exp Blepharospasm/	1,301
	135	blepharospasm*.tw.	1,825
	136	exp Trismus/	1,620
	137	trismus.tw.	2,212
	138	exp Muscle Spasticity/	9,014
	139	(muscle* adj3 spas*).tw.	3,761
	140	clasp knife spasticity.tw.	-
	141	clasp-knife spasticity.tw.	-
	142	muscle spasticity.tw.	421
	143	(limb* adj3 spasticit*).tw.	939
	144	spastic*.tw.	25,133
	145	vomiting/	23,201
	146	nausea/	15,787
	147	emesis.tw.	6,565
	148	emetic.tw.	3,644
	149	Antiemetics/	8,959
	150	Anorexia/	4,919
	151	anorexia.tw.	28,956
	152	(loss adj3 appetite).tw.	4,430



Concept	#	Medline query	Results
	153	(chemotherapy adj3 nausea).tw.	2,129
	154	(chemotherapy adj3 vomiting).tw.	570
	155	(chemotherapy adj3 emesis).tw.	529
	156	Acquired Immunodeficiency Syndrome/	76,090
	157	HIV/	19,560
	158	Acquired Immunodeficiency Syndrome/	76,090
	159	exp Multiple Sclerosis/	57,692
	160	multiple sclerosis.tw.	72,718
	161	exp Amyotrophic Lateral Sclerosis/	18,418
	162	amyotrophic lateral sclerosis.tw.	22,400
	163	Parkinson Disease/	65,020
	164	parkinson* disease.tw.	89,211
	165	Tourette Syndrome/	4,262
	166	tourette* syndrome.tw.	4,555
	167	Spinal Cord Injuries/	37,032
	168	spinal cord injury*.tw.	33,460
	169	spinal cord laceration*.tw.	3
	170	spinal cord transection*.tw.	1,449
	171	spinal cord contusion*.tw.	658
	172	spinal cord trauma*.tw.	915
	173	traumatic mylopath*.tw.	-
	174	post-traumatic mylopath*.tw.	-



Concept	#	Medline query	Results
	175	post traumatic mylopath*.tw.	-
	176	Traumatic Brain Injury/	5,659
	177	traumatic brain injur*.tw.	35,096
	178	exp Dementia/	162,149
	179	dementia*.tw.	105,986
	180	exp Epilepsy/	109,698
	181	epilep*.tw.	133,571
	182	Irritable Bowel Syndrome/	7,102
	183	irritable bowel.tw.	12,923
	184	Neurogenic Bowel/	130
	185	(neurogenic adj3 bowel).tw.	346
	186	exp Stress Disorders, Post-Traumatic/	31,776
	187	posttraumatic stress disorder*.tw.	18,025
	188	post traumatic stress disorder*.tw.	10,888
	189	post-traumatic stress disorder*.tw.	10,888
	190	posttraumatic neuros*.tw.	11
	191	post traumatic neuros*.tw.	39
	192	post-traumatic neuros*.tw.	39
	193	Combat Disorders/	3,092
	194	(combat* adj3 disorder*).tw.	407
	195	(moral adj3 injur*).tw.	163
	196	Anxiety/	78,840



Concept	#	Medline query	Results
	197	Anxiety Disorders/	33,093
	198	anxiet*.tw.	185,021
	199	(anxiet* adj3 order*).tw.	285
	200	hypervigilance.tw.	692
	201	nervousness.tw.	1,599
	202	Anti-Anxiety Agents/	18,503
	203	(anxiety adj3 agent*).tw.	252
	204	(anxiety adj3 drug*).tw.	1,266
	205	(anxiety adj3 medica*).tw.	1,330
	206	exp Depression/	115,709
	207	(depress* adj3 agent*).tw.	866
	208	(depress* adj3 drug*).tw.	4,582
	209	(depress* adj3 medica*).tw.	4,696
	210	exp Sleep Wake Disorders/	87,501
	211	sleep wake disorder*.tw.	287
	212	(sleep adj3 disorder*).tw.	24,148
	213	(sleep adj3 syndrome*).tw.	11,759
	214	Dyssomnias/	390
	215	dyssomnia*.tw.	103
	216	Parasomnias/	492
	217	parasomnia*.tw.	1,190
	218	"Sleep Initiation and Maintenance Disorders"/	12,759



Concept	#	Medline query	Results
	219	insomnia*.tw.	20,388
	220	sleep disorder*.tw.	18,621
	221	exp Schizophrenia/	103,385
	222	schizophreni*.tw.	120,701
	223	exp Psychotic Disorders/	51,428
	224	(Psycho* adj3 disorder*).tw.	26,400
	225	psychos*.tw.	155,460
	226	psychotic.tw.	32,716
	227	(schizoaffective adj3 disorder*).tw.	4,762
	228	(schizophreniform adj3 disorder*).tw.	637
	229	(reactive adj3 psychos*).tw.	288
	230	or/7-229	2,165,706
cannabis + ALL	231	6 and 230	6,293
	232	limit 231 to yr="2016 - 2020"	2,342
reviews only (all	233	limit 232 to (meta analysis or "systematic review" or	557
outcomes)		systematic reviews as topic)	
cannabis + pain	234	or/7-109	722,771
	235	6 and 234	1,255
	236	limit 235 to yr="2016 - 2020"	603
cannabis +	237	or/110-144	71,503
movement dis.	238	6 and 237	316
	239	limit 238 to yr="2016 - 2020"	115

Concept	#	Medline query	Results
cannabis +	240	or/145-155	72,910
nausea / vomiting	241	6 and 240	527
vorniting	242	limit 241 to yr="2016 - 2020"	194
cannabis +	243	or/156-229	1,398,686
neuropsychiatric / immunology	244	6 and 243	5,190
	245	limit 244 to yr="2016 - 2020"	1,853



EMBASE 5

Concept	#	Embase query	Results
	1	exp Cannabis/	36,262
	2	cannabis.tw.	23,223
	3	bhang.tw.	58
	4	cannador.tw.	44
	5	charas.tw.	42
	6	ganja.tw.	93
	7	ganjah.tw.	-
	8	hashish.tw.	904
	9	marihuana.tw.	1,637
	10	marijuana.tw.	16,656
	11	(hemp adj3 extract*).tw.	57
	12	exp medical cannabis/	2,102
	13	(medic* adj3 cannab*).tw.	2,267
	14	(medic* adj3 marihuana).tw.	53
	15	(medic* adj3 marijuana).tw.	1,546
	16	or/1-15	51,456
	17	exp pain/	1,360,076
	18	exp chronic pain/	59,895
	19	(intractable adj3 pain*).tw.	6,267
	20	exp neuropathic pain/	31,950

⁵ Embase: Excerpta Medica Database Guide



Concept	#	Embase query	Results
	21	(neuropathic adj3 pain*).tw.	30,566
	22	exp pain clinic/	3,519
	23	(pain* adj3 clinic*).tw.	25,107
	24	(pain* adj3 managment*).tw.	38
	25	exp cancer pain/	20,430
	26	(cancer* adj3 pain*).tw.	19,173
	27	(malignan* adj3 pain*).tw.	2,124
	28	exp postoperative pain/	66,823
	29	postoperative pain*.tw.	34,689
	30	post operative pain*.tw.	6,353
	31	exp referred pain/	1,170
	32	(referr* adj3 pain*).tw.	6,048
	33	exp breakthrough pain/	1,515
	34	(breakthrough adj3 pain*).tw.	2,118
	35	exp neuralgia/	112,071
	36	neuralgi*.tw.	19,685
	37	postherpetic neuralgia/	5,642
	38	exp trigeminus neuralgia/	11,987
	39	(trigem* adj3 neuralgi*).tw.	8,569
	40	(trigem* adj3 pain*).tw.	2,112
	41	hypoglossal neuralgia/	2
	42	glossopharyngeal neuralgia/	666



Concept	#	Embase query	Results
	43	cervicobrachial neuralgia/	3,767
	44	pudendal neuralgia/	232
	45	burning feet syndrome/	103
	46	(burning adj3 feet).tw.	235
	47	carpal tunnel syndrome/	15,519
	48	carpal tunnel syndrome.tw.	10,796
	49	cauda equina syndrome/	2,612
	50	cauda equina syndrome.tw.	1,995
	51	complex regional pain syndrome/	4,340
	52	(regional adj3 pain*).tw.	6,816
	53	cubital tunnel syndrome/	2,599
	54	cubital tunnel syndrome.tw.	792
	55	metatarsalgia/	1,334
	56	metatarsalgi*.tw.	1,059
	57	morton neuroma*.tw.	92
	58	radicular pain/	4,204
	59	(radicular adj3 pain*).tw.	4,629
	60	sciatica/	2,076
	61	(sciatic* adj3 pain*).tw.	2,902
	62	(sciatic* adj3 neuralgi*).tw.	180
	63	sunct syndrome/	516
	64	tarsal tunnel syndrome/	1,138



Concept	#	Embase query	Results
	65	bilateral neuralgia.tw.	17
	66	nociceptive pain/	1,568
	67	exp complex regional pain syndrome type II/	383
	68	causalg*.tw.	996
	69	exp headache/	220,866
	70	exp "headache and facial pain"/	313,038
	71	(headache* adj3 disorder*).tw.	6,241
	72	cephalgi*.tw.	655
	73	cephalodynia*.tw.	2
	74	hemicrania*.tw.	1,513
	75	headache*.tw.	139,266
	76	exp migraine/	65,704
	77	migraine*.tw.	54,448
	78	exp otalgia/	5,275
	79	(ear* adj3 ache*).tw.	237
	80	(ear* adj3 pain*).tw.	8,445
	81	(ear* adj3 neuralgi*).tw.	58
	82	(otic adj3 neuralgia*).tw.	1
	83	exp eye pain/	9,047
	84	(eye* adj3 pain*).tw.	3,827
	85	occular pain*.tw.	1
	86	exp face pain/	10,946



Concept	#	Embase query	Results
	87	(fac* adj3 pain*).tw.	20,747
	88	exp glossodynia/	566
	89	glossodyni*.tw.	231
	90	glossalgi*.tw.	78
	91	exp neck pain/	23,239
	92	(neck adj3 pain*).tw.	17,529
	93	musculoskeletal pain/	10,752
	94	(musculoskeletal adj3 pain*).tw.	10,258
	95	exp shoulder pain/	16,172
	96	(shoulder* adj3 pain*).tw.	13,203
	97	exp backache/	110,583
	98	backache*.tw.	3,545
	99	(back adj3 ache*).tw.	323
	100	backpain*.tw.	257
	101	(back adj3 pain*).tw.	70,897
	102	dorsalgi*.tw.	172
	103	discogenic pain/	642
	104	(discogenic adj3 pain*).tw.	1,318
	105	failed back surgery syndrome/	1,682
	106	failed back surgery syndrome.tw.	1,299
	107	exp low back pain/	58,308
	108	low* back pain*.tw.	39,291



Concept	#	Embase query	Results
	109	low* backpain*.tw.	50
	110	lowback pain*.tw.	145
	111	low* backache*.tw.	364
	112	chronic low* back pain*.tw.	8,831
	113	(loin* adj3 pain*).tw.	1,039
	114	(lumba* adj3 pain*).tw.	6,979
	115	lumba* syndrome.tw.	134
	116	lumbalgesia*.tw.	1
	117	lumbalgia*.tw.	389
	118	lumba* spine syndrome.tw.	15
	119	lumbodynia*.tw.	47
	120	lumbago*.tw.	2,132
	121	(lumbosacral adj3 pain*).tw.	896
	122	lumbosacral root syndrome.tw.	3
	123	(lumbosacroiliac adj3 strain*).tw.	-
	124	myalgi*.tw.	15,799
	125	exp arthralgia/	60,689
	126	arthralgi*.tw.	15,758
	127	(joint* adj3 pain*).tw.	22,188
	128	arthrodynia*.tw.	17
	129	exp myofascial pain/	7,937
	130	(myofascial adj3 pain*).tw.	3,101



Concept #	ŧ	Embase query	Results
1	31	exp palliative therapy/	112,409
1	32	palliative.tw.	100,947
1	33	exp hospice care/	10,119
1	34	hospice.tw.	18,376
1	35	exp terminal care/	68,487
1	36	(terminal adj3 car*).tw.	32,527
1	37	(symptomatic adj3 treatment*).tw.	28,048
1	38	exp dystonia/	23,959
1	39	dystonia*.tw.	22,869
1	40	exp generalized dystonia/	1,029
1	41	exp dystonic disorder/	11,380
1	42	(dystoni* adj3 disorder*).tw.	1,217
1	43	exp focal dystonia/	8,175
1	44	(focal adj3 dystonia*).tw.	2,620
1	45	exp cervical dystonia/	3,119
1	46	(cerviacal adj3 dystonia*).tw.	-
1	47	anterocollis.tw.	125
1	48	laterocollis.tw.	144
1	49	retrocollis.tw.	213
1	50	(spasmodic adj3 torticollis).tw.	1,234
1	51	exp oromandibular dystonia/	461
1	52	exp blepharospasm/	3,712



Concept	#	Embase query	Results
	153	blepharospasm*.tw.	2,692
	154	exp focal hand dystonia/	915
	155	exp Meige syndrome/	251
	156	meige* syndrome.tw.	374
	157	exp oromandibular dystonia/	461
	158	exp spasmodic dysphonia/	674
	159	exp multifocal dystonia/	75
	160	exp musician's dystonia/	207
	161	(musician* adj3 cramp*).tw.	74
	162	writer's cramp/	498
	163	(writer* adj3 cramp*).tw.	892
	164	exp myoclonus dystonia/	435
	165	exp paroxysmal dystonia/	178
	166	exp segmental dystonia/	401
	167	exp torsion dystonia/	1,236
	168	(torsion* adj3 spasm*).tw.	99
	169	exp torticollis/	5,249
	170	torticollis.tw.	4,640
	171	contracted neck.tw.	9
	172	(neck adj3 torsion).tw.	182
	173	wryneck.tw.	38
	174	exp muscle spasm/	89,048



Concept	#	Embase query	Results
	175	(muscle adj3 spas*).tw.	5,796
	176	(muscular adj3 spas*).tw.	903
	177	involuntary muscle* contraction*.tw.	279
	178	myospas*.tw.	64
	179	exp hemifacial spasm/	2,959
	180	(hemifacial adj3 spasm*).tw.	2,631
	181	(unilateral adj3 spasm*).tw.	113
	182	exp trismus/	4,351
	183	(jaw* adj3 lock*).tw.	142
	184	lockjaw*.tw.	93
	185	exp spasticity/	27,476
	186	(spas* adj3 disease*).tw.	1,049
	187	exp muscle hypertonia/	48,388
	188	(muscle* adj3 hypertoni*).tw.	599
	189	(muscular adj3 hypertoni*).tw.	279
	190	spasticism.tw.	1
	191	exp "chemotherapy induced nausea and vomiting"/	9,030
	192	"chemotherapy-associated nausea and vomiting".tw.	22
	193	"chemotherapy-related nausea and vomiting".tw.	77
	194	"chemotherapy-associated nausea/vomiting".tw.	3
	195	"chemotherapy-induced nausea and emesis".tw.	56



Concept	#	Embase query	Results
	196	"chemotherapy-induced nausea/emesis".tw.	2
	197	"chemotherapy-induced nausea/vomiting".tw.	89
	198	"chemotherapy-related nausea and emesis".tw.	6
	199	exp nausea/	216,838
	200	exp "nausea and vomiting"/	365,766
	201	exp chemotherapy induced nausea/	75
	202	exp vomiting/	214,725
	203	vomiting.tw.	116,474
	204	emesis.tw.	10,851
	205	exp anorexia/	62,362
	206	exp appetite disorder/	117,632
	207	(appetite adj3 disorder*).tw.	304
	208	(loss adj3 appetite).tw.	8,348
	209	exp feeding disorder/	85,033
	210	(feeding adj3 disorder*).tw.	1,172
	211	exp anorexia nervosa/	21,008
	212	anorexia nervosa.tw.	16,627
	213	exp eating disorder/	52,081
	214	(eating adj3 disorder*).tw.	27,252
	215	exp anorexigenic agent/	78,738
	216	anorexi*.tw.	48,494
	217	anorectic*.tw.	4,316



Concept	#	Embase query	Results
	218	anorexant*.tw.	7
	219	antiappetite*.tw.	6
	220	(appetite adj3 depress*).tw.	635
	221	(appetite adj3 inhibit*).tw.	436
	222	(appetite adj3 reduc*).tw.	2,067
	223	(appetite adj3 restrain*).tw.	17
	224	(appetite adj3 suppress*).tw.	2,370
	225	exp Human immunodeficiency virus/	193,169
	226	(immunodeficiency adj3 virus).tw.	98,499
	227	HIV.tw.	389,293
	228	exp acquired immune deficiency syndrome/	140,130
	229	acquired immunodeficiency syndrome.tw.	16,504
	230	exp demyelinating disease/	179,179
	231	(demyelinat* adj3 disease*).tw.	11,859
	232	exp multiple sclerosis/	131,824
	233	multiple sclerosis.tw.	115,503
	234	(disseminated adj3 sclerosis).tw.	1,153
	235	insular sclerosis.tw.	5
	236	exp amyotrophic lateral sclerosis/	38,232
	237	amyotrophic lateral sclerosis.tw.	31,069
	238	(als adj3 dementia).tw.	1,470
	239	Lou Gehrig* disease.tw.	187



Concept #	Embase query	Results
240	exp Parkinson disease/	153,480
241	parkinson* disease.tw.	130,618
242	paralysis agitans.tw.	299
243	parkinson dementia complex.tw.	70
244	exp Gilles de la Tourette syndrome/	8,133
245	Tourette* disease.tw.	142
246	Tourette* syndrome.tw.	5,880
247	tic/	9,655
248	(fac* adj3 twitch*).tw.	482
249	(nervous adj3 tic*).tw.	65
250	(nervous adj3 twitch*).tw.	17
251	tic* disorder*.tw.	1,864
252	exp dementia/	361,053
253	dementia*.tw.	157,661
254	exp Alzheimer disease/	196,945
255	alzheimer disease.tw.	21,658
256	(Alzheimer adj3 dementia).tw.	5,703
257	exp Huntington chorea/	27,010
258	huntington* chorea*.tw.	1,921
259	huntington* disease.tw.	20,040
260	exp spinal cord injury/	78,164
261	exp cervical spinal cord injury/	3,658



Concept	#	Embase query	Results
	262	spinal cord injur*.tw.	49,118
	263	spinal cord lacerati*.tw.	3
	264	exp spinal cord transsection/	3,377
	265	spinal cord transection*.tw.	1,834
	266	exp spinal cord transverse lesion/	739
	267	spinal cord transverse lesion*.tw.	-
	268	spinal cord contusion*.tw.	824
	269	exp spinal cord compression/	16,757
	270	spinal cord compression*.tw.	8,114
	271	exp brown sequard syndrome/	863
	272	brown sequard syndrome.tw.	641
	273	exp traumatic brain injury/	49,121
	274	traumatic brain injur*.tw.	51,303
	275	traumatic brain lesion*.tw.	170
	276	(brain adj3 trauma*).tw.	56,724
	277	(cerebr* adj3 trauma*).tw.	4,501
	278	(trauma adj3 encephalopathy).tw.	90
	279	posttraumatic encephalopathy.tw.	54
	280	exp epilepsy/	253,685
	281	epilep*.tw.	206,516
	282	"seizure, epilepsy and convulsion"/	102
	283	seizure*.tw.	185,688



Concept	#	Embase query	Results
	284	convulsi*.tw.	43,154
	285	exp irritable colon/	26,108
	286	irritable colon syndrome*.tw.	276
	287	irritable bowel syndrome*.tw.	20,317
	288	exp neurogenic bowel/	654
	289	(neurogen* adj3 bowel).tw.	602
	290	exp bladder irritation/	897
	291	(irritabl* adj3 bladder).tw.	225
	292	nervous bladder.tw.	10
	293	exp overactive bladder/	15,958
	294	(bladder adj3 overactiv*).tw.	11,962
	295	(detrusor adj3 overactiv*).tw.	5,167
	296	exp anxiety disorder/	241,092
	297	exp anxiety disorder/	241,092
	298	(anxiety adj3 disorder*).tw.	52,006
	299	nervousness.tw.	2,786
	300	hypervigilance.tw.	971
	301	exp anxiolytic agent/	200,652
	302	(anxi* adj3 agent*).tw.	1,592
	303	(anxi* adj3 drug*).tw.	4,515
	304	(anxi* adj3 medic*).tw.	3,170
	305	anti anxiety agent*.tw.	148



Concept #		Embase query	Results
30	06	anti anxiety drug*.tw.	263
30	07	anti anxiety medic*.tw.	119
30	80	exp posttraumatic stress disorder/	58,848
30	09	posttraumatic stress disorder*.tw.	20,976
31	10	post-traumatic stress disorder*.tw.	14,398
31	11	(posttraumatic adj3 neuros*).tw.	50
31	12	(post-traumatic adj3 neuros*).tw.	83
31	13	(posttraumatic adj3 psych*).tw.	1,096
31	14	post-traumatic psych*.tw.	156
31	15	PTSD.tw.	30,472
31	16	(traumatic adj3 stress*).tw.	20,550
31	17	(combat* adj3 disorder*).tw.	536
31	18	(war* adj3 neuros*).tw.	740
31	19	(war* adj3 psych*).tw.	6,905
32	20	exp depression/	474,606
32	21	depressi*.tw.	537,757
32	22	exp mood disorder/	517,836
32	23	(mood adj3 disorder*).tw.	30,626
32	24	exp dysphoria/	6,000
32	25	dysphoria*.tw.	4,522
32	26	exp dysthymia/	8,882
32	27	dysthymia*.tw.	2,902



Concept	#	Embase query	Results
	328	"mixed anxiety and depression"/	777
	329	"mixed anxiety and depression".tw.	299
	330	"mixed depression and dementia"/	137
	331	"mixed depression and dementia".tw.	5
	332	mourning syndrome/	122
	333	(mourning adj3 syndrome).tw.	3
	334	perry syndrome/	95
	335	perry syndrome.tw.	92
	336	exp antidepressant agent/	441,069
	337	(antidepress* adj3 agent*).tw.	3,546
	338	(antidepress* adj3 drug*).tw.	13,805
	339	(antidepress* adj3 medic*).tw.	8,218
	340	(depressi* adj3 agent*).tw.	701
	341	(depressi* adj3 drug*).tw.	4,659
	342	(depressi* adj3 medic*).tw.	6,425
	343	exp sleep disorder/	237,192
	344	(sleep* adj3 disorder*).tw.	42,690
	345	(disturbanc* adj3 sleep*).tw.	27,904
	346	sleep wake disorder*.tw.	468
	347	dyssomni*.tw.	175
	348	exp insomnia/	68,232
	349	insomnia*.tw.	36,598



_			
Concept	#	Embase query	Results
	350	hyposomnia*.tw.	44
	351	sleepless*.tw.	1,440
	352	"sleep initiation and maintenance disorder*".tw.	16
	353	(sleep adj3 initiation).tw.	691
	354	exp schizophrenia/	194,052
	355	schizophren*.tw.	171,056
	356	exp schizophrenia spectrum disorder/	198,219
	357	"schizophrenia spectrum disorder*".tw.	3,526
	358	exp schizoaffective psychosis/	10,136
	359	(schizoaffective adj3 psychos*).tw.	580
	360	schizo affective psychos*.tw.	80
	361	(schizoaffective adj3 disorder*).tw.	7,252
	362	schizo affective disorder*.tw.	320
	363	exp schizophreniform disorder/	1,583
	364	(schizophreniform adj3 disorder*).tw.	918
	365	(schizophreniform adj3 psychos*).tw.	338
	366	exp psychosis/	307,156
	367	psychos*.tw.	225,587
	368	psychot*.tw.	148,691
	369	psychotic disorder*.tw.	13,973
	370	or/17-369	5,059,534
cannabis + ALL	371	16 and 370	27,296



Concept	#	Embase query	Results
Reviews only	372	limit 371 to yr="2016 - 2020"	8,068
(all outcomes)	373	limit 372 to (meta analysis or "systematic review")	3,916
	374	or/17-137	1,685,112
cannabis + pain	375	16 and 374	4,759
	376	limit 375 to yr="2016 - 2020"	1,988
cannabis +	377	or/138-190	169,899
movement dis.	378	16 and 377	1,058
	379	limit 378 to yr="2016 - 2020"	348
cannabis +	380	or/191-224	587,795
nausea / vomiting	381	16 and 380	3,290
vormang	382	limit 381 to yr="2016 - 2020"	1,184
cannabis +	383	or/225-369	3,344,764
neuropsychiatric / immunology	384	16 and 383	25,160
/ ininunology	385	limit 384 to yr="2016 - 2020"	7,122

PubMed

Concept	#	PubMed query	Results
Cannabis/	1	((((((cannabis[MeSH Terms]) OR cannabis sativa[MeSH Terms]) OR	32,789
cannabinoids		cannabis indica[MeSH Terms]) OR marijuana[MeSH Terms]) OR	
		hashish[MeSH Terms]) OR cannabis[Text Word]) OR marihuana[Text	
		Word]) OR marijuana[Text Word]) OR hashish[Text Word]	
Pain	2		524,816
		(((((chronic pain[MeSH Terms]) OR (intractable pain[MeSH	
		Terms])) OR (neuropathic pain[MeSH Terms])) OR (pain	



Concept	#	PubMed query	Results
		clinic[MeSH Terms])) OR ("cancer pain"[MeSH Terms]))	
		OR (postoperative pain[MeSH Terms])) OR (referred	
		pain[MeSH Terms])) OR (breakthrough pain[MeSH	
		Terms])) OR ("neuralgia"[MeSH Terms])) OR ("burning	
		mouth syndrome"[MeSH Terms])) OR ("carpal tunnel	
		syndrome"[MeSH Terms])) OR ("cauda equina	
		syndrome"[MeSH Terms]))) OR ("complex regional pain	
		syndromes"[MeSH Terms])) OR ("cubital tunnel	
		syndrome"[MeSH Terms])) OR (metatarsalgia[MeSH	
		Terms])) OR ("morton neuroma"[MeSH Terms])) OR	
		("radiculopathy"[MeSH Terms])) OR (sciatica[MeSH	
		Terms])) OR (sunct syndrome[MeSH Terms])) OR (tarsal	
		tunnel syndrome[MeSH Terms])) OR (tarsal tunnel	
		entrapment neuropathy[MeSH Terms])) OR (nociceptive	
		pain[MeSH Terms])) OR ("complex regional pain	
		syndromes"[MeSH Terms])) OR ("causalgia"[MeSH	
		Terms])) OR ("headache"[MeSH Terms])) OR ("headache	
		disorders"[MeSH Terms])) OR ("migraine disorders"[MeSH	
		Terms])) OR ("facial pain"[MeSH Terms]))) OR ("eye	
		pain"[MeSH Terms])) OR ("glossalgia"[MeSH Terms])) OR	
		("neck pain"[MeSH Terms])) OR ("shoulder pain"[MeSH	
		Terms])) OR ("back pain"[MeSH Terms])) OR ("failed back	
		surgery syndrome"[MeSH Terms])) OR ("low back	
		pain"[MeSH Terms])) OR ("myalgia"[MeSH Terms])) OR	
		("myofascial pain syndromes"[MeSH Terms])) OR	
		("arthralgia"[MeSH Terms])) OR ("palliative care"[MeSH	
		Terms])) OR ("hospice care"[MeSH Terms])) OR ("terminal	
		care"[MeSH Terms])) OR (chronic adj3 pain*[Text Word]))	
		OR (chronic pain*[Text Word])) OR (intractable pain*[Text	



Concept	#	PubMed query	Results
		Word])) OR (neuropathic pain*[Text Word])) OR (pain*	
		clinic*[Text Word])) OR (cancer pain*[Text Word])) OR	
		(postoperative pain*[Text Word])) OR (referred pain*[Text	
		Word])) OR (breakthrough pain*[Text Word])) OR	
		(neuralgi*[Text Word])) OR (burning mouth syndrome*[Text	
		Word])) OR (carpal tunnel syndrome[Text Word])) OR	
		(cauda equina syndrome[Text Word])) OR (complex	
		regional pain syndrome*[Text Word])) OR (cubital tunnel	
		syndrome[Text Word])) OR (metatarsalgi*[Text Word])) OR	
		(morton neuroma*[Text Word])) OR (radiculopathy*[Text	
		Word])) OR (sciatic*[Text Word])) OR (sunct	
		syndrome[Text Word])) OR (tarsal tunnel syndrome[Text	
		Word])) OR (tarsal tunnel entrapment neuropath*[Text	
		Word])) OR (nociceptive pain*[Text Word])) OR	
		(causalgia*[Text Word])) OR (headache*[Text Word])) OR	
		(migraine[Text Word])) OR (fac* pain*[Text Word])) OR	
		(eye* pain*[Text Word])) OR (glossalgi*[Text Word])) OR	
		(neck pain*[Text Word])) OR (shoulder* pain*[Text Word]))	
		OR (back pain*[Text Word])) OR (failed back surgery	
		syndrome[Text Word])) OR (low back pain*[Text Word]))	
		OR (lowback pain*[Text Word])) OR (myalgi*[Text Word]))	
		OR (myofascial pain syndrome*[Text Word])) OR	
		(arthralgia*[Text Word])) OR (palliative[Text Word])) OR	
		(hospice[Text Word])) OR (terminal care[Text Word])	
Movement	3	(((((((((((((((((((((((((()))	41,592
disorders		disorders"[MeSH Terms])) OR ("torticollis"[MeSH Terms]))	
		OR ("blepharospasm"[MeSH Terms])) OR ("meige	
		syndrome"[MeSH Terms])) OR (writer's cramp[MeSH	
		Terms])) OR (wryneck[MeSH Terms])) OR ("muscle	



Concept	#	PubMed query	Results
		spasticity"[MeSH Terms])) OR ("hemifacial spasm"[MeSH	
		Terms])) OR ("trismus"[MeSH Terms])) OR (lockjaw[MeSH	
		Terms])) OR ("muscle hypertonia"[MeSH Terms])) OR	
		(dystoni*[Text Word])) OR (torticollis[Text Word])) OR	
		(blepharospasm[Text Word])) OR (meige* syndrome[Text	
		Word])) OR (writer* cramp*[Text Word])) OR (wryneck[Text	
		Word])) OR (muscle* spas*[Text Word])) OR (muscular	
		spas*[Text Word])) OR (hemifacial spasm*[Text Word]))	
		OR (trismus[Text Word])) OR (lockjaw[Text Word])) OR	
		(muscle* hypertoni*[Text Word])) OR (muscular	
		hypertoni*[Text Word])	
Chemotherapy	4	((((((((((((((((((((((((((((()))	593,286
/ AIDS - N&V		("nausea/chemically induced"[MeSH Terms])) OR	
		("vomiting"[MeSH Terms])) OR ("vomiting,	
		anticipatory/chemically induced"[MeSH Terms])) OR	
		("anorexia"[MeSH Terms])) OR ("anorexia nervosa"[MeSH	
		Terms])) OR ("appetite regulation"[MeSH Terms])) OR	
		("appetite stimulants"[MeSH Terms])) OR (appetite	
		disorder[MeSH Terms])) OR ("anorexia nervosa/drug	
		therapy"[MeSH Terms])) OR ("acquired immunodeficiency	
		syndrome"[MeSH Terms])) OR ("immunocompromised	
		host"[MeSH Terms])) OR (nausea[Text Word])) OR	
		(vomiting[Text Word])) OR (chemotherapy induced	
		nausea[Text Word] AND vomiting[Text Word])) OR	
		(chemotherapy associated nausea[Text Word] AND	
		vomiting[Text Word])) OR (chemotherapy related	
		nausea[Text Word] AND vomiting[Text Word])) OR	
		(anorexi*[Text Word])) OR (appetite disorder*[Text Word]))	
		OR (loss of appetite[Text Word])) OR (appetite	



Concept	#	PubMed query	Results
		regulat*[Text Word])) OR (appetite stimula*[Text Word]))	
		OR (anorexigenic agent*[Text Word])) OR (anorexigenic	
		medic*[Text Word])) OR (anorexigenic drug*[Text Word]))	
		OR (anorexigenic treatment*[Text Word])) OR (human	
		immunodeficiency virus[Text Word])) OR (HIV[Text Word]))	
		OR (acquired immune deficiency syndrome[Text Word]))	
		OR (immunocompromi*[Text Word])	
Neuropsychiat	5	((((((((((((((((((((((((((((((((((((((441,909
ric/		sclerosis"[MeSH Terms]) OR ("amyotrophic lateral	
immunotoxicit		sclerosis"[MeSH Terms])) OR ("parkinson	
У		disease"[MeSH Terms])) OR ("tourette	
		syndrome"[MeSH Terms])) OR ("tic disorders"[MeSH	
		Terms])) OR ("dementia"[MeSH Terms])) OR	
		("alzheimer disease"[MeSH Terms])) OR ("huntington	
		disease"[MeSH Terms])) OR ("spinal cord	
		diseases/injuries"[MeSH Terms])) OR ("spinal cord	
		compression"[MeSH Terms]))) OR ("brown-sequard	
		syndrome"[MeSH Terms])))) OR (traumatic brain	
		injury[MeSH Terms])) OR ("epilepsy"[MeSH Terms]))	
		OR ("epileptic syndromes"[MeSH Terms])) OR	
		("seizures"[MeSH Terms])) OR ("irritable bowel	
		syndrome"[MeSH Terms])) OR ("anxiety"[MeSH	
		Terms])) OR ("anxiety disorders"[MeSH Terms])) OR	
		("anxiety disorders/drug therapy"[MeSH Terms])) OR	
		("stress disorders, post-traumatic"[MeSH Terms])) OR	
		("combat disorders"[MeSH Terms])) OR	
		("depression"[MeSH Terms])) OR ("depression/drug	
		therapy"[MeSH Terms])) OR ("depression/drug	
		effects"[MeSH Terms])) OR ("mood disorders"[MeSH	



Concept	#	PubMed query	Results
		Terms])) OR ("mood disorders/drug therapy"[MeSH	
		Terms])) OR ("antidepressive agents"[MeSH Terms]))	
		OR ("sleep disorders, circadian rhythm"[MeSH	
		Terms])) OR ("sleep disorders, circadian rhythm/drug	
		therapy"[MeSH Terms])) OR ("sleep disorders,	
		intrinsic"[MeSH Terms])) OR ("sleep disorders,	
		intrinsic/drug therapy"[MeSH Terms])) OR ("sleep	
		wake disorders"[MeSH Terms])) OR ("sleep wake	
		disorders/drug therapy"[MeSH Terms])) OR ("sleep	
		wake disorders/drug effects"[MeSH Terms])) OR	
		("sleep initiation and maintenance disorders"[MeSH	
		Terms])) OR ("schizophrenia"[MeSH Terms])) OR	
		("schizophrenia spectrum and other psychotic	
		disorders"[MeSH Terms])) OR ("schizophrenia	
		spectrum and other psychotic disorders/drug	
		therapy"[MeSH Terms])) OR ("schizophrenia spectrum	
		and other psychotic disorders/drug effects"[MeSH	
		Terms])) OR (schizoaffective disorder[MeSH Terms]))	
		OR ("schizoid personality disorder"[MeSH Terms])) OR	
		("schizoid personality disorder/therapy"[MeSH	
		Terms])) OR ("psychotic disorders"[MeSH Terms])) OR	
		("psychotic disorders/drug therapy"[MeSH Terms]))	
		OR ("psychotic disorders/drug effects"[MeSH Terms]))	
		OR (multiple sclerosis[Text Word] OR disseminated	
		sclerosis[Text Word] OR amyotrophic lateral	
		sclerosis[Text Word] OR dementia*[Text Word] OR Lou	
		Gehrig* disease[Text Word] OR parkinson*	
		disease[Text Word] OR paralysis agitans[Text Word]	
		OR Tourette* disease[Text Word] OR Tourette*	



Concept	#	PubMed query	
		syndrome[Text Word] OR Tic disorder*[Text Word] OR	
	Alzheimer*[Text Word] OR huntington* chorea*[Text		
Word] OR huntington* disease[Text Word] OR s		Word] OR huntington* disease[Text Word] OR spinal	
	cord injur*[Text Word] OR spinal cord lacerati*[Text Word] OR spinal cord transection*[Text Word] OR spinal cord contusion*[Text Word] OR spinal cord		
		compression*[Text Word] OR brown sequard	
		syndrome[Text Word] OR traumatic brain injur*[Text	
		Word] OR brain trauma*[Text Word] OR epilep*[Text	
		Word] OR seizure*[Text Word] OR convulsi*[Text	
		Word] OR irritabl* colon[Text Word] OR irritabl*	
		bowel[Text Word] OR neurogen* bowel[Text Word] OR	
		irritabl* bladder[Text Word] OR nervous bladder[Text	
		Word] OR overactive bladder[Text Word] OR detrusor	
		overactiv*[Text Word] OR anxiety disorder*[Text Word]	
		OR anxi* agent*[Text Word] OR anxi* drug*[Text Word]	
		OR anxi* medic*[Text Word] OR anti anxiety	
		agent*[Text Word] OR anti anxiety drug*[Text Word]	
		OR anti anxiety medic*[Text Word] OR posttraumatic	
		stress disorder*[Text Word] OR post-traumatic stress	
		disorder*[Text Word] OR posttraumatic neuros*[Text	
		Word] OR post-traumatic neuros*[Text Word] OR	
		posttraumatic psych*[Text Word] OR post-traumatic	
		psych*[Text Word] OR PTSD[Text Word] OR combat*	
		disorder*[Text Word] OR war* neuros*[Text Word] OR	
		war* psych*[Text Word] OR depressi*[Text Word] OR	
		mood disorder*[Text Word] OR dysphoria*[Text Word]	
		OR dysthymia*[Text Word] OR mourning	
		syndrome[Text Word] OR perry syndrome[Text Word]	



Concept	#	PubMed query	Results
		OR antidepress* agent*[Text Word] OR antidepress*	
		drug*[Text Word] OR antidepress* medic*[Text Word]	
		OR depressi* agent*[Text Word] OR depressi*	
		drug*[Text Word] OR depressi* medic*[Text Word] OR	
		sleep* disorder*[Text Word] OR sleep disturbance[Text	
		Word] OR sleep wake disorder*[Text Word] OR	
		insomnia*[Text Word] OR hyposomnia*[Text Word] OR	
		sleepless*[Text Word] OR sleep initiation[Text Word]	
		AND maintenance disorder*[Text Word] OR sleep	
		initiation[Text Word] OR schizophren*[Text Word] OR	
		schizophrenia spectrum disorder*[Text Word] OR	
		schizoaffective[Text Word] OR schizophreniform[Text	
		Word] OR psychos*[Text Word] OR psychot*[Text	
		Word]	
ALL	6	Or/2-5	2,315,5
indications			63
Cannabis +	7	1 and 6	9,479
ALL ind.			
	8	Limit 7 to : ("2016/01/01"[Date - Publication] : "3000"[Date -	2,887
		Publication])	
	9	Limit 8 to: (("meta-analysis"[Publication Type]) OR	596
		("systematic review"[Publication Type]))	
Cannabis +	10	1 and 2	1,037
pain			
	11	("2016/01/01"[Date - Publication] : "3000"[Date -	527
		Publication])	



Concept	#	PubMed query	Results
Cannabis +	12	1 and 3	178
movmt.			
	13	("2016/01/01"[Date - Publication] : "3000"[Date -	50
		Publication])	
Cannabis +	14	1 and 4	2,119
n/v			
	15	("2016/01/01"[Date - Publication] : "3000"[Date -	729
		Publication])	
Cannabis +	16	1 and 5	8,802
ns/ imm			
	17	("2016/01/01"[Date - Publication] : "3000"[Date -	2,520
		Publication])	



Level	Bibliography	Reason for
		exclusion
1	Ahmed, S.,Bachu, R.,Kotapati, P.,Adnan, M.,Ahmed, R.,Farooq, U.,Saeed, H.,Khan, A. M.,Zubair, A.,Qamar, I.,Begum, G. (2019). Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review Front Psychiatry, 10(#issue#), 228	Addiction/Withdrawal
1	 Aldridge, R. W., Story, A., Hwang, S. W., Nordentoft, M., Luchenski, S. A., Hartwell, G., Tweed, E. J., Lewer, D., Vittal Katikireddi, S., Hayward, A. C. (2018). Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis Lancet, 391(10117), 241- 250 	Addiction/Withdrawal
1	Alharbi, F. F.,El-Guebaly, N. (2016). Cannabis and amphetamine-type stimulant-induced psychoses: A systematic overview Addictive Disorders and their Treatment, 15(4), 190-200	Addiction/Withdrawal
1	 Almli, L., Tang, Y., Meyers, J., Koenen, K., Marmar, C., Shin, J., Maihofer, A., Nievergelt, C., Conneely, K., Ressler, K. (2017). Problematic alcohol use behavior comorbidity in a highly traumatized urban cohort and its GWAS association with an eqtl of the SCLT1 gene European Neuropsychopharmacology, 27 (Supplement 2)(#issue#), S135-S136 	Addiction/Withdrawal

Appendix 2. Excluded studies (with reasons for exclusion)



Level	Bibliography	Reason for
		exclusion
1	Anderson, L. J., Flynn, A., Pilgrim, J. L. (2017). A global epidemiological perspective on the toxicology of drug- facilitated sexual assault: A systematic review Journal of Forensic and Legal Medicine, 47(#issue#), 46-54	Addiction/Withdrawal
1	Anonymous, (2018). Abstract Book - 2nd World Congress of World Association on Dual Disorder, WADD Heroin Addiction and Related Clinical Problems. Conference: 2nd World Congress of World Association on Dual Disorder, WADD, 20(Supplement 2), #Pages#	Addiction/Withdrawal
1	Anonymous, (2019). Abstracts of the XXVIth World Congress of Psychiatric Genetics (WCPG), 11 - 15 October 2018, Glasgow, Scotland European Neuropsychopharmacology, 29 (Supplement 4)(#issue#), S1021-S1342	Addiction/Withdrawal
1	Arimany, M. S.,Fortea, A.,Ilzarbe, D.,Sugranyes, G.,Baeza, I. (2018). Long-Acting Injectable Atypical Antipsychotic Use in a Child and Adolescent Inpatient Psychiatry Unit: An Observational Study Journal of the American Academy of Child and Adolescent Psychiatry, 57 (10 Supplement)(#issue#), S169	Addiction/Withdrawal
1	Arranz, B.,Garriga, M.,García-Rizo, C.,San, L. (2018). Clozapine use in patients with schizophrenia and a comorbid substance use disorder: A systematic review Eur Neuropsychopharmacol, 28(2), 227-242	Addiction/Withdrawal
1	Asuzu, K.,Matin, A.,Van Noord, M.,Onigu-Otite, E.	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	(2018). Electronically-delivered interventions to reducecannabis use in adolescents: A systematic reviewAdolescent Psychiatry, 8(3), 195-213	
1	Atkinson, D. L. (2017). Prescription stimulant abuse on college campuses Journal of the American Academy of Child and Adolescent Psychiatry, 56 (10)(#issue#), S79	Addiction/Withdrawal
1	Baandrup, L.,Ostrup Rasmussen, J.,Klokker, L.,Austin, S.,Bjornshave, T.,Fuglsang Bliksted, V.,Fink-Jensen, A.,Hedegaard Fohlmann, A.,Peter Hansen, J.,Kristine Nielsen, M.,Sandsten, K. E.,Schultz, V.,Voss-Knude, S.,Nordentoft, M. (2016). Treatment of adult patients with schizophrenia and complex mental health needs - A national clinical guideline Nordic Journal of Psychiatry, 70(3), 231-240	Addiction/Withdrawal
1	Badowski, S.,Smith, G. (2020). Cannabis use during pregnancy and postpartum Canadian family physician Medecin de famille canadien, 66(2), 98-103	Addiction/Withdrawal
1	Bagot, K. S. (2017). Cannabis use amongst college- aged students Journal of the American Academy of Child and Adolescent Psychiatry, 56 (10)(#issue#), S78	Addiction/Withdrawal
1	Barkin, J. A., Nemeth, Z., Saluja, A. K., Barkin, J. S. (2016). A systematic review of cannabis use and the development of acute pancreatitis American Journal of Gastroenterology, 111 (Supplement 1)(#issue#), S50-	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	S51	
1	Barkin, J. A., Nemeth, Z., Saluja, A. K., Barkin, J. S. (2016). Cannabis induced acute pancreatitis: A systematic review Pancreas, 45 (10)(#issue#), 1497	Addiction/Withdrawal
1	Bartoli, F.,Crocamo, C.,Carra, G. (2019). Cannabis use disorder and suicide attempts in bipolar disorder: A meta-analysis Neuroscience and Biobehavioral Reviews, 103(#issue#), 14-20	Addiction/Withdrawal
1	Basu, K.,Sabesan, P.,Palaniyappan, L. (2019). An effect-size meta-analysis of white matter damage related to cannabis use: Relevance to the anatomy of psychosis Schizophrenia Bulletin, 45 (Supplement 2)(#issue#), S224	Addiction/Withdrawal
1	Batet Sanchez, D. (2016). Neuroimaging of first- episode-psychosis in cannabis users: A review Psiquiatria Biologica, 23(3), 103-111	Addiction/Withdrawal
1	Becerra Darriba, H. (2019). P.744 Is N-acetylcysteine a promising pharmacological treatment for cannabis and cocaine cessation? European Neuropsychopharmacology, 29 (Supplement 6)(#issue#), S500-S501	Addiction/Withdrawal
1	 Belbasis, L.,Köhler, C. A.,Stefanis, N.,Stubbs, B.,van Os, J.,Vieta, E.,Seeman, M. V.,Arango, C.,Carvalho, A. F.,Evangelou, E. (2018). Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses Acta Psychiatr 	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	Scand, 137(2), 88-97	
1	Berry, M. S., Johnson, M. W. (2018). Does being drunk or high cause HIV sexual risk behavior? A systematic review of drug administration studies Pharmacol Biochem Behav, 164(#issue#), 125-138	Addiction/Withdrawal
1	Bevilacqua, L.,Hale, D.,Barker, E. D.,Viner, R. (2017). Conduct problems trajectories and psychosocial outcomes in early adulthood: A systematic review and meta-analysis Archives of Disease in Childhood, 102 (Supplement 1)(#issue#), A50	Addiction/Withdrawal
1	Bevilacqua, L.,Hale, D.,Barker, E. D.,Viner, R. (2018). Conduct problems trajectories and psychosocial outcomes: a systematic review and meta-analysis Eur Child Adolesc Psychiatry, 27(10), 1239-1260	Addiction/Withdrawal
1	Bleckwenn, M.,Heister, L.,Weckbecker, M.,Weckbecker, K.,Mucke, M. (2016). Misuse of Substitution Drugs in the Substitution-Based Therapy European Addiction Research, 22(6), 322-328	Addiction/Withdrawal
1	Bogaty, S. E. R.,Lee, R. S. C.,Hickie, I. B.,Hermens, D.F. (2018). Meta-analysis of neurocognition in young psychosis patients with current cannabis use JPsychiatr Res, 99(#issue#), 22-32	Addiction/Withdrawal
1	Bouhlal, S.,Temko, J. E.,Farokhnia, M.,Lee, M. R.,Leggio, L. (2016). The role of the gut microbiome in phenotypes associated with alcohol and other addictive disorders: A systematic review Alcoholism: Clinical and	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	Experimental Research, 1)(#issue#), 102A	
1	Bowtell, M.,Ratheesh, A.,McGorry, P.,Killackey, E.,O'Donoghue, B. (2018). Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review Schizophr Res, 197(#issue#), 9-18	Addiction/Withdrawal
1	Bridges, S.,Kini, R.,Parker, R.,Handley, M.,Das, M. (2019). Psychiatric disorder and its correlates in indigenous Australian prisoners: A systematic review Australian and New Zealand Journal of Psychiatry, 53 (Supplement 1)(#issue#), 108	Addiction/Withdrawal
1	Brown, R. A., Dakkak, H., Seabrook, J. A. (2018). Is Breast Best? Examining the effects of alcohol and cannabis use during lactation Journal of Neonatal- Perinatal Medicine, 11(4), 345-356	Addiction/Withdrawal
1	Buccelli, C.,Della Casa, E.,Paternoster, M.,Niola, M.,Pieri, M. (2016). Gender differences in drug abuse in the forensic toxicological approach Forensic Science International, 265(#issue#), 89-95	Addiction/Withdrawal
1	Campeny, E.,Lopez-Pelayo, H.,Nutt, D.,Blithikioti, C.,Oliveras, C.,Nuno, L.,Maldonado, R.,Florez, G.,Arias, F.,Fernandez-Artamendi, S.,Villalbi, J. R.,Sellares, J.,Ballbe, M.,Rehm, J.,Balcells-Olivero, M. M.,Gual, A. (2020). The blind men and the elephant: Systematic review of systematic reviews of cannabis	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	use related health harms European Neuropsychopharmacology., #volume#(#issue#), #Pages#	
1	Cancilliere, M. K., Yusufov, M., Weyandt, L. (2018). Effects of Co-occurring marijuana use and anxiety on brain structure and functioning: A systematic review of adolescent studies J Adolesc, 65(#issue#), 177-188	Addiction/Withdrawal
1	Cancino Botello, M. C., Canseco Navarro, M. D. L. A., Pena Serrano, A., Molina Lopez, F., Hernandez Sanchez, J. M. (2016). Psychosis, cause or consequence of substance use disorder European Psychiatry, 33 (SUPPL.)(#issue#), S376	Addiction/Withdrawal
1	Candido, F. J., Souza, R., Stumpf, M. A., Fernandes, L. G., Veiga, R., Santin, M., Kluthcovsky, A. (2018). The use of drugs and medical students: A literature review Revista da Associacao Medica Brasileira, 64(5), 462-468	Addiction/Withdrawal
1	Carbia, C.,Corral, M.,Cadaveira, F. (2017). Episodic memory in young binge drinkers: A neuropsychological approach Alcohol and Alcoholism, 52 (Supplement 1)(#issue#), i4	Addiction/Withdrawal
1	Carey, C.,Agrawal, A.,Hartz, S.,Bierut, L.,Bogdan, R. (2017). Associations between polygenic risk for psychiatric disorders and substance dependence European Neuropsychopharmacology, 27 (Supplement 2)(#issue#), S204	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
1	Carney, T.,Myers, B. J.,Louw, J.,Okwundu, C. I. (2016). Brief school-based interventions and behavioural outcomes for substance-using adolescents Cochrane Database Syst Rev, #volume#(1), Cd008969	Addiction/Withdrawal
1	Carney, R.,Cotter, J.,Firth, J.,Bradshaw, T.,Yung, A. R. (2017). Cannabis use and symptom severity in individuals at ultra high risk for psychosis: a meta- analysis Acta Psychiatr Scand, 136(1), 5-15	Addiction/Withdrawal
1	Carrigan, N.,Barkus, E. (2016). A systematic review of the relationship between psychological disorders or substance use and self-reported cognitive failures Cogn Neuropsychiatry, 21(6), 539-564	Addiction/Withdrawal
1	Casajuana Köguel, C.,López-Pelayo, H.,Balcells- Olivero, M. M.,Colom, J.,Gual, A. (2018). Psychoactive constituents of cannabis and their clinical implications: a systematic review Adicciones, 30(2), 140-151	Addiction/Withdrawal
1	Chand, M.,Walfird, M.,Kanwar, S.,Hirsch, A. (2016). Telemission and telepathy in the absence of schizophrenia Journal of Neuropsychiatry and Clinical Neurosciences, 28 (3)(#issue#), e38-e39	Addiction/Withdrawal
1	Charron, C. B.,Leung, J. M. (2019). The Safety and Efficacy of Marijuana in Persons Living with HIV AIDS Rev, 21(2), 84-92	Addiction/Withdrawal
1	Chronopoulou, E.,Seshadri, S. (2016). Preconceptual health and fertility treatment-an evidence based approach Human Reproduction, 31 (Supplement	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	1)(#issue#), i460-i461	
1	Chye, Y., Christensen, E., Yucel, M. (2020). Cannabis Use in Adolescence: A Review of Neuroimaging Findings Journal of Dual Diagnosis, 16(1), 83-105	Addiction/Withdrawal
1	Coentre, R.,Talina, M. C.,Gois, C.,Figueira, M. L. (2017). Depressive symptoms and suicidal behavior after first-episode psychosis: A comprehensive systematic review Psychiatry Research, 253(#issue#), 240-248	Addiction/Withdrawal
1	Cohen, A., Perkel, C. (2017). The purple hex: Psychosis associated with abuse of propylhexedrine nasal inhalers by a young adult with history of ADHD seeking replacement for stimulant medication-with literature review and historical context ADHD Attention Deficit and Hyperactivity Disorders, 9 (1 Supplement)(#issue#), S50	Addiction/Withdrawal
1	Coleman, J.,Dela Cruz, A.,Wakhlu, S. (2019). Neurostimulation for treatment of addiction: State of the evidence American Journal on Addictions, 28 (3)(#issue#), 184	Addiction/Withdrawal
1	Coles, A. S.,Kozak, K.,George, T. P. (2018). A review of brain stimulation methods to treat substance use disorders American Journal on Addictions, 27(2), 71- 91	Addiction/Withdrawal
1	Coles, A. S., Sasiadek, J., George, T. P. (2019). Pharmacotherapies for co-occurring substance use and	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	bipolar disorders: A systematic review Bipolar Disorders, 21(7), 595-610	
1	Colizzi, M.,Bhattacharyya, S. (2018). Cannabis use and the development of tolerance: a systematic review of human evidence Neurosci Biobehav Rev, 93(#issue#), 1-25	Addiction/Withdrawal
1	Courts, J.,Maskill, V.,Gray, A.,Glue, P. (2016). Signs and symptoms associated with synthetic cannabinoid toxicity: systematic review Australas Psychiatry, 24(6), 598-601	Addiction/Withdrawal
1	d'Angelo, L. S. C., Savulich, G., Sahakian, B. J. (2017). Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure British Journal of Pharmacology, 174(19), 3257-3267	Addiction/Withdrawal
1	Davis, J. P.,Smith, D. C.,Briley, D. A. (2017). Substance use prevention and treatment outcomes for emerging adults in non-college settings: A meta- Analysis Psychology of Addictive Behaviors, 31(3), 242-254	Addiction/Withdrawal
1	Dehghanmehr, S.,Mir, A.,Sheikhi, M.,Mirshekari, N.,Mirsargazi, Z.,Salarzaei, M. (2017). Main causes of drug compatibility and recurrence (A systematic review) Journal of Pharmaceutical Sciences and Research, 9(11), 2011-2015	Addiction/Withdrawal
1	Dellazizzo, L.,Potvin, S.,Beaudoin, M.,Luigi, M.,Dou, B. Y.,Giguere, C. E.,Dumais, A. (2019). Cannabis use	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	and violence in patients with severe mental illnesses: A meta-analytical investigation Psychiatry Research, 274(#issue#), 42-48	
1	Dini, G.,Bragazzi, N. L.,Montecucco, A.,Rahmani, A.,Durando, P. (2019). Psychoactive drug consumption among truck-drivers: A systematic review of the literature with meta-analysis and meta- regression Journal of Preventive Medicine and Hygiene, 60(2), E124-E139	Addiction/Withdrawal
1	Dominguez-Salas, S.,Diaz-Batanero, C.,Lozano-Rojas, O. M.,Verdejo-Garcia, A. (2016). Impact of general cognition and executive function deficits on addiction treatment outcomes: Systematic review and discussion of neurocognitive pathways Neuroscience and Biobehavioral Reviews, 71(#issue#), 772-801	Addiction/Withdrawal
1	Dowling, N. A., Merkouris, S. S., Greenwood, C. J., Oldenhof, E., Toumbourou, J. W., Youssef, G. J. (2017). Early risk and protective factors for problem gambling: A systematic review and meta-analysis of longitudinal studies Clin Psychol Rev, 51(#issue#), 109-124	Addiction/Withdrawal
1	Drummer, O. H.,Gerostamoulos, D.,Woodford, N. W. (2019). Cannabis as a cause of death: A review Forensic Science International, 298(#issue#), 298-306	Addiction/Withdrawal
1	Duailibi, M. S.,Cordeiro, Q.,Brietzke, E.,Ribeiro, M.,LaRowe, S.,Berk, M.,Trevizol, A. P. (2017). N-	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta-analysis American Journal on Addictions, 26(7), 660-666	
1	Dualibe, A. L.,Osório, F. L. (2017). Bipolar Disorder and Early Emotional Trauma: A Critical Literature Review on Indicators of Prevalence Rates and Clinical Outcomes Harv Rev Psychiatry, 25(5), 198-208	Addiction/Withdrawal
1	Dynin, M.,DeVore, H.,Lane, D.,Scafide, K. (2016). Epidemiological analysis of drugfacilitated sexual assault in Washington, DC Annals of Emergency Medicine, 68 (4 Supplement 1)(#issue#), S119-S120	Addiction/Withdrawal
1	Esmaeelzadeh, S.,Moraros, J.,Thorpe, L.,Bird, Y. (2018). Examining the association and directionality between mental health disorders and substance use among adolescents and young adults in the U.S. and Canada-A systematic review and meta-analysis Journal of Clinical Medicine, 7 (12) (no pagination)(543), #Pages#	Addiction/Withdrawal
1	Farooqui, M. T.,Li, A. A.,Khan, Z.,Shrestha, S.,Imam, Z.,Chen, T.,Wu, L.,Cholankeril, G.,Khan, M. A.,Ahmed, A. (2018). Is There Any Association between Marijuana Use and Progression of Hepatic Fibrosis? A Systematic Review and Meta-Analysis Gastroenterology, 154 (6 Supplement 1)(#issue#), S- 784	Addiction/Withdrawal
1	Farris, M. S., Shakeel, M. K., Addington, J. (2019).	Addiction/Withdrawal



Level	Bibliography	Reason for exclusion
	Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review Social psychiatry and psychiatric epidemiology., 03(#issue#), #Pages#	
1	Foglia, E.,Schoeler, T.,Klamerus, E.,Morgan, K.,Bhattacharyya, S. (2017). Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis Psychol Med, 47(10), 1691- 1705	Addiction/Withdrawal
1	Fond, G.,Lancon, C.,Auquier, P.,Boyer, L. (2019). [Prevalence of major depression in France in the general population and in specific populations from 2000 to 2018: A systematic review of the literature] Presse Med, 48(4), 365-375	Addiction/Withdrawal
1	 Fusar-Poli, P.,Salazar de Pablo, G.,Correll, C. U.,Meyer-Lindenberg, A.,Millan, M. J.,Borgwardt, S.,Galderisi, S.,Bechdolf, A.,Pfennig, A.,Kessing, L. V.,van Amelsvoort, T.,Nieman, D. H.,Domschke, K.,Krebs, M. O.,Koutsouleris, N.,McGuire, P.,Do, K. Q.,Arango, C. (2020). Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention JAMA psychiatry., 11(#issue#), #Pages# 	Addiction/Withdrawal
1	Gardner, E. (2019). Cannabis use disorder was predictable from extant preclinical data American Journal on Addictions, 28 (3)(#issue#), 197-198	Addiction/Withdrawal
1	Gates, P. J.,Sabioni, P.,Copeland, J.,Le Foll, B.,Gowing, L. (2016). Psychosocial interventions for	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	cannabis use disorder Cochrane Database Syst Rev, 2016(5), Cd005336	
1	Gates, P.,Albertella, L.,Copeland, J. (2016). Cannabis withdrawal and sleep: A systematic review of human studies Subst Abus, 37(1), 255-69	Addiction/Withdrawal
1	Gobbi, G.,Atkin, T.,Zytynski, T.,Wang, S.,Askari, S.,Boruff, J.,Ware, M.,Marmorstein, N.,Cipriani, A.,Dendukuri, N.,Mayo, N. (2019). Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis JAMA Psychiatry, 76(4), 426-434	Addiction/Withdrawal
1	Gogos, A.,Skokou, M.,Ferentinou, E.,Gourzis, P. (2019). Nicotine consumption during the prodromal phase of schizophrenia - a review of the literature Neuropsychiatric Disease and Treatment, 15(#issue#), 2943-2958	Addiction/Withdrawal
1	Gormley, M.,Blondino, C.,Taylor, D.,Lowery, E.,Clifford, J.,Burkhardt, B.,Graves, W.,Prom-Wormley, E.,Prom- Lu, J. (2019). The impact of opioid treatment on co- occurring substance use: a systematic review Annals of Epidemiology, 36(#issue#), 74	Addiction/Withdrawal
1	Goyal, D.,Parikh, T.,Pruett, J. W. (2017). Challenges of managing adolescent attention-deficit/hyperactivity disorder (ADHD) comorbid with substances use: A review of the literature Journal of the American	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
_	Academy of Child and Adolescent Psychiatry, 56 (10)(#issue#), S282	
1	Gurriaran Bas, X.,Rodriguez-Lopez, J.,Pereiro, C.,Manuel Fernandez, J.,Farinas, E.,Paramo, M.,Calvo, R.,Arrojo, M.,Florez, G.,Costas, J. (2019). Shared Polygenic Risk Analysis of Alcoholism and 5 Major Psychiatric Disorders European Neuropsychopharmacology, 29 (Supplement 3)(#issue#), S881-S882	Addiction/Withdrawal
1	Hart, C.,Argo, T. (2016). Administration considerations with use of paliperidone palmitate long-acting injectable in a patient with breakthrough symptoms of schizoaffective disorder Journal of Pharmacy Practice, 29 (3)(#issue#), 271-272	Addiction/Withdrawal
1	Hasan, A.,von Keller, R.,Friemel, C. M.,Hall, W.,Schneider, M.,Koethe, D.,Leweke, F. M.,Strube, W.,Hoch, E. (2019). Cannabis use and psychosis: a review of reviews European Archives of Psychiatry and Clinical Neuroscience., #volume#(#issue#), #Pages#	Addiction/Withdrawal
1	 Hindley, G.,Beck, K.,Borgan, F.,Ginestet, C. E.,McCutcheon, R.,Kleinloog, D.,Ganesh, S.,Radhakrishnan, R.,D'Souza, D. C.,Howes, O. D. (2020). Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis The Lancet Psychiatry, 7(4), 344-353 	Addiction/Withdrawal
1	Hodgson, K.,Hagenaars, S.,Purves, K.,Gaspar, H.	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	A.,Glanville, K.,Coleman, J.,Forti, M. D.,Breen, G.,O'Reilly, P.,Lewis, C. (2019). 4determining the Relationship between Cannabis Use and Major Depression in Uk Biobank European Neuropsychopharmacology, 29 (Supplement 4)(#issue#), S1067-S1068	
1	 Hook, A., Pardinas, A. F., Walters, J. T. R. (2019). Sa130using Poly-Environmental Risk Scoring to Assess Whether People with Known Psychoses Have Differences in Polygenic Risk Scoring European Neuropsychopharmacology, 29 (Supplement 4)(#issue#), S1260 	Addiction/Withdrawal
1	Hosseini, S.,Oremus, M. (2019). The Effect of Age of Initiation of Cannabis Use on Psychosis, Depression, and Anxiety among Youth under 25 Years Canadian Journal of Psychiatry, 64(5), 304-312	Addiction/Withdrawal
1	Hunt, G. E.,Malhi, G. S.,Cleary, M.,Lai, H. M. X.,Sitharthan, T. (2016). Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990-2015: Systematic review and meta-analysis Journal of Affective Disorders, 206(#issue#), 331-349	Addiction/Withdrawal
1	Hunt, G. E.,Large, M. M.,Cleary, M.,Lai, H. M. X.,Saunders, J. B. (2018). Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis Drug Alcohol Depend,	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	191(#issue#), 234-258	
1	Ilic, B.,Svab, V.,Sedic, B.,Kovacevic, I.,Friganovic, A.,Juric, E. (2017). Mental Health in Domesticated Immigrant Population - a Systematic Review Psychiatria Danubina, 29(3), 273-281	Addiction/Withdrawal
1	Jacobson, M. R.,Watts, J. J.,Boileau, I.,Tong, J.,Mizrahi, R. (2019). A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis European Neuropsychopharmacology, 29(3), 330-348	Addiction/Withdrawal
1	Jones, J. L., Mateus, C. F., Malcolm, R. J., Brady, K. T., Back, S. E. (2018). Efficacy of ketamine in the treatment of substance use disorders: A systematic review Frontiers in Psychiatry, 9 (JUL) (no pagination)(277), #Pages#	Addiction/Withdrawal
1	Kamruzzaman, S. M.,Rasool, A. H. G. (2017). A review on illegal drug abuse in Bangladesh International Medical Journal, 24(3), 253-255	Addiction/Withdrawal
1	Karoly, H. C.,Ross, J. M.,Ellingson, J. M.,Feldstein Ewing, S. W. (2020). Exploring Cannabis and Alcohol Co-Use in Adolescents: A Narrative Review of the Evidence Journal of Dual Diagnosis, 16(1), 58-74	Addiction/Withdrawal
1	Kennedy, M. C. (2017). Cannabis: Exercise performance and sport. A systematic review Journal of Science & Medicine in Sport, 20(9), 825-829	Addiction/Withdrawal
1	Kilani, J. (2018). Association Between Cannabis Use	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	and Psychotic Disorders Journal of the American Academy of Child and Adolescent Psychiatry, 57 (10 Supplement)(#issue#), S141	
1	Kober, H.,MacLean, R.,Wager, T. (2017). Meta- analysis of drug cue reactivity: Towards neuromarkers of craving and relapse Neuropsychopharmacology, 43 (Supplement 1)(#issue#), S281-S282	Addiction/Withdrawal
1	Kondo, K. K., Morasco, B. J., Nugent, S. M., Ayers, C. K., O'Neil, M. E., Freeman, M., Kansagara, D. (2020). Pharmacotherapy for the Treatment of Cannabis Use Disorder: A Systematic Review Annals of internal medicine., 03(#issue#), #Pages#	Addiction/Withdrawal
1	Konkoly Thege, B.,Horwood, L.,Slater, L.,Tan, M. C.,Hodgins, D. C.,Wild, T. C. (2017). Relationship between interpersonal trauma exposure and addictive behaviors: A systematic review BMC Psychiatry, 17 (1) (no pagination)(164), #Pages#	Addiction/Withdrawal
1	Kraan, T.,Velthorst, E.,Koenders, L.,Zwaart, K.,Ising, H. K.,Van Den Berg, D.,De Haan, L.,Van Der Gaag, M. (2016). Current cannabis abuse is associated with transition to psychosis in individuals at ultra-high risk for psychosis Early Intervention in Psychiatry, 10 (Supplement 1)(#issue#), 31	Addiction/Withdrawal
1	Kraan, T.,Velthorst, E.,Koenders, L.,Zwaart, K.,Ising, H. K.,van den Berg, D.,de Haan, L.,van der Gaag, M. (2016). Cannabis use and transition to psychosis in	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	individuals at ultra-high risk: review and meta-analysis Psychol Med, 46(4), 673-81	
1	Krause, M.,Huhn, M.,Schneider-Thoma, J.,Bighelli, I.,Gutsmiedl, K.,Leucht, S. (2019). Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis Eur Neuropsychopharmacol, 29(1), 32-45	Addiction/Withdrawal
1	Lapoint, J.,Meyer, S.,Yu, C. K.,Koenig, K. L.,Lev, R.,Thihalolipavan, S.,Staats, K.,Kahn, C. A. (2018). Cannabinoid hyperemesis syndrome: Public health implications and a novel model treatment guideline Western Journal of Emergency Medicine, 19(2), 380- 386	Addiction/Withdrawal
1	Lecomte, T.,Potvin, S.,Samson, C.,Francoeur, A.,Hache-Labelle, C.,Gagné, S.,Boucher, J.,Bouchard, M.,Mueser, K. T. (2019). Predicting and preventing symptom onset and relapse in schizophrenia-A metareview of current empirical evidence J Abnorm Psychol, 128(8), 840-854	Addiction/Withdrawal
1	Leduc-Pessah, H., Jensen, S. K., Newell, C. (2019). An overview of the adverse effects of cannabis use for Canadian physicians Clinical and investigative medicine, Medecine clinique et experimentale. 42(3), E17-E34	Addiction/Withdrawal
1	Lee, D. C.,Schlienz, N. J.,Peters, E. N.,Dworkin,	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	R.,Turk, D.,Strain, E.,Vandrey, R. (2019). Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder Drug and Alcohol Dependence, 194(#issue#), 500-517	
1	Lee, D. C., Schlienz, N. J., Peters, E. N., Dworkin, R. H., Turk, D. C., Strain, E. C., Vandrey, R. (2019). Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder Drug Alcohol Depend, 194(#issue#), 500-517	Addiction/Withdrawal
1	Lee, R. S. C., Hoppenbrouwers, S., Franken, I. (2019). A Systematic Meta-Review of Impulsivity and Compulsivity in Addictive Behaviors Neuropsychology review, 29(1), 14-26	Addiction/Withdrawal
1	Lemyre, A.,Gauthier-Legare, A.,Belanger, R. E. (2019). Shyness, social anxiety, social anxiety disorder, and substance use among normative adolescent populations: A systematic review American Journal of Drug and Alcohol Abuse, 45(3), 230-247	Addiction/Withdrawal
1	Lewer, D.,Freer, J.,King, E.,Larney, S.,Degenhardt, L.,Tweed, E. J.,Hope, V. D.,Harris, M.,Millar, T.,Hayward, A.,Ciccarone, D.,Morley, K. I. (2019). Frequency of healthcare utilisation by adults who use illicit drugs: a systematic review and meta-analysis Addiction, 09(#issue#), #Pages#	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
1	Li, K.,DeLisi, L. E. (2017). Clozapine related sudden death: A case report and literature review Neuropsychopharmacology, 43 (Supplement 1)(#issue#), S614-S615	Addiction/Withdrawal
1	Liu, Y.,Williamson, V.,Setlow, B.,Cottler, L. B.,Knackstedt, L. A. (2018). The importance of considering polysubstance use: lessons from cocaine research Drug and Alcohol Dependence, 192(#issue#), 16-28	Addiction/Withdrawal
1	Lucia, S.,Antonella, T.,Adriano, S.,Caterina, L. C.,Laura, F.,Mariangela, C.,Daniele, L. B.,Robin, M. M.,Helen, F. (2018). A systematic review of biopsychosocial mediators and moderators of the association between childhood adversity and psychosis Research in Psychotherapy: Psychopathology, Process and Outcome, 21 (Supplement 1)(#issue#), 49-50	Addiction/Withdrawal
1	MacKesy-Amiti, M. E., Strand, L., Nance, R., Chandler, R., Cunningham, W., Riley, E., Mehta, S., Altice, F., Wechsberg, W., Cunningham, C., Cleland, C., Metsch, L., Feaster, D., Del Rio, C., Beckwith, C., Kurth, A., Kuo, I., Kruszka, B., Springer, S. (2016). An example of exposure heterogeneity when pooling epidemiologic studies for meta-analysis of antiretroviral medication adherence Pharmacoepidemiology and Drug Safety, 25 (Supplement 3)(#issue#), 55-56	Addiction/Withdrawal
1	Maguire, A. M.,Grattan, R. E.,Lesh, T. A.,Botello, R. M.,Lara, N.,Demian, A. P.,Blendermann, M.,Carter, C.	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	S.,Niendam, T. (2019). 4.55 Trauma History and	
	Cannabis Use Are Associated with Positive	
	Symptomatology in an Early Psychosis Population	
	Journal of the American Academy of Child and	
	Adolescent Psychiatry, 58 (10 Supplement)(#issue#),	
	S238	
1	Makani, R.,Pradhan, B.,Shah, U.,Parikh, T. (2017). Role of Repetitive Transcranial Magnetic Stimulation (rTMS) in Treatment of Addiction and Related Disorders: A Systematic Review Curr Drug Abuse Rev, 10(1), 31-43	Addiction/Withdrawal
1	Maklad, M.,Al-Shammari, M.,Herrera, K.,Yoo, J.,Makar, R. (2016). Cannabinoid hyperemesis syndrome: A systematic review American Journal of Gastroenterology, 111 (Supplement 1)(#issue#), S410	Addiction/Withdrawal
1	Mammen, G.,Rueda, S.,Roerecke, M.,Bonato, S.,Lev- Ran, S.,Rehm, J. (2018). Association of Cannabis With Long-Term Clinical Symptoms in Anxiety and Mood Disorders: A Systematic Review of Prospective Studies J Clin Psychiatry, 79(4), #Pages#	Addiction/Withdrawal
1	Marangoni, C.,Hernandez, M.,Faedda, G. L. (2016). The role of environmental exposures as risk factors for bipolar disorder: A systematic review of longitudinal studies Journal of Affective Disorders, 193(#issue#), 165-174	Addiction/Withdrawal
1	Marconi, A.,Di Forti, M.,Lewis, C. M.,Murray, R.	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	M.,Vassos, E. (2016). Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis Schizophr Bull, 42(5), 1262-9	
1	Maricich, Y.,Campbell, A.,Nunes, E.,Luderer, H.,Jones, K.,Enman, N. (2019). Safety and efficacy of reset prescription digital therapeutic for substance use disorder American Journal on Addictions, 28 (3)(#issue#), 215-216	Addiction/Withdrawal
1	Martinez, E., Guinart, D., Armendariz, A., Soler, J., Rubio, J. M., Correll, C. (2019). Regional and sociodemographic differences in duration of untreated psychosis (DUP) in first episode schizophrenia: Results from a meta-analysis and exploratory meta-regression analysis European Neuropsychopharmacology, 29 (Supplement 1)(#issue#), S430-S431	Addiction/Withdrawal
1	Miettunen, J.,Immonen, J.,McGrath, J.,Isohanni, M.,Jaaskelainen, E. (2018). The age of onset of schizophrenia spectrum disorders Schizophrenia Bulletin, 44 (Supplement 1)(#issue#), S270	Addiction/Withdrawal
1	Montgomery, L.,Robinson, C.,Seaman, E. L.,Haeny, A. M. (2017). A scoping review and meta-analysis of psychosocial and pharmacological treatments for cannabis and tobacco use among African Americans Psychol Addict Behav, 31(8), 922-943	Addiction/Withdrawal
1	Montgomery, L.,Bagot, K.,Brown, J. L.,Haeny, A. M. (2019). The Association Between Marijuana Use and	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	HIV Continuum of Care Outcomes: a Systematic Review Curr HIV/AIDS Rep, 16(1), 17-28	
1	Murray, R. M., Schoeler, T., Friedman, D., Tunbridge, E., Ajnakina, O., Di Forti, M. (2016). The role of cannabis use and individual susceptibility in Influencing Outcome Among Patients with A) The ARMS and B) frank psychosis Early Intervention in Psychiatry, 10 (Supplement 1)(#issue#), 30	Addiction/Withdrawal
1	Murrie, B.,Lappin, J.,Large, M.,Sara, G. (2019). Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis Schizophrenia bulletin., 16(#issue#), #Pages#	Addiction/Withdrawal
1	Myles, H.,Myles, N.,Large, M. (2016). Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use Aust N Z J Psychiatry, 50(3), 208-19	Addiction/Withdrawal
1	Nandiwada, D. R.,Zuo, J. X.,Hannan, M. K. (2018). Persistent abdominal pain and vomiting in an ERA of legalized marijuana Journal of General Internal Medicine, 33 (2 Supplement 1)(#issue#), 592	Addiction/Withdrawal
1	Nettey, V. (2018). Effects of synthetic cannabinoid in patients with schizophrenia. a case report and literature review American Journal on Addictions, 27 (4)(#issue#), 316	Addiction/Withdrawal
1	Niaz, K.,Khan, F.,Maqbool, F.,Momtaz, S.,Hassan,	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	F.,Nobakht-Haghighi, N.,Rahimifard, M.,Abdollahi, M. (2017). Endo-cannabinoids system and the toxicity of cannabinoids with a biotechnological approach EXCLI Journal, 16(#issue#), 688-711	
1	Nielsen, S.,Gowing, L.,Sabioni, P.,Le Foll, B. (2019). Pharmacotherapies for cannabis dependence Cochrane Database Syst Rev, 1(1), Cd008940	Addiction/Withdrawal
1	Nunes, A. A.,dos Santos, R. G.,Osorio, F. L.,Sanches, R. F.,Crippa, J. A. S.,Hallak, J. E. C. (2016). Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans Journal of Psychoactive Drugs, 48(3), 195-205	Addiction/Withdrawal
1	Oberbarnscheidt, T.,Miller, N. (2019). Marijuana's effect on the adolescent American Journal on Addictions, 28 (3)(#issue#), 193-194	Addiction/Withdrawal
1	O'Donoghue, B.,Bowtell, M.,Ratheesh, A.,Killackey, E.,McGorry, P. (2018). Predictors of outcomes following discontinuation of antipsychotic medication after a first episode of psychosis - Findings from a systematic review and cohort study Early Intervention in Psychiatry, 12 (Supplement 1)(#issue#), 86	Addiction/Withdrawal
1	Olawole-Isaac, A.,Ogundipe, O.,Amoo, E. O.,Adeloye, D. (2018). Substance use among adolescents in sub- Saharan Africa: A systematic review and meta-analysis SAJCH South African Journal of Child Health,	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	12(Special Issue), S79-S84	
1	Olesen, J. A., Posselt, C. M., Nordentoft, M., Hjorthoej, C. (2018). Cannabis may protect against certain disorders of the digestive organs in patients with schizophrenia but not in healthy controls Schizophrenia Bulletin, 44 (Supplement 1)(#issue#), S365	Addiction/Withdrawal
1	O'Neill, A.,Bachi, B.,Bhattacharyya, S. (2020). Attentional bias towards cannabis cues in cannabis users: A systematic review and meta-analysis Drug and Alcohol Dependence, 206 (no pagination)(107719), #Pages#	Addiction/Withdrawal
1	Ooi, S. L., Green, R., Pak, S. C. (2018). N- Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence Biomed Res Int, 2018(#issue#), 2469486	Addiction/Withdrawal
1	Orsolini, L.,Papanti, G. D.,De Berardis, D.,Guirguis, A.,Corkery, J. M.,Schifano, F. (2017). The "Endless Trip" among the NPS users: Psychopathology and psychopharmacology in the Hallucinogen-persisting perception disorder. A systematic review Frontiers in Psychiatry, 8 (NOV) (no pagination)(240), #Pages#	Addiction/Withdrawal
1	Pacheco-Colon, I.,Limia, J. M.,Gonzalez, R. (2018). Nonacute effects of cannabis use on motivation and reward sensitivity in humans: A systematic review Psychology of Addictive Behaviors, 32(5), 497-507	Addiction/Withdrawal
1	Papadimitriou, D.,Geraki, E.,Nedelkos, G.,Tsantekidis,	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	K.,Mironidou-Tzouveleki, M. (2016). Gabapentin as an addiction treatment: An evidenced-based study Hippokratia, 20 (Supplement 1)(#issue#), 15	
1	Patle, V.,Lowe, A. (2016). Refractory status epilepticus Anaesthesia, 2)(#issue#), 56	Addiction/Withdrawal
1	Peh, O. H.,Rapisarda, A.,Lee, J. (2018). Childhood adversities in people at ultra-high risk (UHR) for psychosis: Systematic review & meta-analysis Schizophrenia Bulletin, 44 (Supplement 1)(#issue#), S270-S271	Addiction/Withdrawal
1	Pergolizzi, J.,LeQuang, J. A.,Bisney, J. (2018). Cannabinoid hyperemesis syndrome: A paradoxical property of marijuana Postgraduate Medicine, 130 (Supplement 1)(#issue#), 38-39	Addiction/Withdrawal
1	Petrykiv, S.,Arts, M.,Fennema, J.,De Jonge, L. (2018). Cannabis abuse and the risk of psychosis: A brief review of the clinical evidence European Psychiatry, 48 (Supplement 1)(#issue#), S550	Addiction/Withdrawal
1	Platt, B.,O'Driscoll, C.,Curran, V. H.,Rendell, P. G.,Kamboj, S. K. (2019). The effects of licit and illicit recreational drugs on prospective memory: a meta- analytic review Psychopharmacology, 236(4), 1131- 1143	Addiction/Withdrawal
1	Prat, G.,Rio-Martinez, L.,Marquez-Arrico, J. E.,Forero, D.,Navarro, J. F.,Adan, A. (2018). Factors related to brain impairment in dual schizophrenia Heroin	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	Addiction and Related Clinical Problems, 20 (Supplement 2)(#issue#), 67	
1	 Pries, L. K.,Lage-Castellanos, A.,Delespaul, P.,Kenis, G.,Luykx, J. J.,Lin, B. D.,Richards, A. L.,Akdede, B.,Binbay, T.,Altinyazar, V.,Yalincetin, B.,Gumus-Akay, G.,Cihan, B.,Soygur, H.,Ulas, H.,Cankurtaran, E. S.,Kaymak, S. U.,Mihaljevic, M. M.,Petrovic, S. A.,Mirjanic, T.,Bernardo, M.,Cabrera, B.,Bobes, J.,Saiz, P. A.,Garcia-Portilla, M. P.,Sanjuan, J.,Aguilar, E. J.,Santos, J. L.,Jimenez-Lopez, E.,Arrojo, M.,Carracedo, A.,Lopez, G.,Gonzalez-Penas, J.,Parellada, M.,Maric, N. P.,Atbasoglu, C.,Ucok, A.,Alptekin, K.,Saka, M. C.,Arango, C.,O'Donovan, M.,Rutten, B. P. F.,van Os, J.,Guloksuz, S. (2019). Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study Schizophrenia bulletin, 45(5), 960-965 	Addiction/Withdrawal
1	Ragazzi, T. C. C., Shuhama, R., Menezes, P. R., Del- Ben, C. M. (2018). Cannabis use as a risk factor for psychotic-like experiences: A systematic review of non- clinical populations evaluated with the Community Assessment of Psychic Experiences Early Interv Psychiatry, 12(6), 1013-1023	Addiction/Withdrawal
1	Rebgetz, S.,Kavanagh, D. J.,Hides, L. (2016). Changes in cannabis use among psychotic clients without specialised substance use treatment Schizophr	Addiction/Withdrawal



Level	Bibliography	Reason for exclusion
	Res, 175(1-3), 136-141	
1	Reid, S.,Bhattacharyya, S. (2019). Antipsychotic treatment failure in patients with psychosis and co- morbid cannabis use: A systematic review Psychiatry Research, 280 (no pagination)(112523), #Pages#	Addiction/Withdrawal
1	Richards, J. R.,Gordon, B. K.,Danielson, A. R.,Moulin, A. K. (2017). Pharmacologic Treatment of Cannabinoid Hyperemesis Syndrome: A Systematic Review Pharmacotherapy, 37(6), 725-734	Addiction/Withdrawal
1	Richards, J.,Gordon, B.,Danielson, A.,Moulin, A. (2017). Pharmacologic treatment of cannabinoid hyperemesis syndrome: A systematic review Academic Emergency Medicine, 24 (Supplement 1)(#issue#), S41	Addiction/Withdrawal
1	Richards, J. R.,Bing, M. L.,Moulin, A. K.,Elder, J. W.,Rominski, R. T.,Summers, P. J.,Laurin, E. G. (2019). Cannabis use and acute coronary syndrome Clinical Toxicology, 57(10), 831-841	Addiction/Withdrawal
1	Samavati, R.,Ducza, E.,Hajagos-Toth, J.,Gaspar, R. (2017). Herbal laxatives and antiemetics in pregnancy Reproductive Toxicology, 72(#issue#), 153-158	Addiction/Withdrawal
1	Sanchez-Gutierrez, T.,Fernandez-Castilla, B.,Barbeito, S.,Becerra, J. A.,Calvo, A. (2018). Comparisons between cannabis users and non-users patients with firstepisode psychosis in neurocognitive functioning: A meta-analysis Schizophrenia Bulletin, 44 (Supplement	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	1)(#issue#), S255-S256	
1	Sanchez-Gutierrez, T.,Fernandez-Castilla, B.,Barbeito, S.,Gonzalez-Pinto, A.,Becerra-Garcia, J. A.,Calvo, A. (2020). Cannabis use and nonuse in patients with first- episode psychosis: A systematic review and meta- analysis of studies comparing neurocognitive functioning European psychiatry : the journal of the Association of European Psychiatrists, 63(1), e6	Addiction/Withdrawal
1	Sandfort, T. G. M.,Knox, J. R.,Alcala, C.,EI-Bassel, N.,Kuo, I.,Smith, L. R. (2017). Substance Use and HIV Risk Among Men Who Have Sex With Men in Africa: A Systematic Review J Acquir Immune Defic Syndr, 76(2), e34-e46	Addiction/Withdrawal
1	Schlossarek, S.,Kempkensteffen, J.,Reimer, J.,Verthein, U. (2016). Psychosocial Determinants of Cannabis Dependence: A Systematic Review of the Literature Eur Addict Res, 22(3), 131-44	Addiction/Withdrawal
1	Schoeler, T.,Monk, A.,Sami, M. B.,Klamerus, E.,Foglia, E.,Brown, R.,Camuri, G.,Altamura, A. C.,Murray, R.,Bhattacharyya, S. (2016). Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis Lancet Psychiatry, 3(3), 215-25	Addiction/Withdrawal
1	Schreck, B.,Wagneur, N.,Caillet, P.,Gerardin, M.,Cholet, J.,Spadari, M.,Authier, N.,Tournebize, J.,Gaillard, M.,Serre, A.,Carton, L.,Pain, S.,Jolliet,	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	P.,Victorri-Vigneau, C. (2018). Cannabinoid hyperemesis syndrome: Review of the literature and of cases reported to the French addictovigilance network Drug and Alcohol Dependence, 182(#issue#), 27-32	
1	Scott, J. C., Slomiak, S. T., Jones, J. D., Rosen, A. F. G., Moore, T. M., Gur, R. C. (2018). Association of Cannabis With Cognitive Functioning in Adolescents and Young Adults: A Systematic Review and Meta-analysis JAMA Psychiatry, 75(6), 585-595	Addiction/Withdrawal
1	Sepede, G.,Lorusso, M.,Spano, M. C.,Di Nanno, P.,Di Iorio, G.,Di Giannantonio, M. (2018). Efficacy and Safety of Atypical Antipsychotics in Bipolar Disorder with Comorbid Substance Dependence: A Systematic Review Clinical Neuropharmacology, 41(5), 181-191	Addiction/Withdrawal
1	Sharapova, S. R., Phillips, E., Sirocco, K., Kaminski, J. W., Leeb, R. T., Rolle, I. (2018). Effects of prenatal marijuana exposure on neuropsychological outcomes in children aged 1-11 years: A systematic review Paediatric and Perinatal Epidemiology, 32(6), 512-532	Addiction/Withdrawal
1	Sharma, P. (2019). 64.3 an Overview of the Complex Relationship between Adolescent Cannabis Use and Development of Psychosis in Youth Journal of the American Academy of Child and Adolescent Psychiatry, 58 (10 Supplement)(#issue#), S91	Addiction/Withdrawal
1	Shilpakar, S.,Sangroula, D.,Shipu, S. (2019). Cannabis withdrawal precipitating first manic episode:	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	The first case report American Journal on Addictions, 28 (3)(#issue#), 196	
1	Sideli, L., Quigley, H., La Cascia, C., Murray, R. M. (2020). Cannabis Use and the Risk for Psychosis and Affective Disorders Journal of Dual Diagnosis, 16(1), 22-42	Addiction/Withdrawal
1	Simkin, D. R. (2018). Risk Factors for Substance Use Disorder and Neurodevelopmental Effects of Marijuana Journal of the American Academy of Child and Adolescent Psychiatry, 57 (10 Supplement)(#issue#), S94-S95	Addiction/Withdrawal
1	Singh, S.,Balhara, Y. P. S. (2017). A review of Indian research on co-occurring cannabis use disorders& psychiatric disorders Indian J Med Res, 146(2), 186-195	Addiction/Withdrawal
1	Soe-Agnie, S. E., Paap, M. C. S., VanDerNagel, J. E. L., Nijman, H. J. M., de Jong, C. A. J. (2018). The generalizability of the structure of substance abuse and antisocial behavioral syndromes: A systematic review Psychiatry Research, 259(#issue#), 412-421	Addiction/Withdrawal
1	Sorensen, C. J., DeSanto, K., Borgelt, L., Phillips, K. T., Monte, A. A. (2017). Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review J Med Toxicol, 13(1), 71-87	Addiction/Withdrawal
1	Spadari, M.,Gully, M.,Jourde-Chiche, N.,Frauger,	Addiction/Withdrawal



Level	Bibliography	Reason for exclusion
	E.,Micallef, J. (2017). What are uronephrologic complications related to the consumption of psychoactive substances? Fundamental and Clinical Pharmacology, 31 (Supplement 1)(#issue#), 46-47	
1	Tait, R. J., Caldicott, D., Mountain, D., Hill, S. L., Lenton,S. (2016). A systematic review of adverse eventsarising from the use of synthetic cannabinoids and theirassociated treatment Clin Toxicol (Phila), 54(1), 1-13	Addiction/Withdrawal
1	Temmingh, H. S., Williams, T., Siegfried, N., Stein, D. J. (2018). Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse Cochrane Database Syst Rev, 1(1), Cd011057	Addiction/Withdrawal
1	Thusius, N.,Hickson, L.,Karpyak, V.,Hall-Flavin, D.,Schneekloth, T.,Stark, A. (2017). The cannabis controversy: Two case studies of cannabis use disorders and renal transplantation American Journal on Addictions, 26 (3)(#issue#), 251-252	Addiction/Withdrawal
1	Tirado-Munoz, J.,Mestre-Pinto, J. I.,Farre, M.,Fonseca, F.,Torrens, M. (2018). Comprehensive interventions for reducing cannabis use Current Opinion in Psychiatry, 31(4), 315-323	Addiction/Withdrawal
1	Tomczyk, S.,Isensee, B.,Hanewinkel, R. (2016). Latent classes of polysubstance use among adolescents-a systematic review Drug and Alcohol Dependence, 160(#issue#), 12-29	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
1	Tournebize, J., Gibaja, V., Kahn, J. P. (2017). How safe are synthetic cannabinoids? Fundamental and Clinical Pharmacology, 31 (Supplement 1)(#issue#), 29	Addiction/Withdrawal
1	Tournebize, J., Gibaja, V., Kahn, J. P. (2017). Acute effects of synthetic cannabinoids: Update 2015 Subst Abus, 38(3), 344-366	Addiction/Withdrawal
1	Twomey, C. D. (2017). Association of cannabis use with the development of elevated anxiety symptoms in the general population: a meta-analysis J Epidemiol Community Health, 71(8), 811-816	Addiction/Withdrawal
1	Underner, M.,Perriot, J.,Peiffer, G. (2017). Pneumomediastinum and cocaine use Journal Europeen des Urgences et de Reanimation, 29(3), 221-234	Addiction/Withdrawal
1	Underner, M., Perriot, J., Peiffer, G., Urban, T., Jaafari, N. (2020). Acute eosinophilic pneumonia and illicit psychoactive substance use Revue des Maladies Respiratoires, 37(1), 34-44	Addiction/Withdrawal
1	van der Steur, S. J.,Batalla, A.,Bossong, M. G. (2020). Factors moderating the association between cannabis use and psychosis risk: A systematic review Brain Sciences, 10 (2) (no pagination)(97), #Pages#	Addiction/Withdrawal
1	Vasiliu, O.,Voicu, V. A.,Vasile, D. (2019). Health- related quality of life in cannabis use disorder Medical Cannabis and Cannabinoids, 2 (2)(#issue#), 14	Addiction/Withdrawal
1	Vasiliu, O., Voicu, V. A., Vasile, D. (2019). Cannabis	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	and eating disorders - A literature review Medical Cannabis and Cannabinoids, 2 (2)(#issue#), 15	
1	Vasiliu, O.,Voicu, V. A.,Vasile, D. (2019). Pharmacological treatment of cannabis use disorder and schizophrenia spectrum disorders dually diagnosed patients - Current state of research Medical Cannabis and Cannabinoids, 2 (2)(#issue#), 16	Addiction/Withdrawal
1	Vassos, E.,Sham, P.,Kempton, M.,Trotta, A.,Stilo, S. A.,Gayer-Anderson, C.,Di Forti, M.,Lewis, C. M.,Murray, R. M.,Morgan, C. (2019). The Maudsley environmental risk score for psychosis Psychological medicine, #volume#(#issue#), 1-8	Addiction/Withdrawal
1	Vassos, E., Sham, P., Kempton, M., Trotta, A., Stilo, S., Gayer-Anderson, C., Di Forti, M., Lewis, C., Murray, R., Morgan, C. (2019). F114the Development of the Maudsley Environmental Risk Score for Psychosis European Neuropsychopharmacology, 29 (Supplement 4)(#issue#), S1171-S1172	Addiction/Withdrawal
1	Wang, R. J., Wang, T. Y., Ma, J., Liu, M. X., Su, M. F., Lian, Z., Shi, J., Lu, L., Bao, Y. P. (2017). Substance use among young people in China: A systematic review and meta-analysis The Lancet, 390 (SPEC.ISS 1)(#issue#), 14	Addiction/Withdrawal
1	Werneck, M. A., Kortas, G. T., de Andrade, A. G., Castaldelli-Maia, J. M. (2018). A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	Therapy for Cannabis Withdrawal Symptoms CNS Drugs, 32(12), 1113-1129	
1	Wijayendran, S. B.,O'Neill, A.,Bhattacharyya, S. (2018). The effects of cannabis use on salience attribution: a systematic review Acta Neuropsychiatr, 30(1), 43-57	Addiction/Withdrawal
1	 Wilens, T. E. (2017). What's new in substance use disorders, cigarette use, and attention- deficit/hyperactivity disorder in adolescents? Journal of the American Academy of Child and Adolescent Psychiatry, 56 (10)(#issue#), S144-S145 	Addiction/Withdrawal
1	Wilson, R. P., Bhattacharyya, S. (2016). Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: A systematic review J Psychopharmacol, 30(2), 99- 111	Addiction/Withdrawal
1	Wilson, L., Szigeti, A., Kearney, A., Clarke, M. (2018). Clinical characteristics of primary psychotic disorders with concurrent substance abuse and substance- induced psychotic disorders: A systematic review Schizophr Res, 197(#issue#), 78-86	Addiction/Withdrawal
1	Wolff, V.,Jouanjus, E. (2017). Strokes are possible complications of cannabinoids use Epilepsy and Behavior, Part B. 70(#issue#), 355-363	Addiction/Withdrawal
1	Woodward, K., Fritz, M., Corley, R., Friedman, N., Hewitt, J., Stallings, M., Rhee, S. (2016). The association between Marijuana use and depression Behavior Genetics, 46 (6)(#issue#), 814	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
1	Wycoff, A. M., Metrik, J., Trull, T. J. (2018). Affect and cannabis use in daily life: a review and recommendations for future research Drug and Alcohol Dependence, 191(#issue#), 223-233	Addiction/Withdrawal
1	Yakhkind, A.,Kaushal, A.,Thompson, B. (2017). Acute toxic leukoencephalopathy due to fentanyl overdose Neurocritical Care, 27 (2 Supplement 1)(#issue#), S457	Addiction/Withdrawal
1	Yazdanian, M., Armoon, B., Noroozi, A., Mohammadi, R., Bayat, A. H., Ahounbar, E., Higgs, P., Nasab, H. S., Bayani, A., Hemmat, M. (2020). Dental caries and periodontal disease among people who use drugs: a systematic review and meta-analysis BMC oral health, 20(1), 44	Addiction/Withdrawal
1	Zhand, N.,Milin, R. (2018). What do we know about the pharmacotheraputic management of insomnia in cannabis withdrawal: A systematic review Am J Addict, 27(6), 453-464	Addiction/Withdrawal
1	Zhang, M.,Ying, J.,Wing, T.,Song, G.,Fung, D. S. S.,Smith, H. (2018). A Systematic Review of Attention Biases in Opioid, Cannabis, Stimulant Use Disorders International Journal of Environmental Research & Public Health [Electronic Resource], 15(6), 01	Addiction/Withdrawal
1	Zimmermann, M., Chong, A. K., Vechiu, C., Papa, A. (2020). Modifiable risk and protective factors for anxiety disorders among adults: A systematic review	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	Psychiatry Research, 285 (no pagination)(112705), #Pages#	
1	 Allan, G. M., Finley, C. R., Ton, J., Perry, D., Ramji, J., Crawford, K., Lindblad, A. J., Korownyk, C., Kolber, M. R. (2018). Systematic review of systematic reviews for medical cannabinoids Canadian Family Physician, 64(2), e78-e94 	Duplicate reference
1	Arranz, B.,Garriga, M.,Garcia-Rizo, C.,San, L. (2018). Clozapine use in patients with schizophrenia and a comorbid substance use disorder: A systematic review European Neuropsychopharmacology, 28(2), 227-242	Duplicate reference
1	 Belbasis, L.,Kohler, C. A.,Stefanis, N.,Stubbs, B.,van Os, J.,Vieta, E.,Seeman, M. V.,Arango, C.,Carvalho, A. F.,Evangelou, E. (2018). Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses Acta Psychiatrica Scandinavica, 137(2), 88-97 	Duplicate reference
1	Coentre, R.,Talina, M. C.,Góis, C.,Figueira, M. L. (2017). Depressive symptoms and suicidal behavior after first-episode psychosis: A comprehensive systematic review Psychiatry Res, 253(#issue#), 240- 248	Duplicate reference
1	Dualibe, A. L.,Osorio, F. L. (2017). Bipolar Disorder and Early Emotional Trauma: A Critical Literature Review on Indicators of Prevalence Rates and Clinical Outcomes Harvard Review of Psychiatry, 25(5), 198-	Duplicate reference



Level	Bibliography	Reason for
		exclusion
	208	
1	 Farooqui, M. T.,Khan, M. A.,Cholankeril, G.,Khan, Z.,Abdul, M. K. M.,Li, A. A.,Shah, N.,Wu, L.,Haq, K.,Solanki, S.,Kim, D.,Ahmed, A. (2019). Marijuana is not associated with progression of hepatic fibrosis in liver disease: A systematic review and meta-analysis European Journal of Gastroenterology and Hepatology, 31(2), 149-156 	Duplicate reference
1	 Fitzcharles, M. A., Ste-Marie, P. A., Hauser, W., Clauw, D. J., Jamal, S., Karsh, J., Landry, T., Leclercq, S., McDougall, J. J., Shir, Y., Shojania, K., Walsh, Z. (2016). Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials Arthritis care & research, 68(5), 681-8 	Duplicate reference
1	Fitzcharles, M. A.,Baerwald, C.,Ablin, J.,Hauser, W. (2016). Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials Der Schmerz, 30(1), 47- 61	Duplicate reference
1	Hauser, W., Fitzcharles, M. A., Radbruch, L., Petzke, F. (2017). Cannabinoids in Pain Management and Palliative Medicine Deutsches Arzteblatt International, 114(38), 627-634	Duplicate reference



Level	Bibliography	Reason for
		exclusion
1	 Hauser, W., Petzke, F., Fitzcharles, M. A. (2018). Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - An overview of systematic reviews European Journal of Pain, 22(3), 455-470 	Duplicate reference
1	Hauser, W., Finnerup, N. B., Moore, R. A. (2018). Systematic reviews with meta-analysis on cannabis- based medicines for chronic pain: a methodological and political minefield Pain, 159(10), 1906-1907	Duplicate reference
1	 Häuser, W.,Welsch, P.,Klose, P.,Radbruch, L.,Fitzcharles, M. A. (2019). Efficacy, tolerability and safety of cannabis-based medicines for cancer pain : A systematic review with meta-analysis of randomised controlled trials Schmerz, 33(5), 424-436 	Duplicate reference
1	Hugos, C.,Rice, J.,Cameron, M. (2019). Cannabis use in people with multiple sclerosis and self-reported spasticity Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN, 92(15 Supplement 1), #Pages#	Duplicate reference
1	 Hunt, G. E., Malhi, G. S., Cleary, M., Lai, H. M., Sitharthan, T. (2016). Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990-2015: Systematic review and meta-analysis Journal of Affective Disorders, 206(#issue#), 331-349 	Duplicate reference
1	llić, B.,Švab, V.,Sedić, B.,Kovačević, I.,Friganović, A.,Jurić, E. (2017). Mental Health in Domesticated	Duplicate reference



Level	Bibliography	Reason for
		exclusion
	Immigrant Population - a Systematic Review Psychiatr Danub, 29(3), 273-281	
1	Kafil, T. S., Nguyen, T. M., MacDonald, J. K., Chande, N. (2018). Cannabis for the treatment of Crohn's disease Cochrane Database Syst Rev, 11(11), Cd012853	Duplicate reference
1	Khoury, J. M., Neves, McId, Roque, M. A. V., Queiroz, D.A. B., Corrêa de Freitas, A. A., de Fátima, Â, Moreira, F.A., Garcia, F. D. (2019). Is there a role for cannabidiolin psychiatry? World J Biol Psychiatry, 20(2), 101-116	Duplicate reference
1	 Khoury, J. M., Neves, McId, Roque, M. A. V., Queiroz, D. A. B., Correa de Freitas, A. A., de Fatima, A., Moreira, F. A., Garcia, F. D. (2019). Is there a role for cannabidiol in psychiatry? World Journal of Biological Psychiatry, 20(2), 101-116 	Duplicate reference
1	Lecomte, T.,Potvin, S.,Samson, C.,Francoeur, A.,Hache-Labelle, C.,Gagne, S.,Boucher, J.,Bouchard, M.,Mueser, K. T. (2019). Predicting and preventing symptom onset and relapse in schizophrenia-A metareview of current empirical evidence Journal of Abnormal Psychology, 128(8), 840-854	Duplicate reference
1	Montgomery, L. T.,Bagot, K.,Brown, J. L.,Haeny, A. M. (2019). The Association Between Marijuana Use and HIV Continuum of Care Outcomes: a Systematic Review Current HIV/AIDS Reports, 16(1), 17-28	Duplicate reference
1	Mucke, M.,Carter, C.,Cuhls, H.,Pruss, M.,Radbruch, L.,Hauser, W. (2016). Cannabinoids in palliative care:	Duplicate reference



Level	Bibliography	Reason for exclusion
	Systematic review and meta-analysis of efficacy, tolerability and safety. [German] Schmerz, 30(1), 25- 36	
1	Mucke, M.,Carter, C.,Cuhls, H.,Prus, M.,Radbruch, L.,Hauser, W. (2016). [Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety] Der Schmerz, 30(1), 25-36	Duplicate reference
1	Mücke, M.,Weier, M.,Carter, C.,Copeland, J.,Degenhardt, L.,Cuhls, H.,Radbruch, L.,Häuser, W.,Conrad, R. (2018). Systematic review and meta- analysis of cannabinoids in palliative medicine J Cachexia Sarcopenia Muscle, 9(2), 220-234	Duplicate reference
1	Mücke, M., Phillips, T., Radbruch, L., Petzke, F., Häuser, W. (2018). Cannabis-based medicines for chronic neuropathic pain in adults Cochrane Database Syst Rev, 3(3), Cd012182	Duplicate reference
1	Petzke, F.,Enax-Krumova, E. K.,Hauser, W. (2016). Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies. [German] Schmerz, 30(1), 62-88	Duplicate reference
1	Petzke, F.,Enax-Krumova, E. K.,Hauser, W. (2016). [Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies] Der Schmerz, 30(1), 62-88	Duplicate reference



Level	Bibliography	Reason for
		exclusion
1	Pinto, J. V.,Medeiros, L. S.,Santana da Rosa, G.,Santana de Oliveira, C. E.,Crippa, J. A. D. S.,Passos, I. C.,Kauer-Sant'Anna, M. (2019). The prevalence and clinical correlates of cannabis use and cannabis use disorder among patients with bipolar disorder: A systematic review with meta-analysis and meta-regression Neuroscience and Biobehavioral Reviews, 101(#issue#), 78-84	Duplicate reference
1	Richards, J.,Bing, M. L.,Moulin, A.,Elder, J. W.,Rominski, R.,Summers, P.,Laurin, E.,Greineder, C. (2019). Cannabis use and acute coronary syndrome: A systematic review Academic Emergency Medicine, 26 (Supplement 1)(#issue#), S127	Duplicate reference
1	Tafelski, S.,Hauser, W.,Schafer, M. (2016). Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting-a systematic review of systematic reviews Schmerz, 30(1), 14-24	Duplicate reference
1	Tafelski, S.,Hauser, W.,Schafer, M. (2016). Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomitinga systematic review of systematic reviews Der Schmerz, 30(1), 14-24	Duplicate reference
1	Turna, J.,Syan, S. K.,Frey, B. N.,Rush, B.,Costello, M. J.,Weiss, M.,MacKillop, J. (2019). Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review Alcoholism:	Duplicate reference



Level	Bibliography	Reason for
		exclusion
	Clinical and Experimental Research, 43(4), 550-563	
1	 Vaessen, T. S. J., de Jong, L., Schäfer, A. T., Damen, T., Uittenboogaard, A., Krolinski, P., Nwosu, C. V., Pinckaers, F. M. E., Rotee, I. L. M., Smeets, A. P. W., Ermiş, A., Kennedy, J. L., Nieman, D. H., Tiwari, A., van Os, J., Drukker, M. (2018). The interaction between cannabis use and the Val158Met polymorphism of the COMT gene in psychosis: A transdiagnostic meta - analysis PLoS One, 13(2), e0192658 	Duplicate reference
1	Volz, M. S., Siegmund, B., Hauser, W. (2016). Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review. [German] Schmerz, 30(1), 37-46	Duplicate reference
1	 Volz, M. S., Siegmund, B., Hauser, W. (2016). [Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review] Der Schmerz, 30(1), 37-46 	Duplicate reference
1	Walitt, B.,Klose, P.,Fitzcharles, M. A.,Phillips, T.,Häuser, W. (2016). Cannabinoids for fibromyalgia Cochrane Database Syst Rev, 7(7), Cd011694	Duplicate reference
1	Wilens, T. (2018). 66.1 Medical Marijuana in Kids: So, What Is the Evidence? Journal of the American Academy of Child and Adolescent Psychiatry, 57 (10 Supplement)(#issue#), S94	Duplicate reference
1	Wilens, T. (2019). 59.1 Medical Marijuana in Kids: So,	Duplicate reference



Level	Bibliography	Reason for exclusion
	What Is the Evidence? Journal of the American Academy of Child and Adolescent Psychiatry, 58 (10 Supplement)(#issue#), S84	
1	Bostock, E.,Kirkby, K.,Garry, M.,Taylor, B.,Hawrelak, J. A. (2018). Mania associated with herbal medicines, other than cannabis: A systematic review and quality assessment of case reports Frontiers in Psychiatry, 9 (JUL) (no pagination)(280), #Pages#	Irrelevant exposure
1	dos Santos, R. G.,Bouso, J. C.,Hallak, J. E. C. (2017). Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies Therapeutic Advances in Psychopharmacology, 7(4), 141-157	Irrelevant exposure
1	Lam, L.,Anand, S.,Li, X.,Li Tse, M.,Zhao, J. X.,Chan, E. W. Y. (2018). Efficacy and safety of naltrexone for amphetamine and methamphetamine use disorder: A systematic review of randomized controlled trials Pharmacoepidemiology and Drug Safety, 27 (Supplement 2)(#issue#), 100	Irrelevant exposure
1	Moran, L.,Ongur, D.,Hsu, J.,Castro, V.,Perlis, R.,Schneeweiss, S. (2019). Comparative risk of psychosis with amphetamine versus methylphenidate in adolescents and young adults with attention deficit hyperactivity disorder Schizophrenia Bulletin, 45 (Supplement 2)(#issue#), S201	Irrelevant exposure
1	Siefried, K. J., Acheson, L. S., Lintzeris, N., Ezard, N. (2020). Pharmacological Treatment of	Irrelevant exposure



Level	Bibliography	Reason for
		exclusion
	Methamphetamine/Amphetamine Dependence: A Systematic Review CNS drugs., 17(#issue#), #Pages#	
1	Underner, M.,Perriot, J.,Wallaert, B.,Peiffer, G.,Meurice, J. C.,Jaafari, N. (2018). Alveolar hemorrhage and cocaine use Revue des Maladies Respiratoires, 35(2), 134-148	Irrelevant exposure
1	Jouroukhin, Y.,Zhu, X.,Shevelkin, A. V.,Hasegawa, Y.,Abazyan, B.,Saito, A.,Pevsner, J.,Kamiya, A.,Pletnikov, M. V. (2019). Adolescent DELTA ⁹ -Tetrahydrocannabinol Exposure and Astrocyte-Specific Genetic Vulnerability Converge on Nuclear Factor-kappaB-Cyclooxygenase-2 Signaling to Impair Memory in Adulthood Biological Psychiatry, 85(11), 891-903	Irrelevant population
1	Kubilius, R. A.,Kaplick, P. M.,Wotjak, C. T. (2018). Highway to hell or magic smoke? The dose- dependence of DELTA ⁹ -THC in place conditioning paradigms Learning & Memory, 25(9), 446-454	Irrelevant population
1	Urbi, B.,Owusu, M. A.,Fraser, I.,Katz, M.,Sabet, A. (2018). Effects of cannabinoid in amyotrophic lateral sclerosis (ALS) or motor neurone disease (MND): A preclinical systematic review and metaanalysis Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 19 (Supplement 1)(#issue#), 234	Irrelevant population
1	Creedon, E. S.,Maloy, M. K.,DelloStritto, R. A. (2020).	Irrelevant study



Level	Bibliography	Reason for
		exclusion
	Cannabinoid hyperemesis syndrome: A case study and discussion Journal of the American Association of Nurse Practitioners, 32(3), 269-276	design
1	Damkier, P.,Lassen, D.,Christensen, M. M. H.,Madsen, K. G.,Hellfritzsch, M.,Pottegard, A. (2019). Interaction between warfarin and cannabis Basic and Clinical Pharmacology and Toxicology, 124(1), 28-31	Irrelevant study design
1	Elliott, J.,DeJean, D.,Clifford, T.,Coyle, D.,Potter, B.,Skidmore, B.,Alexander, C.,Repetski, A. E.,McCoy, B.,Wells, G. A. (2018). Cannabis for pediatric epilepsy: Protocol for a living systematic review Systematic Reviews, 7 (1) (no pagination)(95), #Pages#	Irrelevant study design
1	Gandam, H.,Patel, A.,Rico Mora, D.,Walton, L. (2017). Persistent intracranial hypotension after epidural for labor analgesia Journal of Neurosurgical Anesthesiology, 29 (4)(#issue#), 560	Irrelevant study design
1	Häuser, W., Finnerup, N. B., Moore, R. A. (2018). Systematic reviews with meta-analysis on cannabis- based medicines for chronic pain: a methodological and political minefield Pain, 159(10), 1906-1907	Irrelevant study design
1	Hugos, C.,Rice, J.,Cameron, M. (2019). Cannabis use in people with MS and spasticity: A cross-sectional analysis Multiple Sclerosis Journal, 25 (7)(#issue#), 1031-1032	Irrelevant study design
1	Khaled, S. M.,Hughes, E.,Bressington, D.,Zolezzi, M.,Radwan, A.,Badnapurkar, A.,Gray, R. (2016). The	Irrelevant study design



Level	Bibliography	Reason for
		exclusion
	prevalence of novel psychoactive substances (NPS) use in non-clinical populations: A systematic review protocol Systematic Reviews, 5 (1) (no pagination)(195), #Pages#	
1	Lang, J., Jin, L., Yao, Y. (2019). Comparative efficacy of interventions for reducing injection and sexual risk behaviours to prevent HIV in injection drug users: Protocol for Bayesian network meta-analysis BMJ Open, 9 (1) (no pagination)(e022811), #Pages#	Irrelevant study design
1	Lange, N. (2019). Editorial: Brain Mediators of the Cannabis-Prodromal Psychosis Connection Journal of the American Academy of Child and Adolescent Psychiatry., #volume#(#issue#), #Pages#	Irrelevant study design
1	Parekh, T.,Mathew, S.,Goudreau, C.,Lonergan, A.,Piran, P.,Malpe, C. (2017). Awareness of epilepsy risk factors and treatment in a south florida community- an observational study Annals of Neurology, 82 (Supplement 21)(#issue#), S159-S160	Irrelevant study design
1	Pereira, D.,Moreno, M.,Vien, F.,Ponte, A.,Teodoro, T.,Mendes, M.,Goncalves, F. (2019). Suicide: A primary or secondary road in ADHD - Clinical case ADHD Attention Deficit and Hyperactivity Disorders, 11 (1 Supplement)(#issue#), S12-S13	Irrelevant study design
1	Sorensen, C. J., DeSanto, K., Borgelt, L., Phillips, K. T., Monte, A. A. (2017). In Response to Letter to the Editor Regarding: Cannabinoid Hyperemesis	Irrelevant study design



Level	Bibliography	Reason for
		exclusion
	Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review Journal of Medical Toxicology, 13(2), 198	
1	Swaney, J.,Das, M.,Kini, R.,Garg, G.,Parker, R. (2018). Pfropfschizophrenia: A relic of history or a modern psychiatric concept? Australian and New Zealand Journal of Psychiatry, 52 (1 Supplement 1)(#issue#), 153-154	Irrelevant study design
1	Treister-Goltzman, Y., Freud, T., Press, Y., Peleg, R. (2019). Trends in Publications on Medical Cannabis from the Year 2000 Population Health Management, 22(4), 362-368	Irrelevant study design
1	T'Sarumi, O.,Nettey, V. (2019). Cognitive impairment due to synthetic cannabinoids (k2) use and psychosis American Journal on Addictions, 28 (3)(#issue#), 203	Irrelevant study design
1	Venkatesan, T.,Levinthal, D. J.,Li, B. U. K.,Tarbell, S. E.,Adams, K. A.,Issenman, R. M.,Sarosiek, I.,Jaradeh, S. S.,Sharaf, R. N.,Sultan, S.,Stave, C. D.,Monte, A. A.,Hasler, W. L. (2019). Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome Neurogastroenterology and Motility, 31 (S2) (no pagination)(e13606), #Pages#	Irrelevant study design
1	Verbraeken, R.,Luykx, J. J. (2018). Persistent catatonia following epileptic seizures: a case report and systematic literature search BMC Psychiatry, 18(1), 350	Irrelevant study design



Level	Bibliography	Reason for
		exclusion
1	Cardenas-Robledo, S.,Lopez, L.,Guio, C. M. (2018). Multiple sclerosis coverage in the written media of a low prevalence country Multiple Sclerosis Journal, 24 (2 Supplement)(#issue#), 350-351	Irrelevant study focus
1	Carey, C. E., Agrawal, A., Bucholz, K. K., Hartz, S. M., Lynskey, M. T., Nelson, E. C., Bierut, L. J., Bogdan, R. (2016). Associations between polygenic risk for psychiatric disorders and substance involvement Biological Psychiatry, 1)(#issue#), 370S	Irrelevant study focus
1	De Aquino, J. P.,Ranganathan, M.,Rhadhakrishnan, R.,Briones, J. C.,Pittman, B.,D'Souza, D. C. (2018). Highs and lows of cannabinoiddopamine interaction: Effects of genetic and pharmacological modulation of COMT on the acute response to delta-9- tetrahydrocannabinol in humans American Journal on Addictions, 27 (4)(#issue#), 279-280	Irrelevant study focus
1	Degenhardt, L., Charlson, F., Ferrari, A., Santomauro, D., Erskine, H., Mantilla-Herrara, A., Whiteford, H., Leung, J., Naghavi, M., Griswold, M., Rehm, J., Hall, W., Sartorius, B., Scott, J., Vollset, S. E., Knudsen, A. K., Haro, J. M., Patton, G., Kopec, J., Carvalho Malta, D., Topor-Madry, R., McGrath, J., Haagsma, J., Allebeck, P., Phillips, M., Salomon, J., Hay, S., Foreman, K., Lim, S., Mokdad, A., Smith, M., Gakidou, E., Murray, C., Vos, T. (2018). The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden	Irrelevant study focus



Level	Bibliography	Reason for
		exclusion
	of Disease Study 2016 The Lancet Psychiatry, 5(12), 987-1012	
1	Elliott, J.,McCoy, B.,Clifford, T.,Potter, B. K.,Skidmore, B.,Wells, G. A.,Coyle, D. (2019). Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: Protocol for a systematic review of economic evaluations Systematic Reviews, 8 (1) (no pagination)(75), #Pages#	Irrelevant study focus
1	Elliott, J.,van Katwyk, S.,McCoy, B.,Clifford, T.,Potter, B. K.,Skidmore, B.,Wells, G. A.,Coyle, D. (2019). Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations PharmacoEconomics, 37(10), 1261-1276	Irrelevant study focus
1	Forero, D. A., Gonzalez-Giraldo, Y. (2020). Convergent functional genomics of cocaine misuse in humans and animal models American Journal of Drug and Alcohol Abuse, 46(1), 22-30	Irrelevant study focus
1	Grech, V. (2019). Towards evidence-based medical cannabis Malta Medical Journal, 31(2), 3-7	Irrelevant study focus
1	 Herzog, S., Shanahan, M., Grimison, P., Tran, A., Wong, N., Lintzeris, N., Simes, J., Stockler, M., Morton, R. L. (2018). Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis Pharmacoeconomics, 36(1), 67-78 	Irrelevant study focus



Level	Bibliography	Reason for
		exclusion
1	Johnson, E., Demontis, D., Polimanti, R., Walters, R., McClintick, J., Edenberg, H., Gelernter, J., Borglum, A., Agrawal, A. (2019). Genome-Wide Association Study of Cannabis Use Disorder in European and African Ancestries European Neuropsychopharmacology, 29 (Supplement 5) (#issue#), S10-S11	Irrelevant study focus
1	Misiak, B., Stramecki, F., Gawęda, Ł, Prochwicz, K., S (2018). Interactions Between Variation in Candidate Genes and Environmental Factors in the Etiology of Schizophrenia and Bipolar Disorder: a Systematic Review Mol Neurobiol, 55(6), 5075-5100	Irrelevant study focus
1	Misiak, B., Stramecki, F., Gaweda, L., Prochwicz, K., Sasiadek, M. M., Moustafa, A. A., Frydecka, D. (2018). Interactions Between Variation in Candidate Genes and Environmental Factors in the Etiology of Schizophrenia and Bipolar Disorder: a Systematic Review Molecular Neurobiology, 55(6), 5075-5100	Irrelevant study focus
1	 Morris, J.,Bailey, M. E. S.,Baldassarre, D.,Cullen, B.,de Faire, U.,Ferguson, A.,Gigante, B.,Giral, P.,Goel, A.,Graham, N.,Hamsten, A.,Humphries, S. E.,Johnston, K. J. A.,Lyall, D. M.,Lyall, L. M.,Sennblad, B.,Silveira, A.,Smit, A. J.,Tremoli, E.,Veglia, F.,Ward, J.,Watkins, H.,Smith, D. J.,Strawbridge, R. J. (2019). Genetic variation in CADM2 as a link between psychological traits and obesity Scientific reports, 9(1), 7339 	Irrelevant study focus



Level	Bibliography	Reason for
		exclusion
1	Nagelhout, G. E., Hummel, K., de Goeij, M. C. M., de Vries, H., Kaner, E., Lemmens, P. (2017). How economic recessions and unemployment affect illegal drug use: A systematic realist literature review International Journal of Drug Policy, 44(#issue#), 69- 83	Irrelevant study focus
1	Nakamura, M.,Nestor, P. G.,Shenton, M. E. (2020). Orbitofrontal Sulcogyral Pattern as a Transdiagnostic Trait Marker of Early Neurodevelopment in the Social Brain Clinical EEG and Neuroscience., #volume#(#issue#), #Pages#	Irrelevant study focus
1	Olmos, A., Tirado-Muñoz, J., Farré, M., Torrens, M. (2018). The efficacy of computerized interventions to reduce cannabis use: A systematic review and meta- analysis Addict Behav, 79(#issue#), 52-60	Irrelevant study focus
1	Peterson, R.,Bigdeli, T.,Meyers, J.,Genovese, G.,Pato, M.,McCarroll, S.,Pato, C.,Fanous, A. (2019). Su119genetic Overlap and Causality among Schizophrenia and Substance Use: Findings from the Genomic Psychiatry Cohort European Neuropsychopharmacology, 29 (Supplement 4)(#issue#), S1330-S1331	Irrelevant study focus
1	Strickland, J. C., Campbell, E. M., Lile, J. A., Stoops, W. W. (2020). Utilizing the commodity purchase task to evaluate behavioral economic demand for illicit substances: a review and meta-analysis Addiction	Irrelevant study focus



Level	Bibliography	Reason for
		exclusion
	(Abingdon, England), 115(3), 393-406	
1	 Vaessen, T. S. J., de Jong, L., Schafer, A. T., Damen, T., Uittenboogaard, A., Krolinski, P., Nwosu, C. V., Pinckaers, F. M. E., Rotee, I. L. M., Smeets, A. P. W., Ermis, A., Kennedy, J. L., Nieman, D. H., Tiwari, A., van Os, J., Drukker, M. (2018). The interaction between cannabis use and the Val158Met polymorphism of the COMT gene in psychosis: A transdiagnostic meta - analysis PLoS ONE [Electronic Resource], 13(2), e0192658 	Irrelevant study focus
1	Walters, R.,Neale, B.,Edenberg, H.,Gelernter, J.,Agrawal, A. (2018). Genome-wide meta-analysis of[14,000 alcohol dependent individuals highlights psychiatric comorbidities Behavior Genetics, 48 (6)(#issue#), 520	Irrelevant study focus
1	Walters, R.,Substance Use Disorder Group of the Psychiatric Genomics, Consortium,Neale, B.,Edenberg, H.,Gelernter, J.,Agrawal, A. (2019). Genome-Wide Meta-Analysis of >14,000 Alcohol Dependent Individuals Highlights Psychiatric Comorbidities European Neuropsychopharmacology, 29 (Supplement 3)(#issue#), S802	Irrelevant study focus
1	Walters, R. (2019). Polygenic Risk for Alcohol Dependence Symptoms and Diagnosis from Gwas of >14,000 Dependent Cases European Neuropsychopharmacology, 29 (Supplement	Irrelevant study focus



Level	Bibliography	Reason for
		exclusion
	4)(#issue#), S1023	
1	Zvorsky, I.,Nighbor, T. D.,Kurti, A. N.,DeSarno, M.,Naude, G.,Reed, D. D.,Higgins, S. T. (2019). Sensitivity of hypothetical purchase task indices when studying substance use: A systematic literature review Preventive Medicine, 128 (no pagination)(105789), #Pages#	Irrelevant study focus
1	Akram, H.,Mokrysz, C.,Curran, H. V. (2019). What are the psychological effects of using synthetic cannabinoids? A systematic review Journal of Psychopharmacology, 33(3), 271-283	No therapeutic indication
1	Anonymous, (2018). COSA's 45th Annual Scientific Meeting, Mesothelioma and Gastro-Intestinal Cancers: Technology and Genomics Asia Pacific Journal of Clinical Oncology. Conference: 45th Annual Scientific Meeting of the Clinical Oncology Society of Australia, COSA, 14(Supplement 7), #Pages#	No therapeutic indication
1	Bacchus, L. J.,Ranganathan, M.,Watts, C.,Devries, K. (2018). Recent intimate partner violence against women and health: a systematic review and meta- analysis of cohort studies BMJ Open, 8(7), e019995	No therapeutic indication
1	Bahji, A.,Mazhar, M. N.,Hudson, C. C.,Nadkarni, P.,MacNeil, B. A.,Hawken, E. (2019). Prevalence of substance use disorder comorbidity among individuals with eating disorders: A systematic review and meta- analysis Psychiatry Research, 273(#issue#), 58-66	No therapeutic indication



Level	Bibliography	Reason for
		exclusion
1	Boyd, A.,Bleakley, C.,Hurley, D. A.,Gill, C.,Hannon-	No therapeutic
	Fletcher, M.,Bell, P.,McDonough, S. (2019). Herbal medicinal products or preparations for neuropathic pain Cochrane Database of Systematic Reviews, 2019 (4) (no pagination)(CD010528), #Pages#	indication
1	Colizzi, M.,McGuire, P.,Pertwee, R. G.,Bhattacharyya, S. (2016). Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence Neurosci Biobehav Rev, 64(#issue#), 359-81	No therapeutic indication
1	Crocker, C. E., Tibbo, P. G. (2018). The interaction of gender and cannabis in early phase psychosis Schizophrenia Research, 194(#issue#), 18-25	No therapeutic indication
1	Demissie, Z., Johns, M. M. (2020). 161. Assessing Behaviors, Experiences, and School Policies and Practices Impacting Sexual and Gender Minority Students: Surveillance Data from CDC's Division of Adolescent and School Health Journal of Adolescent Health, 66 (2 Supplement)(#issue#), S82	No therapeutic indication
1	Devoe, D.,Addington, J. (2018). Negative symptoms in youth at clinical high risk for psychosis: A systematic review and metaanalysis Early Intervention in Psychiatry, 12 (Supplement 1)(#issue#), 173	No therapeutic indication
1	Dickerson, F. (2019). Smoking and schizophrenia: Still a burning problem Schizophrenia Bulletin, 45 (Supplement 2)(#issue#), S95	No therapeutic indication
1	Dugdale, S., Elison-Davies, S., Semper, H., Ward,	No therapeutic



Level	Bibliography	Reason for
		exclusion
	J.,Davies, G. (2019). Are Computer-Based Treatment Programs Effective at Reducing Symptoms of Substance Misuse and Mental Health Difficulties Within Adults? A Systematic Review Journal of Dual Diagnosis, 15(4), 291-311	indication
1	El Khoury, J.,Noufi, P.,Ahmad, A.,Akl, E.,El Hayek, S. (2019). Attitudes, beliefs, and knowledge of substance use amongst youth in the Eastern Mediterranean region: A systematic review Drug and Alcohol Dependence, 196(#issue#), 71-78	No therapeutic indication
1	Fifi, A. C., Axelrod, C. H., Chakraborty, P., Saps, M. (2018). Herbs and spices in the treatment of functional gastrointestinal disorders: A review of clinical trials Nutrients, 10 (11) (no pagination)(1715), #Pages#	No therapeutic indication
1	Gunawan, C.,Seneviratne, U.,D'Souza, W. (2019). The effect of antiepileptic drugs on epileptiform discharges in genetic generalized epilepsy: A systematic review Epilepsy and Behavior, 96(#issue#), 175-182	No therapeutic indication
1	Hobbs, M.,Kalk, N. J.,Morrison, P. D.,Stone, J. M. (2018). Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review Eur Neuropsychopharmacol, 28(12), 1289-1304	No therapeutic indication
1	Ignaszewski, M.,Sundararaj, D.,Atkinson, D. (2019). Addiction as an attachment disorder: Effects of attachment style on risk of addictive disorders and role in treatment American Journal on Addictions, 28	No therapeutic indication



_		
Level	Bibliography	Reason for
		exclusion
	(3)(#issue#), 188	
1	Kirkbride, J.,Ding, T.,Dliwayo, R.,Wohland, P.,Osborn, D.,French, P.,Baio, G.,Jones, P. (2018). Predicting population-level need for early treatment programmes in first episode psychosis: The advanced psychiatric MAPping translated into innovations for care [PsyMaptic-A] study Early Intervention in Psychiatry, 12 (Supplement 1)(#issue#), 213	No therapeutic indication
1	Kwon, M.,Park, E.,Dickerson, S. S. (2019). Adolescent substance use and its association to sleep disturbances: A systematic review Sleep Health, 5(4), 382-394	No therapeutic indication
1	Lebargy, F.,Picard, D.,Hagenburg, J.,Toubas, O.,Perotin, J. M.,Sandu, S.,Deslee, G.,Dury, S. (2017). Micronodular pattern of organizing pneumonia Case report and systematic literature review Medicine (United States), 96 (3) (no pagination)(e5788), #Pages#	No therapeutic indication
1	Levent, A.,Davelaar, E. J. (2019). Illegal drug use and prospective memory: A systematic review Drug and Alcohol Dependence, 204 (no pagination)(107478), #Pages#	No therapeutic indication
1	Mansoor, K.,Kheetan, M.,Shahnawaz, S.,Shapiro, A. P.,Patton-Tackett, E.,Dial, L.,Rankin, G.,Santhanam, P.,Tzamaloukas, A. H.,Nadasdy, T.,Shapiro, J. I.,Khitan, Z. J. (2017). Systematic review of	No therapeutic indication



Level	Bibliography	Reason for
		exclusion
	nephrotoxicity of drugs of abuse, 2005-2016 BMC Nephrology, 18 (1) (no pagination)(379), #Pages#	
1	Minichino, A., Senior, M., Brondino, N., Zhang, S. H., Godwlewska, B. R., Burnet, P. W. J., Cipriani, A., Lennox, B. R. (2019). Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta-analysis JAMA Psychiatry, 76(9), 914-923	No therapeutic indication
1	Motlagh, F. E.,Ibrahim, F.,Rashid, R. A.,Seghatoleslam, T.,Habil, H. (2016). Acupuncture therapy for drug addiction Chinese Medicine (United Kingdom), 11 (1) (no pagination)(16), #Pages#	No therapeutic indication
1	Muflih, S.,Halum, A.,Bhinder, T.,Shawaqfeh, M.,Fore, J.,Chaar, N. (2019). The linkage between amphetamine-type stimulants and HIV sexual transmission risk behaviors (TRBs): A systematic review Systematic Reviews in Pharmacy, 10(1), S7- S12	No therapeutic indication
1	Murray, R.,Jauhar, S.,MacCabe, J.,Di Forti, M.,Quigley, H.,Gurillo, P. (2019). Does tobacco smoking cause psychosis? Schizophrenia Bulletin, 45 (Supplement 2)(#issue#), S96	No therapeutic indication
1	Murthy, A., Aroke, H., Belviso, N., Wen, X. (2018). Chronic opioid use after surgery: A meta-analysis of observational studies Pharmacoepidemiology and Drug Safety, 27 (Supplement 2)(#issue#), 325	No therapeutic indication



Level	Bibliography	Reason for
		exclusion
1	Odejayi, G.,Zipursky, R. (2018). Is maintenance treatment needed when the first episode of psychosis is not due to schizophrenia? Schizophrenia Bulletin, 44 (Supplement 1)(#issue#), S418	No therapeutic indication
1	Oldham, M. A. (2018). The Probability That Catatonia in the Hospital has a Medical Cause and the Relative Proportions of Its Causes: A Systematic Review Psychosomatics, 59(4), 333-340	No therapeutic indication
1	Patnaik Kuppili, P.,Vengadavaradan, A.,Bharadwaj, B. (2019). Metabolic syndrome and substance use: A narrative review Asian Journal of Psychiatry, 43(#issue#), 111-120	No therapeutic indication
1	 Perry, A. E., Martyn-St James, M., Burns, L., Hewitt, C., Glanville, J. M., Aboaja, A., Thakkar, P., Santosh Kumar, K. M., Pearson, C., Wright, K. (2019). Interventions for female drug-using offenders The Cochrane database of systematic reviews, 12(#issue#), CD010910 	No therapeutic indication
1	Pinto, J. V.,Medeiros, L. S.,Santana da Rosa, G.,Santana de Oliveira, C. E.,Crippa, J. A. S.,Passos, I. C.,Kauer-Sant'Anna, M. (2019). The prevalence and clinical correlates of cannabis use and cannabis use disorder among patients with bipolar disorder: A systematic review with meta-analysis and meta- regression Neurosci Biobehav Rev, 101(#issue#), 78- 84	No therapeutic indication



Level	Bibliography	Reason for
		exclusion
1	Rana, A. Q., Qureshi, A. R., Siddiqui, O., Sarfraz, Z., Rana, R., Shtilbans, A. (2019). Prevalence of pain in atypical parkinsonism: a systematic review and meta- analysis Journal of Neurology, 266(9), 2093-2102	No therapeutic indication
1	Rogers, M. A., Lemmen, K., Kramer, R., Mann, J., Chopra, V. (2017). Internet-Delivered Health Interventions That Work: Systematic Review of Meta- Analyses and Evaluation of Website Availability J Med Internet Res, 19(3), e90	No therapeutic indication
1	Salameh, T. N.,Hall, L. A. (2020). Depression, Anxiety, and Substance Use Disorders and Treatment Receipt Among Pregnant Women in the United States: A Systematic Review of Trend and Population-Based Studies Issues in mental health nursing, 41(1), 7-23	No therapeutic indication
1	Sami, M. B.,Bhattacharyya, S. (2018). Are cannabis- using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders J Psychopharmacol, 32(8), 825-849	No therapeutic indication
1	Stalgaitis, C. A.,Beckerley, S.,Fernandez, P.,Saggese, D. J. (2020). 265. Developing Trauma-Informed Health Education: Understanding the Intersection of Childhood Adversity, Mental Health, and Substance Use Amongst Alternative Teens Journal of Adolescent Health, 66 (2 Supplement)(#issue#), S134	No therapeutic indication
1	Stephen, A. H.,Karlin, D. R.,Luppens, C. L.,Adams, C.	No therapeutic



Level	Bibliography	Reason for
		exclusion
	A. (2018). Self-inflicted penetrating injury: A review Trauma (United Kingdom), 20(2), 81-87	indication
1	Sullivan, R. M., Perlman, G., Moeller, S. J. (2019). Meta-analysis of aberrant post-error slowing in substance use disorder: implications for behavioral adaptation and self-control European Journal of Neuroscience, 50(3), 2467-2476	No therapeutic indication
1	Sun, D.,Ye, T.,Ren, P.,Yu, S. (2018). Prevalence and etiology of oral diseases in drug-addicted populations: A systematic review International Journal of Clinical and Experimental Medicine, 11(7), 6521-6531	No therapeutic indication
1	Thiam-Diouf, A.,Metch, B.,Sharpe, C.,Mulugeta, R.,Andrasik, M. P. (2018). Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention Vaccine, 36(9), 1235-1242	No therapeutic indication
1	Tomkins, A.,George, R.,Kliner, M. (2019). Sexualised drug taking among men who have sex with men: a systematic review Perspectives in Public Health, 139(1), 23-33	No therapeutic indication
1	Wong, E.,Ranapurwala, S. I. (2019). Cardiovascular Risk Associated with Medical Use of Opioids and Cannabinoids: A Systematic Review Current Cardiovascular Risk Reports, 13 (10) (no pagination)(30), #Pages#	No therapeutic indication
1	Yim, J. L. L., Hindocha, C., Yamamori, Y., Jones, A. P.	No therapeutic



Level	Bibliography	Reason for
		exclusion
	 M.,Walker, H. R.,Lawn, W.,Lewis, G.,Howes, O.,Curran, H. V.,Freeman, T. P.,Bloomfield, M. A. P. (2019). P.4.03 The acute effects of cannabidiol on reward processing in humans: an fMRI study European Neuropsychopharmacology, 29 (Supplement 2)(#issue#), S702-S703 	indication
1	Zuleta-Alarcon, A.,Coffman, J. C.,Soghomonyan, S.,Papadimos, T. J.,Bergese, S. D.,Moran, K. R. (2017). Non-opioid anesthetic drug abuse among anesthesia care providers: a narrative review Canadian Journal of Anesthesia, 64(2), 169-184	No therapeutic indication
1	Fitzcharles, M. A.,Baerwald, C.,Ablin, J.,Häuser, W. (2016). Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials Schmerz, 30(1), 47-61	Non-English reference
1	Mücke, M.,Carter, C.,Cuhls, H.,Prüß, M.,Radbruch, L.,Häuser, W. (2016). [Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety] Schmerz, 30(1), 25-36	Non-English reference
1	Petzke, F.,Enax-Krumova, E. K.,Häuser, W. (2016). [Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies] Schmerz, 30(1), 62-88	Non-English reference
1	Volz, M. S., Siegmund, B., Häuser, W. (2016). [Efficacy,	Non-English



Level	Bibliography	Reason for
Lover	Biologiaphy	exclusion
	tolershility and asfaty of connabinaida in	
	tolerability, and safety of cannabinoids in gastroenterology: A systematic review] Schmerz, 30(1), 37-46	reference
1	Badowski, M. E. (2017). A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics Cancer Chemotherapy and Pharmacology, 80(3), 441- 449	Only pharmaceutical cannabinoids
1	Celius, E. G., Vila, C. (2018). The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity Brain and Behavior, 8 (5) (no pagination)(e00962), #Pages#	Only pharmaceutical cannabinoids
1	Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., Busardo, F. P. (2019). Cannabidiol adverse effects and toxicity Current Neuropharmacology, 17(10), 974-989	Only pharmaceutical cannabinoids
2	Farooqui, M. T.,Khan, M. A.,Cholankeril, G.,Khan, Z.,Mohammed Abdul, M. K.,Li, A. A.,Shah, N.,Wu, L.,Haq, K.,Solanki, S.,Kim, D.,Ahmed, A. (2019). Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis Eur J Gastroenterol Hepatol, 31(2), 149-156	Addiction/Withdrawal
2	Goldenberg, M.,IsHak, W. W.,Danovitch, I. (2017). Quality of life and recreational cannabis use American Journal on Addictions, 26(1), 8-25	Addiction/Withdrawal
2	Mohiuddin, M. M., Mizubuti, G. B., Haroutounian, S., Smith, S.	Addiction/Withdrawal



Level	Bibliography	Reason for
		exclusion
	M.,Rice, A. S. C.,Campbell, F.,Park, R.,Gilron, I. (2020). Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Medical Cannabis and Cannabis-based Medicines for Chronic Noncancer Pain: A Systematic Review Clinical Journal of Pain., #volume#(#issue#), #Pages#	
2	Schoeler, T.,Kambeitz, J.,Behlke, I.,Murray, R.,Bhattacharyya, S. (2016). The effects of cannabis on memory function in users with and without a psychotic disorder: findings from a combined meta-analysis Psychol Med, 46(1), 177-88	Addiction/Withdrawal
2	Scott, J. C., Jones, J., Moore, T., Roalf, D., Calkins, M., Wolf, D., Satterthwaite, T., Ruparel, K., Jackson, C., Gur, R. (2017). Cannabis use and neurocognitive functioning in the psychosis spectrum Biological Psychiatry, 81 (10 Supplement 1)(#issue#), S220	Addiction/Withdrawal
2	Turna, J.,Syan, S.,Frey, B. N.,Rush, B.,Costello, J.,Weiss, M.,MacKillop, J. (2019). Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: A systematic review Alcoholism: Clinical and Experimental Research, 43 (Supplement 1)(#issue#), 249A	Addiction/Withdrawal
2	Quintas, A. (2019). Should we legalize marijuana? Ten years of learning from JWH-018 first seizure Annals of Medicine, 51 (Supplement 1)(#issue#), S178	Irrelevant exposure
2	Kim, S. H., Yang, J. W., Kim, K. H., Kim, J. U., Yook, T. H. (2019). A review on studies of Marijuana for Alzheimer's disease - Focusing on CBD, THC Journal of Pharmacopuncture, 22(4), 225-230	Irrelevant population



Level	Bibliography	Reason for
		exclusion
2	Abrams, D. I. (2018). The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report Eur J Intern Med, 49(#issue#), 7-11	Irrelevant study type
2	Agarwal, R.,Burke, S. L.,Maddux, M. (2019). Current state of evidence of cannabis utilization for treatment of autism spectrum disorders BMC Psychiatry, 19 (1) (no pagination)(328), #Pages#	Irrelevant study type
2	Araujo, R., Sorensen, A. A., Konkiel, S., Bloem, B. R. (2017). Top Altmetric Scores in the Parkinson's Disease Literature Journal of Parkinson's Disease, 7(1), 81-87	Irrelevant study type
2	Bakshi, C.,Barrett, A. M. (2019). Impact of recreational and medicinal marijuana on surgical patients: A review American Journal of Surgery, 217(4), 783-786	Irrelevant study type
2	Boongmongkol, T., Jitkritsadakul, O., Bhidayasiri, R. (2019). The systematic review on cannabinoids as a treatment of Parkinson's disease Movement Disorders Clinical Practice, 6 (Supplement 1)(#issue#), S55-SS57	Irrelevant study type
2	 Busse, J.,Wang, L.,Kamal El Din, M.,Craigie, S.,Montoya, L.,Riva, J.,Mulla, S.,Lopes, L.,Vogel, N.,Chen, E.,Kirmayr, K.,De Oliveira, K.,Olivieri, L.,Kaushal, A.,Chaparro, L.,Oyberman, I.,Agarwal, A.,Couban, R.,Tsoi, L.,Lam, T. (2018). Opioids for chronic non-cancer pain: A systematic review of randomized controlled trials Pain Practice, 18 (Supplement 1)(#issue#), 54-55 	Irrelevant study type
2	Chapman, E. J., Edwards, Z., Boland, J. W., Maddocks, M., Fettes, L., Malia, C., Mulvey, M. R., Bennett, M. I. (2020). Practice review: Evidence-based and effective management of pain in patients with advanced cancer Palliative Medicine.,	Irrelevant study type



Level	Bibliography	Reason for
		exclusion
	#volume#(#issue#), #Pages#	
2	Chen, J. W.,Borgelt, L. M.,Blackmer, A. B. (2019). Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes Annals of Pharmacotherapy, 53(6), 603-611	Irrelevant study type
2	Claflin, S.,Claflin, S. B.,Van Der Mei, I.,Taylor, B. V. (2017). Complementary and alternative treatments of multiple sclerosis: A review of the evidence from 2001-2016 Multiple Sclerosis, 23 (13)(#issue#), NP13	Irrelevant study type
2	Cooper, Z. D., Abrams, D. I. (2019). Considering abuse liability and neurocognitive effects of cannabis and cannabis- derived products when assessing analgesic efficacy: a comprehensive review of randomized-controlled studies American Journal of Drug and Alcohol Abuse, 45(6), 580- 595	Irrelevant study type
2	Darkovska-Serafimovska, M.,Serafimovska, T.,Arsova- Sarafinovska, Z.,Stefanoski, S.,Keskovski, Z.,Balkanov, T. (2018). Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases Journal of Pain Research, 11(#issue#), 837-842	Irrelevant study type
2	Doeve, B., Van Schaik, F., Van De Meeberg, M., Fidder, H. (2019). Cannabis and cannabinoids for the treatment of inflammatory bowel disease: A systematic review and meta- analysis Journal of Crohn's and Colitis, 13 (Supplement 1)(#issue#), S335-S336	Irrelevant study type
2	Doyle, A.,Harvey, J. (2020). Cannabis and Epilepsy Journal of Dual Diagnosis, 16(1), 75-82	Irrelevant study type
2	Ferreira-Junior, N. C., Campos, A. C., Guimaraes, F. S., Del-	Irrelevant study type



Level	Bibliography	Reason for
		exclusion
	Bel, E.,Zimmermann, P. M. D. R.,Brum Junior, L.,Hallak, J. E.,Crippa, J. A.,Zuardi, A. W. (2019). Biological bases for a possible effect of cannabidiol in Parkinson's disease Revista brasileira de psiquiatria, #volume#(pagination), #Pages#	
2	Hauser, W., Finn, D. P., Kalso, E., Krcevski-Skvarc, N., Kress, H. G., Morlion, B., Perrot, S., Schafer, M., Wells, C., Brill, S. (2018). European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management European Journal of Pain (United Kingdom), 22(9), 1547-1564	Irrelevant study type
2	Hugos, C.,Rice, J.,Cameron, M. (2019). Cannabis use in people with MS and spasticity: A cross-sectional analysis Multiple Sclerosis Journal, 25 (7)(#issue#), 1031-1032	Irrelevant study type
2	Hwang, J. K.,Clarke, H. (2016). Cannabis and pain: A review Journal of Pain Management, 9(4), 395-413	Irrelevant study type
2	Khanna, R., Khanna, R., Denny, G., & Kwatra, S. (2019). Cannabinoids for the treatment of refractory chronic pruritus Journal of the American Academy of Dermatology, 81 (4 Supplement 1)(#issue#), AB29	Irrelevant study type
2	Kolar, D. (2018). Addictive potential of novel treatments for refractory depression and anxiety Neuropsychiatric Disease and Treatment, 14(#issue#), 1513-1519	Irrelevant study type
2	Kupfer, M.,Formal, C. S. (2020). Non-opioid pharmacologic treatment of chronic spinal cord injury-related pain The journal of spinal cord medicine, #volume#(#issue#), 1-10	Irrelevant study type
2	Lanza, G., Ferri, R., Bella, R., Ferini-Strambi, L. (2017). The impact of drugs for multiple sclerosis on sleep Multiple Sclerosis, 23(1), 5-13	Irrelevant study type



	•	
Level	Bibliography	Reason for
		exclusion
2	Lochte, B. C.,Beletsky, A.,Samuel, N. K.,Grant, I. (2017). The Use of Cannabis for Headache Disorders Cannabis and Cannabinoid Research, 2(1), 61-71	Irrelevant study type
2	Makary, P.,Parmar, J. R.,Mims, N.,Khanfar, N. M.,Freeman, R. A. (2018). Patient Counseling Guidelines for the Use of Cannabis for the Treatment of Chemotherapy-Induced Nausea/Vomiting and Chronic Pain Journal of Pain and Palliative Care Pharmacotherapy, 32(4), 216-225	Irrelevant study type
2	McGaw, C. D. (2017). The cannabinoids as therapeutic agents in the management of pain West Indian Medical Journal, 66(5), 576-580	Irrelevant study type
2	Miller, N. S.,Oberbarnscheidt, T. (2017). Health policy for marijuana Journal of Global Drug Policy and Practice, 11(3), #Pages#	Irrelevant study type
2	Norton, C.,Czuber-Dochan, W.,Artom, M.,Sweeney, L.,Hart, A. (2017). Systematic review of interventions for chronic abdominal pain management in inflammatory bowel disease Journal of Crohn's and Colitis, 11 (Supplement 1)(#issue#), S363	Irrelevant study type
2	Oberbarnscheidt, T.,Miller, N. (2019). Marijuana-is it medicine? American Journal on Addictions, 28 (3)(#issue#), 202-203	Irrelevant study type
2	Pamplona, F. A., Da Silva, L. R., Coan, A. C. (2018). Potential clinical benefits of CBD-Rich cannabis extracts over purified CBD in treatment-resistant epilepsy: Observational data meta-analysis Frontiers in Neurology, 9 (SEP) (no pagination)(3389), #Pages#	Irrelevant study type
2	Park, J. Y., Wu, L. T. (2017). Prevalence, reasons, perceived	Irrelevant study type



Laval	Diblicgrophy	Baasan far
Level	Bibliography	Reason for
		exclusion
	effects, and correlates of medical marijuana use: A review	
	Drug and Alcohol Dependence, 177(#issue#), 1-13	
2	Peng, M.,Khaiser, M.,Ahrari, S.,Pasetka, M.,DeAngelis, C. (2016). Medical marijuana as a therapeutic option for cancer anorexia and cachexia: A scoping review of current evidence Journal of Pain Management, 9(4), 435-447	Irrelevant study type
2	Pergjika, A.,Ballard, R. R.,DeAntonio, M. (2019). Kids and Cannabinoids: What Is the Evidence? Journal of the American Academy of Child and Adolescent Psychiatry, 58 (10 Supplement)(#issue#), S83-S84	Irrelevant study type
2	Pratt, M., Stevens, A., Thuku, M., Butler, C., Skidmore, B., Wieland, L. S., Clemons, M., Kanji, S., Hutton, B. (2019). Benefits and harms of medical cannabis: A scoping review of systematic reviews Systematic Reviews, 8 (1) (no pagination)(320), #Pages#	Irrelevant study type
2	Pupillo, E.,Bianchi, E.,Pasina, L.,Beghi, E. (2018). Potentially severe drug-drug interactions in ALS patients Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 19 (Supplement 1)(#issue#), 358	Irrelevant study type
2	Rice, J.,Cameron, M. (2018). Cannabinoids for Treatment of MS Symptoms: State of the Evidence Current Neurology and Neuroscience Reports, 18 (8) (no pagination)(50), #Pages#	Irrelevant study type
2	Rohleder, C.,Muller, J. K.,Lange, B.,Leweke, F. M. (2016). Cannabidiol as a potential new type of an antipsychotic. A critical review of the evidence Frontiers in Pharmacology, 7 (NOV) (no pagination)(422), #Pages#	Irrelevant study type
2	Rong, C.,Lee, Y.,Carmona, N. E.,Cha, D. S.,Ragguett, R. M.,Rosenblat, J. D.,Mansur, R. B.,Ho, R. C.,McIntyre, R. S.	Irrelevant study type



Level	Bibliography	Reason for
		exclusion
	(2017). Cannabidiol in medical marijuana: Research vistas and potential opportunities Pharmacological Research, 121(#issue#), 213-218	
2	Sarzi-Puttini, P.,Ablin, J.,Trabelsi, A.,Fitzcharles, M. A.,Marotto, D.,Hauser, W. (2019). Cannabinoids in the treatment of rheumatic diseases: Pros and cons Autoimmunity Reviews, 18 (12) (no pagination)(102409), #Pages#	Irrelevant study type
2	Schaefer, M., Tafelski, S., Hauser, W. (2019). Efficacy, tolerability, and safety of cannabinoids for chemotherapy- induced nausea and vomiting Medical Cannabis and Cannabinoids, 2 (2)(#issue#), 81	Irrelevant study type
2	Schloss, J.,Brown, D.,Steel, A. (2017). Medicinal cannabis and cancer: A narrative systematic literature review Asia- Pacific Journal of Clinical Oncology, 13 (Supplement 4)(#issue#), 221	Irrelevant study type
2	Sheriff, T.,Lin, M. J.,Dubin, D.,Khorasani, H. (2019). The potential role of cannabinoids in dermatology Journal of Dermatological Treatment., #volume#(#issue#), #Pages#	Irrelevant study type
2	Turna, J.,Patterson, B.,Van Ameringen, M. (2017). Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depression and Anxiety, 34(11), 1006-1017	Irrelevant study type
2	Valentino, W. L.,McKinnon, B. J. (2019). What is the evidence for cannabis use in otolaryngology?: A narrative review American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 40(5), 770-775	Irrelevant study type
2	Walsh, Z.,Gonzalez, R.,Crosby, K.,S. Thiessen M,Carroll,	Irrelevant study type



Level	Bibliography	Reason for
		exclusion
	C.,Bonn-Miller, M. O. (2017). Medical cannabis and mental health: A guided systematic review Clin Psychol Rev, 51(#issue#), 15-29	
2	Wilens, T.,Wong, S. S. (2019). 46.2 Medical Marijuana in Kids: Evidence Sufficient for Legalization? Journal of the American Academy of Child and Adolescent Psychiatry, 58 (10 Supplement)(#issue#), S369	Irrelevant study type
2	Freeman, A. M., Petrilli, K., Lees, R., Hindocha, C., Mokrysz, C., Curran, H. V., Saunders, R., Freeman, T. P. (2019). How does cannabidiol (CBD) influence the acute effects of delta- 9-tetrahydrocannabinol (THC) in humans? A systematic review Neuroscience and Biobehavioral Reviews, 107(#issue#), 696-712	Mixed cannabinoids
2	Kosiba, J. D., Maisto, S. A., Ditre, J. W. (2019). Patient- reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis Social Science and Medicine, 233(#issue#), 181-192	No outcome data
2	Akgun, K.,Essner, U.,Seydel, C.,Ziemssen, T. (2019). Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies Journal of Central Nervous System Disease, 11(no pagination), #Pages#	Only pharmaceutical cannabinoids
2	Hauser, W.,Welsch, P.,Klose, P.,Radbruch, L.,Fitzcharles, M. A. (2019). Efficacy, tolerability and safety of cannabis- based medicines for cancer pain : A systematic review with meta-analysis of randomised controlled trials Der Schmerz, 33(5), 424-436	Only pharmaceutical cannabinoids



_evel	Bibliography	Reason for
		exclusion
	Lattanzi, S.,Brigo, F.,Trinka, E.,Zaccara, G.,Cagnetti, C.,Del Giovane, C.,Silvestrini, M. (2018). Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta- Analysis Drugs, 78(17), 1791-1804	Only pharmaceutical cannabinoids
	Walitt, B.,Klose, P.,Fitzcharles, M. A.,Phillips, T.,Hauser, W. (2016). Cannabinoids for fibromyalgia Cochrane Database of Systematic Reviews, 7(#issue#), CD011694	Only pharmaceutical cannabinoids
	Ali, A. (2016). Cannabis usage in the context of neurological disease: Clinical cases and a review of the literature West Indian Medical Journal, 65 (Supplement 1)(#issue#), 22	Unavailable full-text
2	Amato, L., Minozzi, S., Mitrova, Z., Parmelli, E., Saulle, R., Cruciani, F., Vecchi, S., Davoli, M. (2017). [Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy] Epidemiol Prev, 41(5-6), 279-293	Unavailable full-text
	Carrillo, M. R., Jennings, G. E., Le, C., Dong, A., Devineni, D., Sahafi, R., Goo, H., Afghani, B. (2016). Use of medical marijuana for treatment of pediatric patients with epilepsy Journal of Investigative Medicine, 64 (1)(#issue#), 200-201	Unavailable full-text
	De Almeida Pereira, F.,Torres, A. C.,Philadelpho, V. O.,Ornellas, L. I.,Veloso, C. R.,Viana, G. P. M.,Filho, A. D. S. A. (2018). Effects of cannabidiol on the frequency of epileptic seizures: A systematic review. [Portuguese] Revista Brasileira de Neurologia e Psiquiatria, 22(1), 86-100	Unavailable full-text
	Farzaei, M. H.,Shahpiri, Z.,Bahramsoltani, R.,nia, M. M.,Najafi, F.,Rahimi, R. (2017). Efficacy and Tolerability of Phytomedicines in Multiple Sclerosis Patients: A Review	Unavailable full-text



		<u> </u>
Level	Bibliography	Reason for
		exclusion
	CNS Drugs, 31(10), 867-889	
2	Ferber, S. G., Namdar, D., Hen-Shoval, D., Eger, G., Koltai, H., Shoval, G., Shbiro, L., Weller, A. (2020). The "entourage effect": Terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders Current Neuropharmacology, 18(2), 87-96	Unavailable full-text
2	Fitzcharles, M. A., Hauser, W. (2019). Cannabis-Based Medicines and Medical Cannabis in Rheumatic Diseases: A Treasure Chest or Pandora's box Current Treatment Options in Rheumatology, 5(4), 258-271	Unavailable full-text
2	Häuser, W., Petzke, F., Fitzcharles, M. A. (2018). Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - An overview of systematic reviews Eur J Pain, 22(3), 455-470	Unavailable full-text
2	Jett, J. (2019). IBS11.03 Cannabis and Lung Cancer Journal of Thoracic Oncology, 14 (10 Supplement)(#issue#), S102	Unavailable full-text
2	Jouanjus, E.,Barreiros, P.,Lapeyre-Mestre, M. (2019). The therapeutic benefits of cannabis and cannabinoids evaluated by phase 3 randomized controlled clinical trials: a systematic review of recent literature European Journal of Clinical Pharmacology, 75 (Supplement 1)(#issue#), S66	Unavailable full-text
2	Kayser, R. R., Snorrason, I., Haney, M., Lee, F. S., Simpson, H. B. (2019). The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder? Cannabis and Cannabinoid Research, 4(2), 77-87	Unavailable full-text
2	Lattanzi, S.,Brigo, F.,Cagnetti, C.,Trinka, E.,Silvestrini, M. (2018). Efficacy and Safety of Adjunctive Cannabidiol in	Unavailable full-text



Level	Bibliography	Reason for
		exclusion
	Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis CNS Drugs, 32(10), 905-916	
2	Likar, R.,Kostenberger, M.,Nahler, G. (2020). Cannabidiol in cancer treatment. [German] Schmerz., #volume#(#issue#), #Pages#	Unavailable full-text
2	Mallaret, M.,Micallef, J.,Fouilhe-Sam Lai, N. (2019). Cannabidiol is bad for you! Fundamental and Clinical Pharmacology, 33 (Supplement 1)(#issue#), 77	Unavailable full-text
2	Mamalis, S.,Sidiropoulou, K.,Pliakou, E.,Passos, I. D.,Mironidou-Tzouveleki, M. (2016). The use of cannabis and cannabinoids for medical purposes Hippokratia, 20 (Supplement 1)(#issue#), 18	Unavailable full-text
2	Moller, J.,Kelber, O.,Nieber, K. (2019). Herbal medicinal products are an important option for the treatment of functional GI diseases in children-a systematic review Planta Medica, 85 (18)(#issue#), 1559	Unavailable full-text
2	Oxentine, H.,Musec, M.,Johnson, T. (2017). Medical marijuana: Can't we all just get a bong? American Journal on Addictions, 26 (3)(#issue#), 277	Unavailable full-text
2	Parekh, T.,Mathew, S.,Goudreau, C.,Lonergan, A.,Piran, P.,Malpe, C. (2017). Awareness of epilepsy risk factors and treatment in a south florida community-an observational study Annals of Neurology, 82 (Supplement 21)(#issue#), S159-S160	Unavailable full-text
2	Pinho, C.,Leitao, M.,Oliveira, A. I. (2016). Cannabis sativa L. and inflammatory bowel disease Atencion Primaria, 48 (Supplement C)(#issue#), 147	Unavailable full-text
2	Sanadgol, N.,Zahedani, S. S.,Sharifzadeh, M.,Khalseh,	Unavailable full-text



Level	Bibliography	Reason for
		exclusion
	R.,Barbari, G. R.,Abdollahi, M. (2017). Recent Updates in Imperative Natural Compounds for Healthy Brain and Nerve Function: A Systematic Review of Implications for Multiple Sclerosis Curr Drug Targets, 18(13), 1499-1517	
2	Santibanez, R. A., Sepehry, A. A., Hsiung, G. Y. R. (2017). Cannabis and Alzheimer's disease: A systematic review of the evidence Alzheimer's and Dementia, 13 (7)(#issue#), P614	Unavailable full-text
2	Shatkin, J. P. (2017). Sleep education and hygiene Journal of the American Academy of Child and Adolescent Psychiatry, 56 (10)(#issue#), S146	Unavailable full-text
2	Wong, S. S., Wilens, T. E. (2017). Medical uses of cannabinoids in children and adolescents: A systematic review Journal of the American Academy of Child and Adolescent Psychiatry, 56 (10)(#issue#), S295	Unavailable full-text
3	Elliott, J.,DeJean, D.,Clifford, T.,Coyle, D.,Potter, B. K.,Skidmore, B.,Alexander, C.,Repetski, A. E.,Shukla, V.,McCoy, B.,Wells, G. A. (2019). Cannabis-based products for pediatric epilepsy: A systematic review Epilepsia, 60(1), 6-19	As the review by Elliot et al. 2020 represented a repetition of its earlier report in 2019 with few relevant updates, we opted in to examine the more updated version of 2020.
3	Aviram, J.,Samuelly-Leichtag, G. (2017). Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Pain Physician, 20(6), E755-e796	Reference contained inconsistent information and was deemed unnecessary.





Appendix 3. Assessing quality of evidence and risk of bias

AMSTAR2

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or nonrandomised studies of healthcare interventions, or both

The authors state that they had a written protocol or guide that included ALL the bollowing: As for partial yes, plus the protocol should also have specified: Image: Provide that included ALL the bollowing: Image: Provide that included ALL the bollowing: Image: Provide that included ALL the bollowing: Image: Provide that included ALL the bollowing: Image: Provide that included ALL the bollowing: Image: Provide that included ALL the bollowing: Image: Provide that include the protocol should be registered and should also have specified: Image: Provide that including the protocol should be registered and should also have specified: Image: Provide that they had a written protocol inclusion criteria Image: Provide that protocol inclusion in the review of the protocol				a criteria for the review include th	ie com	ponents of PICO:
Intervention Intervention Comparator group Outcome 2. Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant dew from the protocol? For Partial Yes: For Yes: The authors state that they had a written as structure of? For Yes: For eview question(s) Image: a meta-analysis/synthesis plan, if appropriate, and is a search strategy Image: propriate, and is a search strategy Image: a mich of bias assessment Image: applant their selection of the study designs for inclusion in the review from the protocol 3. Did the review authors explain their selection of the study designs for inclusion in the review from the protocol No 3. Did the review authors use a comp reheasive literature search strategy? For Yes, should also have (all the following): Baserch strategy Image: searched the reference lists / Image: plantation for including only NESI No 4. Did the review authors use a comp reheasive literature search strategy? For Yes, should also have (all the following): For Yes, should also have (all the following): Image: searched at least 2 databases searched the reference lists / Image: Ima						
Comparator group Qubcome 2. Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant dew from the protoc ol? For Partial Yes: For Yes: The authors state that they had a written protocol or guide that inchded ALL the biolowing: For Yes: a search strategy a meta-analysis/synthesis is plan, if appropriate, and is not be protocol of the review question(s) No a search strategy a plan for investigating causes of the review authors explain their selection of the study designs for inclusion in the review for the following: No 3. Did the review authors explain their selection of the study designs for inclusion in the review following: Yes Cor Partial Yes (all the following): For Yes, should also have (all the following): Yes For Partial Yes (all the following): For Yes, should also have (all the following): No searched at least 2 databases searched the reference lists / Yes Yes months of completion of the review authors perform study selection if uplication of the review No Searched at least 2 databases searched the reference lists / Yes Yes for Partial Yes (all the following): searched this/study registries No grey litization restrictione		<u>P</u> opulation		Timeframe for follow-up		Yes
Quecome Quecom Quec		Intervention				No
2. Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant dev from the protocol? For Partial Yes: For Yes: The authors state that they had a written protocol or guide that included ALL the should be registered and should also have specified: Image: Partial Yes: Image: Protocol or guide that included ALL the should be registered and should also have specified: Image: Partial Yes: Image: Protocol or guide that included ALL the should be registered and should also have specified: Image: Partial Yes: Image: Protocol or guide that included ALL the should be registered and should also have specified: Image: Partial Yes: Image: Protocol or guide that included ALL the should be registered and should also have specified: Image: Partial Yes: Image: Protocol or guide that include ALL the should be registered and should also have specified: Image: Partial Yes: Image: Protocol or guide that include ALL the should be registered and should also have specified: Image: Partial Yes: Image: Protocol or guide that including only RCTs Image: Partial Yes: Image: Partial Yes: Image: Partial Yes (all the following: Image: Yes: Image: Partial Yes: Image: Partial Yes: Image: Partial Yes (all the following: Image: Partial Yes: Image: Partial Yes: Image: Partial Yes:		Comparator group				
2. Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant dev from the protocol? For Partial Yes: For Yes: The authors state that they had a written protocol or guide that included ALL the should be registered and should also have specified: Image: Partial Yes: Image: Protocol or guide that included ALL the should be registered and should also have specified: Image: Partial Yes: Image: Protocol or guide that included ALL the should be registered and should also have specified: Image: Partial Yes: Image: Protocol or guide that included ALL the should be registered and should also have specified: Image: Partial Yes: Image: Protocol or guide that included ALL the should be registered and should also have specified: Image: Partial Yes: Image: Protocol or guide that include ALL the should be registered and should also have specified: Image: Partial Yes: Image: Protocol or guide that include ALL the should be registered and should also have specified: Image: Partial Yes: Image: Protocol or guide that including only RCTs Image: Partial Yes: Image: Partial Yes: Image: Partial Yes (all the following: Image: Yes: Image: Partial Yes: Image: Partial Yes: Image: Partial Yes (all the following: Image: Partial Yes: Image: Partial Yes: Image: Partial Yes:		Outcome				
The authors state that they had a written protocol or guide that included ALL the protocol or guide that included ALL the should be registered and should also have specified: generation of the state of	2.	Did the report of the review co established prior to the conduc				
protocol or guide that included ALL the billowing: should be registered and should also have specified: Image: Specified:	for Part	ial Yes:	For Yes	5:		
protocol or guide that included ALL the following: should be registered and should also have specified: Image: specified: Image: specified: Image: specified: Image: specified: Image: specified: Image: specified: Image: specified: Image: specified: Image: specified: Image: specified: Image: specified: <	The aut	nors state that they had a written	As for p	partial yes, plus the protocol		
billowing: have specified: Image: Yes Image: review question(s) a meta-analysis/synthesis plan, if appropriate, and Image: Partial Yes Image: a search strategy a plan for investigating causes of heterogeneity Image: No Image: a nisk of bias assessment justification for any deviations from the protocol No 3. Did the review authors explain their selection of the study designs for inclusion in the review from the protocol Yes For Yes, the review authors explain their selection of the study designs for inclusion in the review from the protocol Yes OR Explanation for including only RCTs Yes Yes OR Explanation for including only NKSI No No OR Explanation for including both RCTs and NRS I No No Statisty Call the following: For Yes, should also have (all the following): Searched the reference lists / Yes (relevant to research question) bib liographies of included Partial Yes No provided keyword and/or searched thial/study registries No No isstified publication restrictions included/consulted content No No search strategy searched trial/study registries No No isstifi	protocol	or guide that included ALL the				
Image: search strategy I						
review question(s) a meta-analysis/synthesis plan, Partial Ye a search strategy if appropriate, and No a inchasion/exclusion criteria a plan for investigating causes of heterogeneity No a nisk of bias assessment justification for any deviations from the protocol No 3. Did the review authors explain their selection of the study designs for inclusion in the review for Yes, the review should satisfy ONE of the following: Yes Core Sequencing for including only NCTs Ves No OR Explanation for including only NCTs No No OR Explanation for including both RCTs and NRSI No No 4. Did the review authors use a comp rehensive literature search strategy? No For Partial Yes (all the following): For Yes, should also have (all the following): No searched at least 2 databases searched the reference lists / Yes (relevant to research question) bb liographies of included Partial Yes include/consulted content experts in the field No where relevant, searched for grey literature conducted search within 24 months of completion of the review 5. Did the review authors perform study selection in duplicate? No For Yes, either ON		-				Yes
a search strategy if a ppropriate, and No a search strategy a plan for investigating causes of heterogeneity No a nisk of bias assessment justification for any deviations from the protocol No 3. Did the review authors explain their selection of the study designs for inclusion in the review for Yes, the review should satisfy ONE of the following: Yes B Explanation for including only RCTs Yes OR Explanation for including both RCTs and NRS I No 4. Did the review authors use a comp rehensive literature search strategy? No For Partial Yes (all the following): For Yes, should also have (all the following): Yes searched at least 2 databases searched the reference lists / Yes (relevant to research question) bib liographies of included Partial Yes justified publication restrictions include/consulted content experts in the field No where relevant, searched for grey literature conducted search within 24 months of completion of the review Yes 5. Did the review authors perform study selection in duplicate? Yes No Cor Yes, either ONE of the following: at least two reviewers independently agreed on selection of eligible studies and achieved consensus on which studies to include No	п	review question(s)	П	a meta-analysis/synthesis plan	_	Partial Yes
a plan for investigating causes of heterogeneity a plan for investigating causes of heterogeneity a nisk of bias assessment justification for any deviations from the protocol 3. Did the review authors explain their selection of the study designs for inclusion in the review from the protocol 3. Did the review authors explain their selection of the study designs for inclusion in the review from the protocol 3. Did the review authors explain their selection of the study designs for inclusion in the review of Explanation for including only RCTs Yes B OR Explanation for including only NRSI No OR Explanation for including both RCTs and NRSI No 4. Did the review authors use a comp rehensive literature search strategy? For Partial Yes (all the following): For Yes, should also have (all the following): searched at least 2 databases searched the reference lists / Yes included/consulted content (relevant to research question) bibliographies of included Partial Yes included/consulted content (e.g. language) included/consulted content experts in the field No where relevant, searched for grey literature conducted search within 24 months of completion of the review Yes 5. Did the review authors perform study selection in duplicate? No No Gor Yes, either ONE of the following: No<			-		_	
a nick of bias assessment of heterogeneity a nick of bias assessment justification for any deviations from the protocol 3. Did the review authors explain their selection of the study designs for inclusion in the review from the protocol 3. Did the review authors explain their selection of the study designs for inclusion in the review for Yes, the review authors only RCTs Yes Cor Explanation for including only NCSI No OR Explanation for including both RCTs and NRSI No 4. Did the review authors use a comp rehensive literature search strategy? For Partial Yes (all the following): For Yes, should also have (all the following): searched at least 2 databases Searched the reference lists / Yes growided key word and/or studies No search strategy searched the reference lists / Yes included/consulted content experts in the field No search strategy experts in the field No search of the review authors perform study selection in duplicate? Yes For Yes, either ONE of the following: at least two reviewers independently agreed on selection of eligible studies Yes and achieved consensus on which studies to include No No OR two reviewers independently agre			п			110
Image: state of the sevent of the sevent of the study deviations from the protocol 3. Did the review authors explain their selection of the study designs for inclusion in the review for Yes, the review should satisfy ONE of the following: Baylamation for including only RCTs OR Explanation for including only NRSI OR Explanation for including both RCTs and NRSI Image: Noise including only NRSI 4. Did the review authors use a comp rehensive literature search strategy? For Partial Yes (all the following): For Yes, should also have (all the following): searched at least 2 databases Image: searched the reference lists / Image: Noise search strategy Yes provided keyword anl/or studies Image: Noise search strategy Image: Noise search strategy Image: Noise search strategy Image: provided keyword anl/or studies Image:			U			
from the protocol 3. Did the review authors explain their selection of the study designs for inclusion in the review For Yes, the review should satisfy ONE of the following:		a risk of bias assessment		÷ .		
3. Did the review authors explain their selection of the study designs for inclusion in the review For Yes, the review should satisfy ONE of the following:			Ц			
For Yes, the review should satisfy ONE of the following: Image: Statistic of the following only RCTs Image: Statistic of the following only NRSI Image: Statistic of the following only NRSI Image: OR Explanation for including only NRSI Image: Statistic of the following only NRSI Image: Statistic of the following only NRSI Image: Statistic of the following only NRSI Image: OR Explanation for including both RCTs and NRSI Image: Statistic of the following only NRSI Image: Statistic of the following only NRSI Image: OR Explanation for including both RCTs and NRSI Image: Statistic of the following only NRSI Image: Statistic of the following only NRSI Image: OR Explanation for including both RCTs and NRSI Image: Statistic only NRSI Image: Statistic only NRSI Image: OR Explanation for including both RCTs and NRSI Image: Statistic only NRSI Image: Statistic only NRSI Image: Or Partial Yes (all the following): Image: Statistic only NRSI of Included Image: Partial Yes Image: Or provided key word and/or statistic on the following statistic on the				-		
Explanation for including only RCTs Image: Yes OR Explanation for including only NRSI Image: No OR Explanation for including both RCTs and NRSI Image: No 4. Did the review authors use a comp rehensive literature search strategy? For Partial Yes (all the following): For Yes, should also have (all the following): Image: searched at least 2 databases Image: searched the reference lists / Image: No Image: Yes Image: searched at least 2 databases Image: searched the reference lists / Image: No Image: Yes Image: searched at least 2 databases Image: searched the reference lists / Image: Search question Image: Yes Image: provided keyword and/or studies Image: No Image: provided keyword and/or Image: Searched trial/study registries Image: No Image: provided keyword and/or Image: Searched trial/study registries Image: No Image: provided keyword and/or Image: Searched trial/study registries Image: No Image: provided keyword and/or Image: Searched trial/study registries Image: No Image: provided keyword and/or Image: Searched trial/study registries Image: No Image: provided keyword and/or Image: Searched trial/study registries Image: No Image: provided keywo	3.	Did the review authors explain	their sele	ection of the study designs for incl	lusion	in the review?
OR Explanation for including only NRSI Including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI Image: Constraint of the including both RCTs and NRSI including both RCTs and Research	For Yes	, the review should satisfy ONE o	f the follo	wing:		
OR Explanation for including both RCTs and NRS I 4. Did the review authors use a comp rehensive literature search strategy? For Partial Yes (all the following): For Yes, should also have (all the following): searched at least 2 databases searched the reference lists / Yes (relevant to research question) bib liographies of included Partial Yes provided keyword and/or studies No search strategy searched trial/study registries No justified publication restrictions included/consulted content No (e.g. language) experts in the field where relevant, searched for grey literature conducted search within 24 months of completion of the review review Yes 5. Did the review authors perform study selection in duplicate? Yes at least two reviewers independently agreed on selection of eligible studies and achieved consensus on which studies to include No OR two reviewers selected a sample of eligible studies and achieved good agreement (at least 80 percent), with the remainder selected by one No		Explanation for including only R	CTs			Yes
OR Explanation for including both RCTs and NRSI 4. Did the review authors use a comp rehensive literature search strategy? For Partial Yes (all the following): For Yes, should also have (all the following): searched at least 2 databases searched the reference lists / Yes (relevant to research question) bib liographies of included Partial Yes provided keyword and/or studies No search strategy searched trial/study registries No justified publication restrictions included/consulted content No (e.g. language) experts in the field where relevant, searched for grey literature conducted search within 24 months of completion of the review To Yes, either ONE of the following: Yes at least two reviewers independently agreed on selection of eligible studies and achieved consensus on which studies to include No No OR two reviewers selected a sample of eligible studies_and achieved good agreement (at least 80 percent), with the remainder selected by one No						No
 4. Did the review authors use a comp rehensive literature search strategy? For Partial Yes (all the following): searched at least 2 databases searched the reference lists / Yes (relevant to research question) bib liographies of included Partial Yes provided keyword and/or studies No provided keyword and/or searched trial/study registries justified publication restrictions (e.g. language) where relevant, searched for grey literature conducted search within 24 months of completion of the review 5. Did the review authors perform study selection in duplicate? For Yes, either ONE of the following: at least two reviewers independently agreed on selection of eligible studies No No 			-	and NRSI		
following): gearched at least 2 databases searched the reference lists / Yes (relevant to research question) bib liographies of included Partial Yes provided keyword and/or studies No search strategy searched trial/study registries No justified publication restrictions included/consulted content No (e.g. language) where relevant, searched for grey literature conducted search within 24 months of completion of the review 5. Did the review authors perform study selection in duplicate? Yes For Yes, either ONE of the following: Yes at least two reviewers independently agreed on selection of eligible studies and achieved consensus on which studies to include No OR two reviewers selected a sample of eligible studies_and achieved good agreement (at least 80 percent), with the remainder selected by one No						
 (relevant to research question) provided keyword and/or studies provided keyword and/or search strategy search strategy search strategy included/consulted content experts in the field where relevant, searched for grey literature conducted search within 24 months of completion of the review 5. Did the review authors perform study selection in duplicate? For Yes, either ONE of the following: at least two reviewers independently agreed on selection of eligible studies OR two reviewers selected a sample of eligible studies ard achieved good agreement (at least 80 percent), with the remainder selected by one	For Part	ial Yes (all the following):				
 provided keyword and/or studies provided keyword and/or studies search strategy justified publication restrictions included/consulted content experts in the field where relevant, searched for grey literature conducted search within 24 months of completion of the review 5. Did the review authors perform study selection in duplicate? For Yes, either ONE of the following: at least two reviewers independently agreed on selection of eligible studies Yes and achieved consensus on which studies to include OR two reviewers selected a sample of eligible studies and achieved good agreement (at least 80 percent), with the remainder selected by one 		searched at least 2 databases		searched the reference lists /		Yes
provided keyword and/or studies No search strategy searched trial/study registries No justified publication restrictions included/consulted content no (e.g. language) where relevant, searched for grey literature order of the field conducted search within 24 months of completion of the review months of completion of the review 5. Did the review authors perform study selection in duplicate? Yes and achieved consensus on which studies to include No OR two reviewers selected a sample of eligible studies and achieved good agreement (at least 80 percent), with the remainder selected by one		(relevant to research question)		bibliographies of included		Partial Yes
 search strategy searched trial/study registries justified publication restrictions included/consulted content experts in the field where relevant, searched for grey literature conducted search within 24 months of completion of the review 5. Did the review authors perform study selection in duplicate? For Yes, either ONE of the following: at least two reviewers independently agreed on selection of eligible studies Yes and achieved consensus on which studies to include No OR two reviewers selected a sample of eligible studies and achieved good agreement (at least 80 percent), with the remainder selected by one 	п				_	
 justified publication restrictions justified publication restrictions included/consulted content experts in the field where relevant, searched for grey literature conducted search within 24 months of completion of the review Did the review authors perform study selection in duplicate? For Yes, either ONE of the following:			п			NO
(e.g. language) experts in the field Image: Instance where relevant, searched for grey literature Image: Instance conducted search within 24 months of completion of the review 5. Did the review authors perform study selection in duplicate? For Yes, either ONE of the following: Image: Provide the studies of the studies of the studies of the studies of the studies to include Image: Im	-		_			
 where relevant, searched for grey literature conducted search within 24 months of completion of the review 5. Did the review authors perform study selection in duplicate? For Yes, either ONE of the following: at least two reviewers independently agreed on selection of eligible studies Yes and achieved consensus on which studies to include No OR two reviewers selected a sample of eligible studies and achieved good agreement (at least 80 percent), with the remainder selected by one 	Ц		Ľ			
grey literature conducted search within 24 months of completion of the review 5. Did the review authors perform study selection in duplicate? For Yes, either ONE of the following: at least two reviewers independently agreed on selection of eligible studies at least two reviewers independently agreed on selection of eligible studies OR two reviewers selected a sample of eligible studies and achieved good agreement (at least 80 percent), with the remainder selected by one		(e.g. language)	_	-		
 conducted search within 24 months of completion of the review 5. Did the review authors perform study selection in duplicate? For Yes, either ONE of the following: at least two reviewers independently agreed on selection of eligible studies Yes and achieved consensus on which studies to include No OR two reviewers selected a sample of eligible studies and achieved good agreement (at least 80 percent), with the remainder selected by one 			0	•		
months of completion of the review 5. Did the review authors perform study selection in duplicate? For Yes, either ONE of the following: at least two reviewers independently agreed on selection of eligible studies and achieved consensus on which studies to include OR two reviewers selected a sample of eligible studies and achieved good agreement (at least 80 percent), with the remainder selected by one			_	0,		
review 5. Did the review authors perform study selection in duplicate? For Yes, either ONE of the following: at least two reviewers independently agreed on selection of eligible studies Yes and achieved consensus on which studies to include No OR two reviewers selected a sample of eligible studies and achieved good agreement (at least 80 percent), with the remainder selected by one						
 5. Did the review authors perform study selection in duplicate? For Yes, either ONE of the following: at least two reviewers independently agreed on selection of eligible studies Yes and achieved consensus on which studies to include No OR two reviewers selected a sample of eligible studies <u>and</u> achieved good agreement (at least 80 percent), with the remainder selected by one 				months of completion of the		
For Yes, either ONE of the following: at least two reviewers independently agreed on selection of eligible studies Yes and achieved consensus on which studies to include No OR two reviewers selected a sample of eligible studies and achieved good agreement (at least 80 percent), with the remainder selected by one				review		
 at least two reviewers independently agreed on selection of eligible studies Yes and achieved consensus on which studies to include No OR two reviewers selected a sample of eligible studies <u>and</u> achieved good agreement (at least 80 percent), with the remainder selected by one 	5.	Did the review authors perform	n stud y se	election in duplicate?		
 at least two reviewers independently agreed on selection of eligible studies Yes and achieved consensus on which studies to include No OR two reviewers selected a sample of eligible studies <u>and</u> achieved good agreement (at least 80 percent), with the remainder selected by one 	For Yes	, either ONE of the following:	-			
 OR two reviewers selected a sample of eligible studies <u>and</u> achieved good agreement (at least 80 percent), with the remainder selected by one 	_	-	ntly agree	d on selection of eligible studies		Yes
OR two reviewers selected a sample of eligible studies <u>and</u> achieved good agreement (at least 80 percent), with the remainder selected by one		and achieved consensus on which	n studies t	to include		No
agreement (at least 80 percent), with the remainder selected by one		OR two reviewers selected a sam	ple of elia	gible studies_and_achieved_good		
	_	agreement (at least 80 percent), v				



6.	Did the review authors perform	ı data ext	raction in duplicate?		
For Yes	, eitherONE of the following:				
	at least two reviewers achieved co included studies	onsensus (on which data to extract from		Yes No
	OR two reviewers extracted data achieved good agreement (at leas extracted by one reviewer.				
7.	Did the review authors provide	a list of e	excluded studies and justify the excl	lusio	ns?
For Par	tial Yes:	For Yes	, must also have:		
	provided a list of all potentially relevant studies that were read in full-text form but excluded from the review		Justified the exclusion from the review of each potentially relevant study		Yes Partial Yes No
8.	Did the review authors describ	e the incb	uded stulies in adequate detail?		
For Par	tial Yes (ALL the following):	For Yes followin	, should also have ALL the ng:		
	described populations		described population in detail	_	Yes
	described interventions			_	Partial Yes
	described comparators		detail (including doses where		No
	described outcomes		relevant) described comparator in detail		
	des cribed research designs	L	(including doses where relevant)		
			described study's setting		
			timeframe for follow-up		
9.	Did the review authors use a sa individual studies that were inc		v technique for assessing the risk of the review?	bias	(RoB) in
RCTs					
for Par from	tial Yes, must have assessed RoB		, mustalso have assessed RoB		
	unconcealed allocation, and	from:	allocation sequence that was	п	Yes
_	,		not truly random, and		
	lack of blinding of patients and assessors when assessing		selection of the reported result	ū	No
	outcomes (unnecessary for	_	from among multiple		Includes only
	objective outcomes such as all-		measurements or analyses of a		NRSI
	-		specified outcome		
	cause mortality)		speaned outcome		
			-		
For Par	cause mortality) tial Yes, must have assessed		, must also have assessed RoB:	_	_
For Par RoB:	tial Yes, must have assessed	For Yes	, must also have assessed RoB: methods used to ascertain	0	Ув
For Par RoB:	tial Yes, must have assessed from confounding, and		, must also have assessed RoB: methods used to ascertain exposures and outcomes, <i>and</i>		Partial Yes
RoB:	tial Yes, must have assessed		, must also have assessed RoB: methods used to ascertain	_	
For Par RoB: D	tial Yes, must have assessed from confounding, <i>and</i> from selection bias		, must also have assessed RoB: methods used to ascertain exposures and outcomes, <i>and</i> selection of the reported result from among multiple measurements or analyses of a		Partial Yes No Includes only RCTs
For Par RoB: D	tial Yes, must have assessed from confounding, <i>and</i> from selection bias Did the review authors report o		, must also have assessed RoB: methods used to ascertain exposures and outcomes, <i>and</i> selection of the reported result from among multiple measurements or analyses of a specified outcome		Partial Yes No Includes only RCTs





11. If meta-analysis was performed did the review authors use appropriate combination of results?	meth	ods for statistical
RCTs For Yes:		
 The authors justified combining the data in a meta-analysis AND they used an appropriate weighted technique to combine study results and adjusted for heterogeneity if present. 		Yes No No meta-analysis
AND investigated the causes of any heterogeneity		conducted
For NRSI For Yes:		
Tor res: The authors justified combining the data in a meta-analysis		Yes
 AND they used an appropriate weighted technique to combine study results, adjusting for heterogeneity if present 		No No meta-analysis
AND they statistically combined effect estimates from NRS I that were adjusted for confounding, rather than combining raw data, or justified combining raw data when adjusted effect estimates were not available		conducted
AND they reported separate summary estimates for RCTs and NRS I separately when both were included in the review		
12. If meta-analysis was performed, did the review authors assess the potent individual studies on the results of the meta-analysis or other evidence sy		-
For Yes:		
included only low risk of bias RCTs	-] Yes] No
 OR, if the pooled estimate was based on RCTs and/or NRSI at variable RoB, the authors performed analyses to investigate possible impact of RoB on summary estimates of effect. 	-] No meta-analysis conducted
13. Did the review authors account for RoB in individual studies when inter results of the review?	preti	ing/ discussing the
For Yes:		
included only low risk of bias RCTs	-] Yes
OR, if RCTs with moderate or high RoB, or NRSI were included the review provided a discussion of the likely impact of RoB on the results	L	J No
14. Did the review authors provide a satisfactory explanation for, and discuble terogeneity observed in the results of the review?	ssion	of, any
For Yes:		
 There was no significant heterogeneity in the results OR if heterogeneity was present the authors performed an investigation of 	г] Yes
sources of any heterogeneity in the results and discussed the impact of this on the results of the review		I No
15. If they performed quantitative synthesis did the review authors carry or investigation of publication bias (small study bias) and discuss its likely the review?		-
For Yes:	_	
performed graphical or statistical tests for publication bias and discussed the liberitude and memory of investor from liberitude in] Yes
the likelihood and magnitude of impact of publication bias	-] No] Nometa-analysis conducted
16. Did the review authors report any potential sources of conflict of interes they received for conducting the review?	st, inc	luding any funding
For Yes:	_	
 The authors reported no competing interests OR The authors described their funding sources and how they managed potential conflicts of interest 	0 0	Yes No



Assessment of risk of bias for systematic reviews of original studies using AMSTAR2

Reference	1	2	3	4	5	6	7	8	9 RCT	9 NRSI	10	11 RCT	11 NRSI	12	13	14	15	16	Total Score
Boland 2020	Yes	Ρ	Yes	Yes	Yes	Yes	Yes	Р	Yes	Only RCT	Yes	No MA	No	No MA	Yes	Yes	No MA	Yes	Н
Charernboon 2020	Yes	No	No	No	Yes	Yes	No	Ρ	Yes	Only RCT	No	No MA	No MA	No MA	Yes	Yes	No MA	Yes	CL
de Carvalho 2020	Yes	No	Yes	Ρ	No	No	No	Ρ	No	Only RCT	Yes	No	No	Yes	Yes	No	No	Yes	CL
Elliott 2020	Yes	Yes	No	Р	Yes	Yes	Yes	No	Only NRSI	Ρ	Yes	No MA	No MA	No MA	Yes	No	No MA	Yes	CL
Hindocha 2020	Yes	Ρ	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	No MA	No MA	No MA	Yes	No	No MA	Yes	CL
Johal 2020	Yes	Ρ	Yes	Р	Yes	Yes	No	No	Yes	Only RCT	No	Yes	No	Yes	Yes	Yes	Yes	Yes	CL
Khan 2020	No	No	Yes	Ρ	Yes	Yes	No	No	No	No	No	No MA	No MA	No MA	No	No	No	Yes	CL
Mun 2020	Yes	Ρ	Yes	Ρ	Yes	Yes	No	Ρ	No	Only RCT	No	No MA	No MA	No MA	Yes	Yes	No MA	Yes	CL
Rabgay 2020	Yes	Ρ	Yes	Ρ	Yes	Yes	Yes	Ρ	Yes	Only RCT	Yes	Yes	No	No	No	No	No	Yes	CL
Sarris 2020	Yes	No	Yes	Ρ	No	No	No	No	No	No	Yes	No MA	No MA	No MA	No	Yes	No MA	Yes	CL
Amaniti 2019	Yes	Ρ	Yes	Ρ	Yes	Yes	No	Ρ	Yes	Only RCT	Yes	No MA	No MA	No MA	Yes	Yes	No MA	Yes	CL
Black 2019	Yes	Р	Yes	Р	Yes	Yes	Yes	Yes	Yes	Р	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	L
Bonaccorso 2019	Yes	No	No	No	Yes	Yes	No	Ρ	No	Only RCT	No	No MA	No MA	No MA	Yes	No	No MA	Yes	CL
Calapai 2019	No	Ρ	Ρ	Only RCT	No	No MA	No MA	No MA	No	No	No MA	Yes	CL						
Khoury 2019	No	No	No	Р	Yes	No	No	Ρ	No	No	Yes	No MA	No MA	No MA	Yes	No	No MA	Yes	CL
Millar 2019	Yes	No	Yes	No	Yes	Yes	No	Ρ	Yes	No	Yes	No	No	No	Yes	Yes	No	Yes	CL

Review on Use of Cannabis for Medical Purposes



Reference	1	2	3	4	5	6	7	8	9 RCT	9 NRSI	10	11 <i>RCT</i>	11 NRSI	12	13	14	15	16	Total Score
												MA	MA	MA			MA		
Orsolini 2019	No	No	No	Ρ	Yes	Yes	No	Ρ	No	No	Yes	No MA	No MA	No MA	No	No	No MA	Yes	CL
Wang 2019	Yes	No	Yes	Ρ	Yes	Yes	No	Ρ	Yes	Only RCT	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	CL
Yanes 2019	Yes	No	Yes	No	Yes	Yes	No	No	No	Only RCT	No	Yes	No	No	No	Yes	No	No	CL
Advani 2018	No	Ρ	Yes	Ρ	Yes	Yes	No	No	Yes	Only RCT	No	No MA	No MA	No MA	No	No	No MA	Yes	CL
Behm 2018	No	No	Yes	Ρ	No	No	No	Yes	Ρ	Only RCT	No	No MA	No MA	No MA	Yes	No	No MA	Yes	CL
De Vita 2018	No	Yes	Yes	No	No	No	No	No	Yes	Only RCT	No	Yes	No MA	No	Yes	Yes	Yes	Yes	CL
Ishak 2018	No	No	No	No	Yes	No	No	No	No	No	Yes	No MA	No MA	No MA	No	No	No MA	Yes	CL
Kafil 2018	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Only RCT	Yes	No MA	No MA	No MA	Yes	No	No MA	Yes	L
Mucke 2018	Yes	Ρ	Yes	No	Yes	Yes	Yes	No	Yes	Only RCT	Yes	Yes	No MA	No	Yes	Yes	No	Yes	CL
Mucke 2018a	Yes	Only RCT	Yes	Yes	No MA	Yes	Yes	Yes	Yes	Yes	Н								
Stockings 2018	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Н								
Stockings 2018a	Yes	Yes	Yes	Ρ	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	L
Torres-Moreno 2018	Yes	Ρ	Yes	Ρ	Yes	Yes	Ρ	Yes	Yes	Only RCT	Yes	Yes	No MA	Yes	Yes	Yes	Yes	Yes	CL
Zhang 2018	Yes	No	Yes	No	No	Yes	Yes	No	Yes	Only RCT	No	No MA	No MA	No MA	Yes	Yes	No MA	Yes	CL
da Rovare 2017	Yes	No	Yes	No	Yes	Yes	No	Yes	Yes	Only RCT	No	No	No MA	Yes	Yes	No	Yes	No	CL
Goldenberg 2017	No	No	No	Р	No	Yes	No	Р	Р	No	No	No	No	No	No	No	No	Yes	CL
Lim 2017	No	No	Yes	Ρ	No	No	No	No	Yes	Only RCT	No	No MA	No MA	No MA	Yes	No	No MA	No	CL

Review on Use of Cannabis for Medical Purposes



Reference	1	2	3	4	5	6	7	8	9 RCT	9 NRSI	10	11 <i>RCT</i>	11 NRSI	12	13	14	15	16	Total Score
Norton 2017	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Р	Р	No	No MA	No MA	No MA	Yes	Yes	No MA	Yes	CL
Nugent 2017	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	No	Yes	Yes	Yes	No	Yes	CL
Osborne 2017	No	No	No	Ρ	No	No	Yes	Ρ	No	No	No	No MA	No MA	No MA	No	No	No MA	Yes	CL
Stevens 2017	Yes	Yes	Yes	Р	Yes	Yes	No	Yes	Yes	Only RCT	No	No MA	No MA	No MA	Yes	Yes	No MA	Yes	CL
Wong 2017	No	No	No	Ρ	No	Yes	No	No	No	No	No	No MA	No MA	No MA	Yes	No	No MA	Yes	CL
Fitzcharles 2016	No	No	Yes	Р	No	Yes	No	Ρ	Yes	Only RCT	No	No MA	No MA	No MA	Yes	No	No MA	No	CL
Gruenbaum 2016	No	No	Yes	Ρ	Yes	Yes	No	No	No	No	No	No MA	No MA	No MA	No	No	No MA	No	CL
Merlin 2016	No	No	Yes	Ρ	Yes	Yes	No	Ρ	No	Only RCT	No	No MA	No MA	No MA	Yes	No	No MA	No	CL
Wilkinson 2016	No	No	Yes	No	No	No	No	No	No	Ρ	No	No MA	No MA	No MA	No	No	No MA	Yes	CL

CL: critically low; H: high; L: low; MA: meta-analysis; P: partial



Health Evidence (McMaster University)

Health Evidence

Helping public health use best evidence in practice

Quality Assessment Tool – Review Articles

First Author:

Reviewer:

Ye an: Journal:

Instructions for completion:

Please refer to the attached dictionary for definition of terms and instructions for completing each section. For each criteria, score by placing a check mark in the appropriate box.

CRITERION							
01. Did the authors have a clearly focused question [population, intervention (strategy), and outcome(s)]?							
02. Were appropriate inclusion criteria u	ised to select primary studie	s?					
•	trategy that was comprehen • health databases • psychological databases • social science databases • educational databases • other	nsive? • handsearching • key informants • reference lists • unpublished					
			. /	4			

04. Did search strategy cover an adequate number of years?

For questions 5, 6, and 8, please choose the column relating to the appropriate methodology. Strike a line through the column that does not apply.

 Q5, Quantitative reviews: Did the authors describe the level of evidence in the primary studies included in the review? Level I → RCTs only Level II → non-randomized, cohort, case-control Level II → uncontrolled studies 	05. Qualitative reviews: Do the authors provide a clear description of the range of methods in each of the primary studies included in the review?	
 Q6. Quantitative reviews: Did the review assess the methodological quality of the primary studies, including: (Minimum requirement: 4/7 of the following) Rese arch design Study sample Participation rates Sources of bias (confounders, respondent bias) D at a collection (measurement of independent/dependent variables) Follow-up/attrition rates D at a analysis 	 0.6. Qualitative reviews: Did the review assess the methodological quality of the primary studies, including: (Minimum requirement: 4/7 of the following) Suitability of methodology/paradigm to the research question Sampling (selection of participants / settings / documentation) Clear description of context, data collection and data analysis Rigor: Audit trail Some coding by 2 or more coders, if appropriate Deviant case analysis (negative cases) Respondent validation (member checking) Tri angul ation Relevance (credibility, consistency, applic ability, transferability) 	
07. Are the results of the review transparent?		
08. Quantitative reviews: Was it appropriate to combine the findings of results across studies?	0.8. Qualitative reviews: Is there a description of how reviewers determined results were similar enough across studies to compare or combine them?	
09. Were appropriate methods used for combining of	or comparing results across studies?	
010. Do the data support the author's interpretation?	?	
	TOTAL SCORE :	
Quality Assessment Rating: Strong (Circle one) (total œore θ = 10)	Moderate Weal((total soore 5 - 7) (total soore 4 or less)	



Assessment of risk of bias of systematic reviews of systematic reviews using the Health Evidence Tool

	Q1. Did the authors have a clearly focused question [population, intervention (strategy), and outcome(s)]?	Q2. Were appropriate inclusion criteria used to select primary studies?	Q3. Did the authors describe a search strategy that was comprehensive?	Q4. Did search strategy cover an adequate number of years?	Q5. Did the authors describe the level of evidence in the primary studies included in the review?	Q6. Did the review assess the methodological quality of the primary studies, including:	Q7. Are the results of the review transparent?	Q8. Was it appropriate to combine the findings of results across studies?	Q9. Were appropriate methods used for combining or comparing results across studies?	Q10. Do the data support the author's interpretation?	Final Score	Final Appraisal
Hoch 2019	1	1	1	1	1	1	1	1	1	1	10	Strong
Allan 2018	0	1	1	1	1	1	1	1	1	1	9	Strong
Nielsen 2018	1	1	0	1	1	1	1	1	1	1	9	Strong
Hauser 2017	1	1	1	1	1	1	1	1	1	1	10	Strong
Houze 2017	1	1	0	1	1	1	1	1	1	1	9	Strong
O'Neil 2017	1	1	1	1	1	0	0	0	1	1	7	Moderate
Tafelski 2017	1	1	0	1	1	1	1	1	1	1	9	Strong



Appendix 4: Reviews sorted by indication and cannabis formulation^{*, **}

* as reported by the original authors

** Cannabis type (MC: medical cannabis, Unspecified: cannabis reported without any specifications, Plant: plant-based cannabinoids, Synthetic: synthetic cannabinoids)

Study	Cannabis	Cannabis	Indications
	type	formulation	
Black 2019	MC	Cannabis sativa	ADHD
Khan 2020	Unspecified	CBD	ADHD
Lim 2017	Unspecified	THC	ALS
Wilkinson 2016	Unspecified	THC	Alzheimer's disease (agitation)
Hoch 2019	Unspecified	THC	Alzheimer's disease (dementia)
Lim 2017	Unspecified	THC	Anorexia nervosa
Black 2019	MC	Cannabis sativa	Anxiety
Black 2019	MC	CBD	Anxiety
Lim 2017	Unspecified	CBD	Anxiety
Black 2019	MC	THC	Anxiety
Lim 2017	Unspecified	THC	Anxiety
Lim 2017	Unspecified	THC 0.5 mg/kg : CBD 1 mg/kg	Anxiety
Black 2019	MC	THC-CBD	Anxiety
Calapai 2019	Unspecified	CBD	Anxiety (SAD)
Khan 2020	Unspecified	CBD	Anxiety (SAD)
Khoury 2019	Unspecified	CBD	Anxiety (SAD)
Millar 2019	Synthetic	CBD	Anxiety (SAD)







Study	Cannabis	Cannabis	Indications
	type	formulation	
Osborne 2017	Unspecified	THC-CBD	Cognition
Millar 2019	Synthetic	CBD	Crohn's disease
Hauser 2017	Unspecified	THC	Crohn's disease
Norton 2017	MC	Cannabis	Crohn's disease (pain)
Norton 2017	MC	Marijuana	Crohn's disease (pain)
Charernboon 2020	Unspecified	THC	Dementia
Ishak 2018	Unspecified	Cannabinoids	Depression
Black 2019	MC	Cannabis sativa	Depression
Black 2019	MC	THC	Depression
Black 2019	MC	THC-CBD	Depression
de Carvalho 2020	MC	Cannabis	Epilepsy
de Carvalho 2020	Unspecified	CBD	Epilepsy
Stockings 2018	Unspecified	CBD	Epilepsy
Wong 2017	Unspecified	CBD	Epilepsy
Wong 2017	MC	CBD enriched OCE	Epilepsy
Stockings 2018	Unspecified	CE	Epilepsy
Stockings 2018	MC	Hemp-based plant extract (Elixinol)	Epilepsy
Stockings 2018	Unspecified	THC : CBD	Epilepsy
Stockings 2018	Unspecified	THCA	Epilepsy



Study	Cannabis	Cannabis	Indications
	type	formulation	
Wong 2017	MC	OCE	Epilepsy
Millar 2019	Synthetic	CBD	Epilepsy (adults)
Stockings 2018	MC	MC	Epilepsy (adults)
Elliott 2020	Unspecified	CBD	Epilepsy (pediatric)
Millar 2019	Synthetic	CBD	Epilepsy (pediatric)
Elliott 2020	Unspecified	CBD : THC	Epilepsy (pediatric)
Stockings 2018	MC	MC	Epilepsy (pediatric)
Millar 2019	Synthetic	CBD	Fatty liver disease
Hauser 2017	Unspecified	FAAH hydrolase	Fibromyalgia
		inhibitor	
Goldenberg 2017	MC	MC	Health-related quality of life
Ishak 2018	Unspecified	Cannabinoids	HIV (anxiety)
Ishak 2018	Unspecified	Cannabinoids	HIV (depression)
Ishak 2018	Unspecified	Cannabinoids	HIV (muscle pain)
Ishak 2018	Unspecified	Cannabinoids	HIV (neuropathy)
Johal 2020	MC	Cannabis	HIV (sensory neuropathy)
Amaniti 2019	MC	Cannabis	HIV (sensory neuropathy)
		cigarettes	
Johal 2020	MC	Cannabis	HIV sensory neuropathy
Hauser 2017	Unspecified	THC	HIV/AIDS
Lim 2017	Unspecified	CBD	Huntington's disease
Millar 2019	Synthetic	CBD	Huntington's disease



Study	Cannabis	Cannabis	Indications
	type	formulation	
Bonaccorso 2019	Unspecified	CBD	Huntington's disease
Khan 2020	Unspecified	CBD	Insomnia
Sarris 2020	Unspecified	CBD	Insomnia
Nielsen 2018	Unspecified	THC : CBD	MS (ataxia and tremor)
Torres-Moreno 2018	MC	Cannabis sativa	MS (bladder dysfunction)
Nielsen 2018	Unspecified	THC	MS (bladder function) <u>no cl recom</u>
Nielsen 2018	Unspecified	THC : CBD	MS (bladder function) no cl recom
Nielsen 2018	MC	Cannabis sativa	MS (disability)
Nielsen 2018	Unspecified	THC : CBD	MS (disability)
Behm 2018	MC	Cannabis cigarettes	MS (gait disorders)
Behm 2018	Unspecified	CE-THC	MS (gait disorders)
Yanes 2019	THC	Cigarettes	MS (pain)
Nielsen 2018	MC	Cannabis sativa	MS (pain)
Torres-Moreno 2018	Plant	Cannabis sativa	MS (pain)
Nielsen 2018	Unspecified	CBD	MS (pain)
Nielsen 2018	Unspecified	THC	MS (pain)
Nielsen 2018	Unspecified	THC : CBD	MS (pain)
Nielsen 2018	MC	Cannabis sativa	MS (QOL)
Nielsen 2018	Unspecified	THC : CBD	MS (QOL)
Nielsen 2018	Unspecified	THC	MS (sleep)



<u>Ctuch</u>	Connohio	Connohio	Indiantiona
Study	Cannabis	Cannabis	Indications
	type	formulation	
Nielsen 2018	Unspecified	CBD	MS (sleep) <u>no cl recom</u>
Nielsen 2018	Unspecified	CBD: THC	MS (sleep) <u>no cl recom</u>
da Rovare 2017	MC	A whole-plant CE (1 THC : 1	MS (spasticity)
		CBD)	
Johal 2020	MC	Cannabinoids	MS (spasticity)
Johal 2020	MC	Cannabis	MS (spasticity)
Johal 2020	MC	Cannabis	MS (spasticity)
da Rovare 2017	MC	Cannabis	MS (spasticity)
		cigarettes	
Nielsen 2018	MC	Cannabis sativa	MS (spasticity)
Torres-Moreno	Plant	Cannabis sativa	MS (spasticity)
2018			
da Rovare 2017	MC	CE (2.5 mg	MS (spasticity)
		THC: 1.25 mg CBD)	
Allan 2018	Unspecified	Medical	MS (spasticity)
		cannabinoids	
Nielsen 2018	Unspecified	THC	MS (spasticity)
Nielsen 2018	Unspecified	THC : CBD	MS (spasticity)
da Rovare 2017	MC	Whole-plant CE	MS (spasticity)
		(2.5 mg THC : 0.9 mg CBD)	
Hauser 2017	Unspecified	FAAH hydrolase	Osteoarthritis







Study	Cannabis	Cannabis	Indications
	type	formulation	
Hauser 2017	MC	Medical	Pain, neuropathic
		marijuana	
Rabgay 2020	MC	SCT	Pain, neuropathic
Yanes 2019	THC	Smoke	Pain, neuropathic
Hauser 2017	Unspecified	THC	Pain, neuropathic
Mucke 2018	MC	Herbal cannabis	Pain, neuropathic (adults)
Hauser 2017	Unspecified	FAAH hydrolase inhibitor	Pain, neuropathic (chemotherapy)
Merlin 2016	MC	Cannabis	Pain, neuropathic (HIV/AIDS)
Johal 2020	MC	Cannabis	Pain, postoperative/ nociceptive
Rabgay 2020	MC	SCET	Pain, postoperative/ nociceptive
Rabgay 2020	Unspecified	THC	Pain, postoperative/ nociceptive
Yanes 2019	THC	Capsule	Pain, postoperative/ nociceptive
Hauser 2017	Unspecified	THC	Pain, visceral
Hauser 2017	Unspecified	THC	Palliative care (cancer)
Mucke 2018	Unspecified	THC (2,5 mg, herbal)	Palliative care (cancer)
Mucke 2018	Unspecified	THC : CB (2,5 mg:1 mg, herbal)	Palliative care (cancer)
Mucke 2018	MC	Herbal Cannabis (0.9 g and 3,95% THC)	Palliative care (HIV/AIDS)







Study	Cannabis	Cannabis	Indications
	type	formulation	
Hindocha 2020	MC	Herbal cannabis	PTSD
O'Neil 2017	MC	Plant-based	PTSD
		cannabis	
Hindocha 2020	Unspecified	THC	PTSD
Orsolini 2019	Unspecified	THC	PTSD
Wilkinson 2016	Unspecified	THC	PTSD
Orsolini 2019	MC	THC	PTSD
Orsolini 2019	MC	THC-CBD	PTSD
O'Neil 2017	Synthetic	Cannabis	PTSD
Lim 2017	Unspecified	CBD	Rheumatic diseases
Fitzcharles 2016	Unspecified	PF-04457845	Rheumatic diseases
Hauser 2017	Unspecified	THC	Rheumatic diseases
Hauser 2017	Unspecified	FAAH hydrolase inhibitor	Rheumatoid arthritis
Hoch 2019	Unspecified	CBD	SAD
Calapai 2019	Unspecified	CBD	Schizophrenia
Hoch 2019	Unspecified	CBD	Schizophrenia
Khoury 2019	Unspecified	CBD	Schizophrenia
Millar 2019	Synthetic	CBD	Schizophrenia
Khan 2020	Unspecified	CBD	Schizophrenia
Sarris 2020	Unspecified	CBD	Schizophrenia
Hoch 2019	Unspecified	CBD	Schizophrenia (chronic)

Study	Cannabis	Cannabis	Indications
	type	formulation	
Millar 2019	Synthetic	CBD	Sleep disturbance
Black 2019	MC	Cannabis sativa	Tourette syndrome/tics
Khan 2020	Unspecified	CBD	Tourette syndrome/tics
Black 2019	MC	THC	Tourette syndrome/tics
Hoch 2019	Unspecified	THC	Tourette syndrome/tics
Lim 2017	Unspecified	THC	Tourette syndrome/tics
Wilkinson 2016	Unspecified	THC	Tourette syndrome/tics
Wong 2017	Unspecified	THC	Tourette syndrome/tics
Zhang 2018	Unspecified	THC	Tourette syndrome/tics
Gruenbaum 2016	MC	Marijuana	Traumatic brain injury
Millar 2019	Synthetic	CBD	Type II DM
Kafil 2018	MC	Cannabis	Ulcerative colitis
		cigarettes	
Kafil 2018	Unspecified	CBD	Ulcerative colitis
Norton 2017	MC	Cannabis	Ulcerative colitis (pain)
Norton 2017	MC	Marijuana	Ulcerative colitis (pain)





Appendix 5: Major evidence for prescribing cannabis and non-pharmaceutical cannabinoids

using evidence from major grey literature

Source	Year	Agent	Indication	Level of evidence
CADTH (<u>85</u>)	2020	Cannabis (oral) CBD	Pediatric epilepsy	Limited
		Cannabis (5% oil formulation containing CBD:THC as 20:1 or 6:1)	Reducing spasticity, sleep difficulties, pain, and improving quality of life relative to baseline in pediatric patients with severe complex motor disorder	Limited
		Medical cannabis	Improving rigidity and cognitive scores, and reducing agitation, disinhibition, irritability, aberrant behavior, and nocturnal behavior disorders as well as aberrant vocalization and resting care in patients with dementia	Low quality
		Cannabis (smoked)	Reducing some PTSD	Low quality
		THC (oral)		
CADTH (<u>86</u>)	2019	Cannabis-based medicines	Chronic neuropathic pain and non-cancer pain	Possible
		Cannabis-based medicines	Fibromyalgia, musculoskeletal pain, headache, rheumatoid arthritis, osteoarthritis, Crohn's disease, and multiple sclerosis.	Inconsistent
CADTH (<u>87</u>)	2019a	Medical cannabis / cannabinoids	Refractory cancer-related/palliative pain (to be considered if two or more other prescribed analgesics have failed, with careful consideration of risks versus benefits, and to be prescribed as an adjunct to other analgesics)	Weak evidence / Alternative option



Appendix 6: Reported adverse events with cannabis and non-pharmaceutical cannabinoids

Review	Formulation	Adverse Events
Boland 2020	THC, THC:CBD, pharmaceutical	Cannabinoids (THC, THC:CBD, and some pharmaceutical) had a higher risk of adverse events when compared with placebo, especially somnolence (OR 2.69 (1.54 to 4.71), p<0.001) and dizziness (OR 1.58 (0.99 to 2.51), p=0.05).
Charernboon 2020	THC	Two studies of THC demonstrated no significant differences for adverse events between THC and placebo (eg. somnolence, dizziness, falls, or europhic mood).
de Carvalho 2020	Cannabis, CBD	Meta-analyses conducted for AEs determining that CBD is safe. Medicinal CNB is as safe as CBD, though only at low THC levels. Adverse events were more prevalent under short-term compared with long-term CBD treatment, suggesting lower AE profiles during long-term treatment. Weight loss was the only AE found to be significantly higher for CBDs compared to cannabis.
Elliott 2020	CBD, CBD:THC	Increased risk of gastrointestinal adverse events in children that received a cannabis-based product (CBD) compared to placebo.
Hindocha 2020	Herbal cannabis, cannabis resin, THC, CBD, CBD oil	For THC, no serious adverse events reported in studies. No additional details provided for CBD or whole plant cannabis products in terms of AEs.



Review	Formulation	Adverse Events
Johal 2020	Cannabis (inhaled), cannabinoids	Compared with placebo, cannabinoids were associated with a similar risk of serious AE; however there were a greater number of non-serious treatment related AEs reported for cannabinoids, due largely to events such as dizziness, throat discomfort, asthenia, fatigue, drowsiness, dry mouth, increased appetite, hallucinations, nausea, and refractory spasticity (results described for pharmaceutical and non-pharmaceutical cannabis combined).
Khan 2020	CBD	For schizophrenia and psychosis, no adverse events reported. For cannabis related disorders, no adverse events reported. For other disorders (ADHD, ASD, PTSD) adverse events such as muscular seizures and spasms, somnolence and changes in appetite, fatigue, and sexually inappropriate behavior in a patient with developmental disorder, mild sedation, and mild xerostomia were reported (results not reported by cannabis type).
Mun 2020	Cannabis, cannabinoids	NR
Rabgay 2020	Cannabis (standardized dried)	The analysis results showed statistically significant incidence of euphoria compared with placebo: standardized cannabis with THC (7% of THC; relative risk [RR] 1.74, 95% CI 1.13 to 2.267), THC/CBD (RR 3.14, 95% CI 1.39 to 7.09), and THC (RR 2.98, 95% CI, 1.34 to 6.62)
Sarris 2020	Cannabis, CBD	Occcasional adverse effects revealed in clinical trials include co-ordination problems, dizziness, disorientation, euphoria, drowsiness or fatigue, dry



Review	Formulation	Adverse Events
		mouth, nausea and gastrointestinal upsets (results described for pharmaceutical and non-pharmaceutical cannabis in combination).
Amaniti 2019	Cannabis cigarettes	Amoung the two cannabis studies included, one study reported confusion, dizziness, nausea, significantly more frequent in cannabis group ($p < 0.01$), and the other reported greater frequency of concentration difficulties, fatigue, sleepiness or sedation, increased duration of sleep, reduced salivation, and thirst in cannabis week than placebo week.
Black 2019	Cannabis sativa, cannabis resin, CBD extract, Marijuana	No significant increases in the number of people having adverse events or withdrawing compared with active and placebo comparators for CBD or medical cannabis.
Bonaccorso 2019	CBD, THC	No side effects other than sedation has been reported throughout the studies for CBD. However, further study to assess its impact on suicidal ideation are needed, and the risk of gastrointestinal adverse events; possible alteration in liver function tests; and drug interactions have recently been emphasized.
Calapai 2019	CBD	CBD was well tolerated, and rates of adverse events were similar between the CBD and placebo groups in one of the included studies. No information on adverse events or safety reported for other studies.
Hoch 2019	CBD, THC	Side effects can occur, but severe AEs were mentioned in single cases only.



Review	Formulation	Adverse Events
(55)		No adverse effects have been reported for cannabidiol as treatment for mental disorders. Results for non-pharmaceutical THC not discussed.
Khoury 2019 (27)	CBD	AEs were not always carefully detailed in the studies; when reported, they were insignificant or less intense than the comparative treatment (statement based on mix of pharmaceutical and non-pharmaceutical AEs, including CBD). The most frequently reported AEs are sedation and dizziness.
Millar 2019 (28)	CBD	Mild to moderate adverse events were reported in some studies included in review, while CBD was well tolerated in others. No summary statement explicitly provided by authors.
Orsolini 2019 (29)	THC, CBD	Despite improvements in PTSD symptomatology, there are demonstrable adverse health risks associated with cannabis use, as chronic recreational use is associated with dependence and THC-related cognition dysfunction and risk of psychosis
Wang 2019 (30)	CE, THC, THC:CBD	Treatment related AEs the present meta-analysis included nausea, fatigue, pain, anemia, dizziness, dyspnea, diarrhea, obstipation, somnolence, raised γ -GT, hypercalcemia, hypotension, and so on. A total of 441 patients had 607 AEs (496 in the cannabinoids and 111 in the placebo groups) in the three studies.
Yanes 2019	MC/CE	NR



Review	Formulation	Adverse Events
Advani 2018	CE, THC	NR
Behm 2018	CE, THC cannabis cigarettes	NR
De Vita 2018	Plant-based cannabis cigarettes with THC- specific dosages, THS standardized CE, THC	Authors discuss that psychotropic adverse effects also remain a salient concern among those considering cannabis-based medicines for pain. No other discussion of adverse events or safety.
lshak 2018	Cannabis	NR
Kafil 2018	Cannabis, CBD	Amoung the two studies included, one study on CBD reported significantly higher risk of adverse events, however the events were mild or moderate in severity. Common adverse events included dizziness, disturbance in attention, headache, nausea and fatigue. The second study, conducted on cannabis as the intervention, reported no adervse events.
Mucke 2018	Herbal Cannabis Marijuana cigarettes	Tolerability (measured by the number of withdrawals because of adverse events) did not differ significantly in cancer (RD: 1.15 [0.80; 1.66]; P = 0.46) and HIV patients (RD: 1.87 [0.60; 5.84]; P = 0.28). Safety did not differ in cancer (RD: 1.12 [0.86; 1.46]; P = 0.39) or HIV patients (4.51 [0.54; 37.45]; P = 0.32) although there was large uncertainty about the latter reflected in the width of the CI



Review	Formulation	Adverse Events
		(statement for both pharmaceutical and non-pharmaceutical cannabis).
Mucke 2018a	Herbal cannabis	There was no difference between all cannabis-based medicines pooled together and placebo in the frequency of serious adverse events (low-quality evidence) (herbal cannabis, THC/CBD oromucosal spray, synthetic or plant-based THC). Herbal cannabis (two studies with 152 participants) was not different to placebo. RD was 0.00 (95% CI -0.08 to 0.08) (P value 0.71).
Nielsen 2018	MC, cannabinoids, whole plant extract	Adverse effects were consistently rated as more common in study participants who received cannabinoids than placebo. However, no specific cannabinoid was identified as having a more serious adverse effect profile than another. Review findings were inconsistent on the effect of the addition of CBD to THC on the adverse effect profile of THC. Some reviews identified evidence of an attenuation of adverse effects related to THC, while other reviews identified greater adverse effects from THC:CBD combinations than THC.
Stockings 2018	MC, CE, CBD, THC:CBD, THCA	There was a greater likelihood of an AE in the intervention group compared to placebo when all studies were pooled together (pharmaceutical and non- pharmaceutical) (RCT pooled RR: 1.24 [95%CI: 1.13-1.36]) overall. For MC, CE, and THC:CBD, there was insufficient evidence to determine AEs. For CBD, mild-to-moderate AEs were likely in the intervention groups.



Review	Formulation	Adverse Events
Stockings	Cannabis sativa, THC,	Compared with placebo groups, patients receiving cannabinoids were more
2018a	CBD, THC-HS, CT-3	likely to report individual AEs such as dizziness (OR 5.52, 95% CI 4.47- 6.83), cognitive attention or disturbance (OR 5.67, 95% CI 2.72-11.79), and confusion and disorientation (OR 5.35, 95% CI 2.31-12.39).
Torres-Moreno 2018	Cannabis sativa plant extract	In the total adverse events analysis, there was a higher risk of withdrawals due to adverse events in the CE (RR, 3.11 patient-years; 95%CI, 1.54-6.28 patient-years) group.
Zhang 2018	THC	Tiredness, dry mouth, dizziness, and muzziness in 41.67% (5/12) of patients in single included studied on THC.
da Rovare 2017	Cannabis cigarettes, whole-plant CE (THC:CBD)	Cannabinoid users experienced an approximately three-fold increased risk of dizziness, somnolence and dry mouth, and an approximately two-fold increased risk of nausea, relative to placebo. These adverse events are significantly more tolerable than those related to the use of the current spasticity therapy, such as respiratory depression, ataxia and hallucinations (result reported as combined for pharmaceutical and non-pharmaceutical).
Goldenberg 2017	MC	Limted data from original studies for AEs, as reported by authors.
Hauser	Medical marijuana, FAAH inhibitor, THC	Two SRs found no statistically significant increase in the incidence of serious adverse events for cannabinoids in comparison with placebo in



Review	Formulation	Adverse Events
	cigarettes	neuropathic or cancer pain (THC cigarettes). The 3 prospective
		observational studies on medical marijuana and THC/CBD spray detected
		frequent central nervous and psychiatric adverse events. Overall, authors
		reported cannabinoid use in pain management and palliative medicine may
		cause relevant central nervous system (e.g. dizziness) and psychiatric
		adverse events (e.g. confusion, psychosis).
Houze 2017	Cannabis	Occurrence of adverse effects was particularly frequent with cannabis
		preparations among first-time cannabinoid users and included symptoms
		such as euphoria, dysphoria, alterations motor or cognitive function.
Lim 2017	THC, CBD, THC-CBD	Cannabinoids appear to be well-tolerated in these trials. The common short-
	cannador	term effects included dry mouth, dizziness, tiredness, and headache.
		Indeed, reviews that discussed
		the adverse effect of cannabis administration have reported that cannabis or
		cannabinoid administration was associated with a greater risk of non-serious
		adverse events (when considering both pharmaceutical and non-
		pharmaceutical cannabis products).
Norton 2017	Cannabis	In one selected study, authors recommended caution in the use of cannabis
		by CD patients until further studies explore effectiveness and safety. No
		other discussion of adverse events or safety.



Review	Formulation	Adverse Events
Nugent 2017	THC	Among general populations, limited evidence suggests that cannabis is associated with an increased risk for adverse mental health effects.
O'Neil 2017	Plant-based cannabis, synthetic cannabis	As reported by authors: We found moderate-strength evidence that light to moderate cannabis smoking does not adversely affect lung function over about 20 years. We found low-strength evidence that light to moderate cannabis use is not associated with lung cancer or head and neck cancer diagnoses independent of tobacco use. We found insufficient evidence examining whether cannabis use is associated with cardiovascular events over the long term. We found a consistent association between cannabis use and the development of psychotic symptoms over the short and long term (results discussed for both pharmaceutical and non-pharmaceutical cannabis together).
Osborne 2017	CE, THC, CBD, THC- CBD	NR
Stevens 2017	THC	Significantly more patients in the M-9-THC group reported increased awareness of surroundings compared to those in the placebo group (40% compared to 5%; $P = 0.04$). No other statistically significant differences existed between groups for adverse effects.
Wong 2017	OCE, OCE (CBD	In controlled trials, THC most commonly led to side effects of drowsiness



Formulation	Adverse Events
enriched), THC, CBD	and dizziness, with severity associated with higher doses. However, no
	major side effects were reported with dose reduction. The most common
	side effects with CBD were somnolence, diarrhea, and decreased appetite.
	Overall, studies were heterogeneous in the cannabinoid composition and
	dosage and lacked long-term follow-up to identify potential adverse effects.
PF-04457845	Single included study was stopped at interim analysis due to futility. No AEs
	reported at study termination.
Marijuana	NR
Cannabis cigarettes	NR
Tafelski 2016 THC	Hallucinations, paranoia, sedation, euphoria, dizziness, dysphoria,
	depression, hallucinations, focal dystonia
Cannabis (smoked),	AEs reported were generally mild. Patients with pre-existing psychosis or
THC	those that are marijuana naïve had greater risk of AEs.
	enriched), THC, CBD PF-04457845 Marijuana Cannabis cigarettes THC Cannabis (smoked),



References

1. BC Cancer. Cannabis for Medical Purposes. British Columbia Provincial Health Services Authority 2020.

 Green C, Bassett K. Herbal cannabis and pharmaceutical cannabinoid treatment following motor vehicle accidents: A state of the science review. Final Report.
 Therapeutics Initiative, University of British Columbia 2018.

3. Hauser W, Finn DP, Kalso E, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. European Journal of Pain (United Kingdom) 2018;22:1547-1564.

4. Freeman AM, Petrilli K, Lees R, et al. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neuroscience and Biobehavioral Reviews 2019;107:696-712.

5. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.

6. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration, 2011 March 2011 [cited; Version 5.1.0:[Available from: <u>www.cochrane-handbook.org</u>

7. Endnote [Computer Program] [Philadelphia, PA, USA; 2018.

8. Distiller SR [Computer Application] [Ottawa, ON, Canada; 2020.

9. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Bmj 2017;358:j4008.

10. Health Evidence-McMaster University. Quality Assessment Tool – Review Articles.2013 [cited 4 July 2020]; Available from:

https://www.healthevidence.org/documents/our-appraisal-



tools/QA_tool&dictionary_18.Mar.2013.pdf

11. Guyatt G, Rennie D, Meade M, et al. Users' guides to the medical literature: a manual for evidence-based clinical practice: AMA press Chicago; 2002.

12. Guyatt G, Rennie D. Users guides: essentials of evidence-based clinical practice: AMA press Chicago; 2002.

13. Boland EG, Bennett MI, Allgar V, et al. Cannabinoids for adult cancer-related pain: systematic review and meta-analysis. BMJ supportive & palliative care 2020;10:14-24.

14. Charernboon T, Lerthattasilp T, Supasitthumrong T. Effectiveness of Cannabinoids for Treatment of Dementia: A Systematic Review of Randomized Controlled Trials. Clinical gerontologist 2020:1-9.

15. de Carvalho Reis R, Almeida KJ, da Silva Lopes L, et al. Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis. Epilepsy and Behavior 2020;102 (no pagination).

16. Elliott J, DeJean D, Clifford T, et al. Cannabis-based products for pediatric epilepsy: An updated systematic review. Seizure 2020;75:18-22.

17. Hindocha C, Cousijn J, Rall M, et al. The Effectiveness of Cannabinoids in the Treatment of Posttraumatic Stress Disorder (PTSD): A Systematic Review. Journal of Dual Diagnosis 2020;16:120-139.

 Johal H, Devji T, Chang Y, et al. Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2020;13.

19. Khan R, Naveed S, Mian N, et al. The therapeutic role of Cannabidiol in mental health: A systematic review. Journal of Cannabis Research 2020;2 (1) (no pagination).

20. Mun CJ, Letzen JE, Peters EN, et al. Cannabinoid effects on responses to quantitative sensory testing among individuals with and without clinical pain: a



systematic review. Pain 2020;161:244-260.

21. Rabgay K, Waranuch N, Chaiyakunapruk N, et al. The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis. Journal of the American Pharmacists Association 2020;60:225-234.e6.

22. Sarris J, Sinclair J, Karamacoska D, et al. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC psychiatry 2020;20:24.

23. Amaniti A, Sardeli C, Fyntanidou V, et al. Pharmacologic and Non-Pharmacologic Interventions for HIV-Neuropathy Pain. A Systematic Review and a Meta-Analysis. Medicina 2019;55.

24. Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry 2019;6:995-1010.

25. Bonaccorso S, Ricciardi A, Zangani C, et al. Cannabidiol (CBD) use in psychiatric disorders: A systematic review. NeuroToxicology 2019;74:282-298.

26. Calapai G, Mannucci C, Chinou I, et al. Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry. Evidence-based Complementary and Alternative Medicine 2019;2019 (no pagination).

27. Khoury JM, Neves M, Roque MAV, et al. Is there a role for cannabidiol in psychiatry? World J Biol Psychiatry 2019;20:101-116.

28. Millar SA, Stone NL, Bellman ZD, et al. A systematic review of cannabidiol dosing in clinical populations. British Journal of Clinical Pharmacology 2019;85:1888-1900.

29. Orsolini L, Chiappini S, Volpe U, et al. Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review. Medicina (Kaunas) 2019;55.



30. Wang J, Wang Y, Tong M, et al. Medical Cannabinoids for Cancer Cachexia: A Systematic Review and Meta-Analysis. BioMed Research International 2019;2019 (no pagination).

31. Yanes JA, McKinnell ZE, Reid MA, et al. Effects of cannabinoid administration for pain: A meta-analysis and meta-regression. Exp Clin Psychopharmacol 2019;27:370-382.

32. Advani SM, Advani PG, Vonville HM, et al. Pharmacological management of cachexia in adult cancer patients: A systematic review of clinical trials. BMC Cancer 2018;18 (1) (no pagination).

33. Behm K, Morgan P. The effect of symptom-controlling medication on gait outcomes in people with multiple sclerosis: a systematic review. Disabil Rehabil 2018;40:1733-1744.

34. De Vita MJ, Moskal D, Maisto SA, et al. Association of Cannabinoid Administration With Experimental Pain in Healthy Adults: A Systematic Review and Meta-analysis. JAMA Psychiatry 2018;75:1118-1127.

35. IsHak WW, Wen RY, Naghdechi L, et al. Pain and Depression: A Systematic Review. Harvard Review of Psychiatry 2018;26:352-363.

36. Kafil TS, Nguyen TM, MacDonald JK, et al. Cannabis for the treatment of ulcerative colitis. Cochrane Database Syst Rev 2018;11:Cd012954.

37. Mucke M, Weier M, Carter C, et al. Systematic review and meta-analysis of cannabinoids in palliative medicine. Journal of Cachexia, Sarcopenia and Muscle 2018;9:220-234.

38. Mucke M, Phillips T, Radbruch L, et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2018;3:CD012182.



39. Stockings E, Zagic D, Campbell G, et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry 2018;89:741-753.

40. Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain 2018;159:1932-1954.

41. Torres-Moreno MC, Papaseit E, Torrens M, et al. Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis: A Systematic Review and Meta-analysis. JAMA network open 2018;1:e183485.

42. Zhang Z, Yang C, Zhang LL, et al. Pharmacotherapies to tics: A systematic review. Oncotarget 2018;9:28240-28266.

43. da Rovare VP, Magalhaes GPA, Jardini GDA, et al. Cannabinoids for spasticity due to multiple sclerosis or paraplegia: A systematic review and meta-analysis of randomized clinical trials. Complementary Therapies in Medicine 2017;34:170-185.

44. Goldenberg M, Reid MW, IsHak WW, et al. The impact of cannabis and cannabinoids for medical conditions on health-related quality of life: A systematic review and meta-analysis. Drug Alcohol Depend 2017;174:80-90.

45. Lim K, See YM, Lee J. A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders. Clinical Psychopharmacology and Neuroscience 2017;15:301-312.

46. Norton C, Czuber-Dochan W, Artom M, et al. Systematic review: interventions for abdominal pain management in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2017;46:115-125.

47. Nugent SM, Morasco BJ, O'Neil ME, et al. The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms: A Systematic Review. Ann Intern Med 2017;167:319-331.



48. Osborne AL, Solowij N, Weston-Green K. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia. Neurosci Biobehav Rev 2017;72:310-324.

49. Stevens AJ, Higgins MD. A systematic review of the analgesic efficacy of cannabinoid medications in the management of acute pain. Acta Anaesthesiologica Scandinavica 2017;61:268-280.

50. Wong SS, Wilens TE. Medical Cannabinoids in Children and Adolescents: A Systematic Review. Pediatrics 2017;140.

51. Fitzcharles MA, Ste-Marie PA, Häuser W, et al. Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials. Arthritis Care Res (Hoboken) 2016;68:681-8.

52. Gruenbaum SE, Zlotnik A, Gruenbaum BF, et al. Pharmacologic Neuroprotection for Functional Outcomes After Traumatic Brain Injury: A Systematic Review of the Clinical Literature. CNS Drugs 2016;30:791-806.

53. Merlin JS, Bulls HW, Vucovich LA, et al. Pharmacologic and non-pharmacologic treatments for chronic pain in individuals with HIV: a systematic review. AIDS Care 2016;28:1506-1515.

54. Wilkinson ST, Radhakrishnan R, D'Souza DC. A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications. J Clin Psychiatry 2016;77:1050-64.

55. Hoch E, Niemann D, von Keller R, et al. How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. Eur Arch Psychiatry Clin Neurosci 2019;269:87-105.

56. Nielsen S, Germanos R, Weier M, et al. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Curr Neurol Neurosci Rep 2018;18:8.



57. Hauser W, Fitzcharles MA, Radbruch L, et al. Cannabinoids in Pain Management and Palliative Medicine. Deutsches Arzteblatt International 2017;114:627-634.

58. Houze B, El-Khatib H, Arbour C. Efficacy, tolerability, and safety of nonpharmacological therapies for chronic pain: An umbrella review on various CAM approaches. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2017;Part B. 79:192-205.

59. O'Neil ME, Nugent SM, Morasco BJ, et al. Benefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder: A Systematic Review. Ann Intern Med 2017;167:332-340.

60. Tafelski S, Hauser W, Schafer M. Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting--a systematic review of systematic reviews. Der Schmerz 2016;30:14-24.

61. Allan GM, Finley CR, Ton J, et al. Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms. Canadian Family Physician 2018;64:e78-e94.

62. Elliott J, DeJean D, Clifford T, et al. Cannabis-based products for pediatric epilepsy: A systematic review. Epilepsia 2019;60:6-19.

63. Aviram J, Samuelly-Leichtag G. Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pain Physician 2017;20:E755-e796.

64. International Association for the Study of Pain. IASP Taxonomy. Pain terms. Neuropathic pain. Updated 2017 Dec 14. 2017 [cited; Available from: <u>https://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698#Neuropathicpain</u>

65. Workplace Safety Insurance Board. Cannabis for Medical Purposes. Operational Policy Manual 2019.



66. Canadian Pain Task Force-Health Canada. Chronic Pain in Canada: Laying a Foundation for Action. A Report by the Canadian Pain Task Force. 2019.

67. College of Physicians and Surgeons of Alberta. Cannabis for Medical Purposes. 2019.

68. Health Canada. Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids [Dried or fresh plant and oil for administration by ingestion or other means. Psychoactive agent] 2018.

69. Hesketh PJ. Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress. Oncology (Williston Park) 2004;18:9-14.

70. Brigden M. An Update on Medical Marijuana/Cannabinoid Prescribing in Cancer Patients. College of Physicians and Surgeons of Alberta, 2019.

71. Arthritis Society. Arthritis Society Position on Medical Cannabis. 2018.

72. American Psychological Association. Encyclopedia of Psychology; 2000.

73. Blessing EM, Steenkamp MM, Manzanares J, et al. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics 2015;12:825-36.

74. Mayo Clinic. Social anxiety disorder (social phobia). 2020 [cited 20 July 2020]; Available from: <u>https://www.mayoclinic.org/diseases-conditions/social-anxiety-</u> <u>disorder/symptoms-causes/syc-20353561</u>

75. Mayo Clinic. Generalized anxiety disorder. 2020 [cited 20 July 2020]; Available from: <u>https://www.mayoclinic.org/diseases-conditions/generalized-anxiety-</u> <u>disorder/symptoms-causes/syc-20360803</u>

76. Alberta Medical Association. PEER Simplified Guideline: Medical Cannabinoids -Clinical Practice Guideline. 2018.



77. World Health Organization (WHO). Epilepsy. 2019 [cited 20 July 2020]; Available from: <u>https://www.who.int/news-room/fact-sheets/detail/epilepsy</u>

78. National Libraray of Medicine. Psychosis. 2020 [cited 20 July 2020]; Available from: <u>https://medlineplus.gov/ency/article/001553.htm</u>

79. National Institute of Neurological Disorders and Stroke-NINDS. Tourette Syndrome Fact Sheet. 2020 [cited; Available from: <u>https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Tourette-Syndrome-Fact-Sheet</u>

80. Multiple Sclerosis Society of Canada. About MS. 2020 [cited 20 July 2020]; Available from: <u>https://mssociety.ca/about-ms</u>

81. National Institute of Neurological Disorders and Stroke-NINDS. Parkinson's Disease Information Page. 2020 [cited; Available from:

https://www.ninds.nih.gov/Disorders/All-Disorders/Parkinsons-Disease-Information-Page

82. National Institute of Neurological Disorders and Stroke-NINDS. Alzheimer's Disease Information Page. 2020 [cited; Available from:

https://www.ninds.nih.gov/Disorders/All-Disorders/Alzheimers-Disease-Information-Page

83. Canadian Rheumatology Association (CRA). Canadian Rheumatology Association (CRA) Position Statement on Medical Cannabis Use in Rheumatic Disease. 2019.

84. Woolridge E, Barton S, Samuel J, et al. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage 2005;29:358-67.

85. CADTH. Research Gaps for Medical Cannabis 2020 [cited; Available from:

86. CADTH. Medical Cannabis for the Treatment of Chronic Pain: A Review of Clinical Effectiveness and Guidelines. CADTH Rapid Response Report: Summary with Critical Appraisal 2019 [cited; Available from:

87. CADTH. Medical Cannabis Use in Palliative Care: Review of Clinical Effectiveness and Guidelines – An Update. CADTH Rapid Response Report: Summary with Critical



Appraisal 2019 [cited; Available from: